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Glycosylation is a post-translational modification where carbohydrates are attached to a protein 
or other organic molecule. Defects in glycosylation are seen in many human pathologies and 
may even be the underlying cause of some disorders. Here we have studied CEL and ABO, two 
genes that play a role in exocrine pancreatic disease, in particular as risk factors for chronic 
pancreatitis and pancreatic cancer. CEL encodes carboxyl-ester lipase, a glycosylated digestive 
enzyme secreted by the pancreas. The last exon of CEL contains a variable number of tandem 
repeats (VNTR) region, a highly polymorphic sequence translated into a protein C-terminal tail 
that undergoes mucin-type glycosylation. The ABO gene gives rise to a glycosyltransferase that 
synthesizes the A and B antigens of the ABO blood group system.  
We first examined whether genetic variants of CEL influenced the risk for the most common 
and serious type of pancreatic cancer, namely pancreatic ductal adenocarcinoma (PDAC). No 
association, neither for VNTR length nor for copy number variants (CNVs), was observed. 
Next, we tested the influence of ABO blood group on the risk for PDAC. Blood group O seemed 
to have a protective effect as individuals with this blood group were under-represented among 
cases compared with controls and also exhibited better survival when the tumour was 
unresectable. We then investigated the expression of CEL in PDAC resection specimens and 
pancreatic cell lines. CEL could not be detected in the neoplastic cells, neither at the mRNA 
nor at the protein level. When serine-/threonine-linked glycans were released from the 
mucinous domain of CEL and analysed by high-sensitivity mass spectrometry, we detected core 
1- and core 2-based ABH antigen-containing structures in coherence with the genetically 
determined ABO blood type and FUT2 secretor status of each analyzed individual. The finding 
of ABH antigens on CEL raises interesting questions of additional biological roles of carboxyl-
ester lipase, for example in the gastrointestinal mucosal barrier. 
Finally, we performed glycan profiling of the disease-associated CEL variants CEL-MODY 
and CEL-HYB as well as the normal CEL protein after expression in HEK293 cells. Altered 
O- and N-linked glycan patters were seen in, respectively, the VNTR and the globular domain 
of the pathogenic CEL protein variants. In conclusion, although CEL VNTR length does not 
appear to influence susceptibility to exocrine pancreatic disease, aberrant glycosylation of CEL 
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1.1. The healthy pancreas 
The mature pancreas is a lobulated organ of approximately 15 cm in length, and weighing, on 
average, about 80 g in adults. It is located in the peritoneum posterior to the stomach, stretching 
from the duodenum to the spleen. The gland can be divided into a head, neck, body and the tail 
region (Fig. 1). The pancreatic head is surrounded by the curved part of the duodenum. The 
body lies behind the stomach while the protruding tail is in contact with the left kidney and 
spleen. The main pancreatic duct, averaging 3 mm in diameter, expands across the gland 
collecting and directing the exocrine secretions into the duodenum. The common bile duct 
connects the gall bladder with the main pancreatic duct in the head of the pancreas and both 
open to the duodenum via the major duodenal papilla, also called papilla of Vateri.  
 
 
Figure 1. Anatomical relations of the pancreas. The stomach, on the upper front side, and the liver and 
gall bladder, on the left upper side of the image, are not shown. From the book Tumors of the pancreas (1). 
 
The pancreatic gland has a dual physiological role: 1) It stimulates digestion by releasing food-
degrading enzymes into the duodenum (exocrine function) and, 2) it produces hormones for 





1.1.1. The exocrine pancreas 
The exocrine pancreas consists of acinar cells arranged in small rounded groups (designated 
acini) and ductal cells (Fig. 2). The acinar cells are highly differentiated and polarized cells 
with a basally located nucleus and numerous secretory granules in the apical part. The 
cytoplasm of these cells is strongly basophilic reflecting the specialization of these cells for 
protein synthesis and secretion of digestive enzymes. In an acinar cell, only 5% of the total cell 
membrane fraction is plasma membrane whereas up to 60% corresponds to rough 
endoplasmatic reticulum. In comparison, rough endoplasmatic reticulum constitutes only 35% 
of total cell membranes in a hepatocyte (2). More than twenty different digestive enzymes, 
including proteases, amylases, lipases and nucleases (3) are produced and secreted by the acinar 
cells. Proteases are secreted as inactive precursors, and most of them become activated once 
they enter the duodenum by a sequential proteolytic cleavage cascade that is initiated by the 
duodenal enzyme enteropeptidase. On the other hand, amylase, nucleases and lipases are 
secreted in their partly or fully active form.  
 
 
Figure 2. Histology of the normal pancreas. Hematoxylin and eosin staining of normal human pancreas. 
(A) General histological organization of the pancreatic parenchyma. Islets of Langerhans are circumscribed 
by a dotted line. (B, C) Higher magnification of acinar cells arranged in acini. The red arrows indicate how 
secretion is directed towards an internal lumen created by small interconnecting ducts. The black dots 
symbolize the transiting digestive enzymes. (D) An intralobular duct surrounded by connective tissue. The 
asterisk indicates amorphic material corresponding to the pancreatic secretion. (E) An islet of Langerhans. 





The pancreatic ducts are arranged into a branching system that transports the pancreatic 
secretion towards the duodenum. The ducts vary in diameter and the smallest in size are termed 
intercalating ducts and are the first that receive the digestive enzymes secreted by the acini (4). 
The ductal cells secrete water and bicarbonate (HCO3-) in which the digestive enzymes become 
suspended. This forms the pancreatic secretion, which commonly is referred to as pancreatic 
juice. From the intercalated ducts the secretion is passed into the intralobular ducts, which then 
pass it to interlobular ducts, which are larger in size, followed by the main pancreatic duct 
before its drainage into the duodenum. Around one liter of pancreatic juice is secreted every 
day, and its alkaline pH serves to neutralize the acidic gastric contents (5).  
 
Another important integrant of the exocrine parenchyma are the so-called pancreatic stellate 
cells (PSCs). This cell type constitutes roughly 4% of the pancreas cell mass (6). In the healthy 
pancreas, PSCs appear in a quiescent state where they contribute to maintaining normal tissue 
structure and architecture by regulating the synthesis and degradation of extracellular matrix 
(ECM) (7). For this, they do not only secrete ECM proteins but they also produce matrix-
degrading enzymes (matrix metalloproteinases), as well as their inhibitors to fine-tune ECM 
deposition (8). However, in cases of injury, due to a series of phenotypical changes that lead to 
PSCs activation, the balance between ECM formation and degradation is severely disturbed 
and excessive fibrogenesis, known as fibrosis, occurs (9). Thus, PSCs play a central role in the 
desmoplastic reaction in severely damaging pancreatic disorders such as chronic pancreatitis 
and cancer (10,11). 
 
1.1.2 The endocrine pancreas 
The endocrine pancreas consists of a mixed population of cells that are arranged in 
morphologically recognizable groups called the islets of Langerhans. They are scattered in the 
exocrine parenchyma and range from 50 to 300 µm in diameter (Fig. 2A and E). The total 
volume of endocrine cells varies through life, ranging from 15% at the time of birth to only 2-
3% in adulthood (12). Each type of endocrine cell produces a single peptide hormone that 
contributes to the body’s glucose homeostasis. α-cells constitute around 15-20% of an islet and 
secrete glucagon, which stimulates the degradation of glycogen into glucose (glycogenolysis) 
in liver and skeletal muscle cells and also new synthesis of glucose (gluconeogenesis) in the 
liver; β-cells make up around 80% of the total islet mass and secrete insulin. This hormone 




energy via formation of glycogen (glycogenesis) or fat reserves (lipogenesis). Insulin secretion 
also blocks glucose production and secretion by the liver. γ-cells or PP-cells are the least 
frequent cell type in the islets and they produce pancreatic polypeptide, which alters insulin and 
glucagon secretion, and also has anorexic effects on gastrointestinal functions; δ-cells comprise 
around 5% of the endocrine tissue and secrete somatostatin that acts in a paracrine manner, 
exerting inhibitory effects on both α- and β-cells via the somatostatin-receptor expressed in 
both cell types (13). 
 
1.1. Diseases of the pancreas 
The common disorders of the pancreas can be divided into three broad disease groups: diabetes, 
inflammation (pancreatitis) and neoplasms (cancer). The two latter groups mainly affect the 
exocrine part of the gland, whereas diabetes is primarily an endocrine disorder. 
1.1.1.  Diabetes mellitus 
The most widespread disease involving the pancreas is diabetes mellitus, often referred to as 
only diabetes. In this disorder, the hallmark is chronic hyperglycemia due to a deficiency in 
insulin secretion and/or insulin action. The American Diabetes Association classifies diabetes 
in four major types: type 1 diabetes, type 2 diabetes, gestational diabetes and other types of 
diabetes due to specific causes (14). 
 
Type 1 diabetes 
Accounting for up to 10% of all diabetes cases, type 1 diabetes is characterized by an 
autoimmune destruction of the endocrine tissue that leads to severe β-cell loss. Once known as 
“juvenile-onset diabetes” or “insulin-dependent diabetes”, type 1 diabetes is a heterogenous 
disease most commonly seen in children and youths, and presenting with variable clinical 
features and disease progression (15,16). The majority of diagnosed type 1 cases are 
characterized by a T-lymphocyte-mediated autoimmune destruction of the β-cells that leads to 
insulin deficiency (17). Anti-islet autoantibodies are present in most cases; the most commonly 
targeted islet components are insulin, glutamic acid decarboxylase protein 65 (GAD65) and 
zinc transporter 8 (ZnT8) (18). Diabetic ketoacidosis, another hallmark of the disease, is seen 
in approximately one third of all type 1 patients at the time of diagnosis (19). As the β-cells are 
permanently destructed, the patients will depend on an exogenous supply of insulin for the rest 




Type 2 diabetes 
The by far most common form of diabetes is type 2, which accounts for around 90% of all 
diagnosed cases. According to the World Health Organization, the number of people with type 
2 diabetes has risen from 108 million in 1980 to 422 million in 2014 (20). The number of 
affected adults is still expected to rise worldwide, in an epidemic fashion, as this disorder is 
associated with obesity, a sedentary life style and age (21). Similarly to type 1 diabetes, type 2 
diabetes is a heterogeneous disease with a polygenic inheritance pattern and influence of 
environmental risk factors (22-24).  
 
Type 2 diabetes is characterized by the development of insulin resistance, which occurs in the 
peripheral tissues such as liver, muscle and adipose tissues when the cells lose their ability to 
take up glucose from the circulation despite normal or even elevated insulin secretion. As the 
disease progresses, impaired insulin secretion may also develop. Although there is no 
autoimmune destruction of β-cells in type 2 diabetes, β-cell dysfunction and finally depletion 
are linked to the pathophysiology of the disease (25-27). Both type 1 and type 2 diabetes are 
associated with a high risk for developing diabetes-related complications such as cardiovascular 
disease, nephropathy, retinopathy and neuropathy (28). This is the reason why diabetes is 
associated with increased morbidity and mortality. 
 
Monogenic diabetes: MODY 
Among the other causes of diabetes recognized by American Diabetes Association are 
mutations that occur in a single gene. This form of the disease is designated monogenic 
diabetes. The number of cases probably represents a small fraction of the patients (between 1 
and  5%) (29). Up to date, mutations in around 20 different genes have been reported to cause 
monogenic diabetes (30).  
 
The most common type of monogenic diabetes is called maturity-onset diabetes of the young 
(MODY) (14). MODY usually occurs in adolescence or early adulthood and an important 
diagnostic criterion is onset of diabetes before the age of 25 (31). This is, however, the reason 
why MODY is often misdiagnosed as type 1 diabetes (32). Other criteria for a MODY diagnosis 






Over 90% of all MODY cases are caused by mutations in the genes GCK,  HNF1A and HNF4A. 
In addition, there are eight much rarer forms of MODY which are caused by mutations in the 
genes PDX1, HNF1B, NEUROD1, KLF11, CEL, PAX4, INS and BLK (33,34). Single-base 
deletions in the CEL gene cause MODY8, a syndrome of endocrine and exocrine dysfunction. 
MODY8 syndrome will be described in more detail in Section 1.6.  
 
The different MODY forms are associated with different clinical presentation of the disease. 
Moreover, the optimal treatment options may vary according to which gene is mutated. Thus, 
patients with mutations in the genes HNF1A and HNF4A, with MODY1 and 2, respectively, 
tend to respond well to sulfonylurea drugs (14,35). On the other hand, MODY2 patients 
(affecting GCK) normally do not require medication as they exhibit mild hyperglycemia that 
can be controlled mainly by dietary measures. Thus, genetic testing of suspected MODY cases 
is important for optimal treatment and also to avoid a misdiagnosis as type 1 or type 2 diabetes 
(30,32). 
 
1.1.2.  Inflammatory diseases of the pancreas 
Acute pancreatitis 
Acute pancreatitis is a sudden and transient inflammation of the pancreas. In most cases, it 
develops due to passage of biliary tract stones through the main pancreatic duct or as a 
consequence of prolonged alcohol abuse (36). In the majority of cases, it is a relatively mild 
form of pancreatitis characterized by interstitial edema and minor foci of necrosis (37). The 
mild form does usually not involve organ dysfunction and resolves with intravenous fluid 
rehydration and fasting. However, in 10-20% of all cases, the disease presents in a severe form 
where abscess, extended necrosis, pseudocysts and hemorrhage are common features. Thus, 
severe acute pancreatitis can lead to multi-organ failure and be fatal for the patient (38).  
 
Chronic pancreatitis 
Chronic pancreatitis (CP) is a long-standing and progressive inflammatory disease 
characterized by fibrotic destruction of the glandular pancreatic parenchyma (39). The 
inflammatory process leads to irreversible morphological changes such as loss of the lobular 
morphology and structure of the pancreas and changes in the arrangement of the islets. 
Extensive fibrosis, mainly caused by activated PSCs (9), ductal dilation and calcifications are 




pancreatic exocrine and endocrine insufficiency manifesting as maldigestion and diabetes, 
respectively (39). 
 
CP is caused by a complex combination of environmental and genetic factors. In Western 
countries, alcohol abuse is the leading cause of CP, accounting for approximately 70% of all 
cases. In approximately 20% of CP cases, no etiological factors can be identified and these are 
collectively termed idiopathic CP (40). Hereditary CP, an extremely rare condition with an 
estimated prevalence of only 3 in one million individuals (41), is diagnosed when three or more 
family members are affected by chronic pancreatitis and at least two generations are invvolved. 
The most common cause of hereditary CP are highly penetrant mutations in the cationic 
trypsinogen gene PRSS1 (42). This leads to intra-acinar activation of trypsinogen, which is 
considered pivotal in triggering the pathogenic process. Patients suffering from the hereditary 
form of CP have a greatly increased risk of developing pancreatic cancer (41,43). 
 
Studies of patient cohorts with familial, early onset and/or or idiopathic CP have revealed 
several other genes than PRSS1 to confer susceptibility to the disease. The most classical are 
the genes coding for the serine protease inhibitor Kazal-type 1 (SPINK1) (44), cystic fibrosis 
transmembrane conductance regulator (CFTR) (45), chymotrypsinogen C (CTRC) (46) and 
carboxypeptidase A1 (CPA1) (47). In a genome wide association study (GWAS) conducted by 
Whitcomb et al. (48), in addition to the PRSS1-2 loci, variants of the chromosome X-linked 
CLDN2 gene, coding for the cation channel-forming tight junction protein claudin-2, were also 
seen to influence the risk of pancreatitis. Moreover, Weiss et al. identified ABO B-blood type 
and FUT2 non-secretor status as common population-wide risk factors for developing this 
disease (49).  
 
 
1.1.3.  Neoplastic diseases of the pancreas 
From the more than a dozen types of pancreatic neoplasms are listed in the tumour classification 
system published by the World Health Organization (50), pancreatic ductal adenocarcinoma 
(PDAC) is the dominating histologic subtype which accounts for more than 90% of all cases. 
Pancreatic neuroendocrine tumours are very rare in comparison with those arising in the 




tumours, nearly half are functioning neoplasms, i.e. those that secrete hormones. Insulinomas 
are the most frequent type, although with an incidence of only one case per million (51). 
 
There is a variety of uncommon exocrine tumours of the pancreas such as mucinous and serous 
cystadenocarcinomas, acinar cell carcinomas and solid-pseudopapillary carcinoma (50). 
However, the next chapter will focus only on PDAC as it encompasses the vast majority of 
exocrine pancreatic cancer cases.  
 
1.2. Pancreatic ductal adenocarcinoma (PDAC) 
1.2.1. Clinical aspects  
Among neoplastic malignancies of the gastrointestinal tract, PDAC represents 20% of the total 
cases, and is the disease that bears the worst prognosis (52,53). With a long-term survival rate 
as small as 1-3% PDAC is the fourth leading cause of cancer-related deaths in the industrialized 
countries (54). Surgical resection of the tumour is today’s only possible curative treatment, 
although only offered to 15-20 % of the patients. The inaccessible anatomical location of the 
pancreatic gland and the asymptomatic course of PDAC aggravates the disease’s bad prognosis. 
Moreover, PDAC is one of the stiffest tumour types, characterized by a very prominent 
desmoplastic reaction with a dense fibrotic stroma and low cellularity, implying that a typical 
primary tumour often contains only 5-20% neoplastic cellularity (55). In addition, the low 
vascular density of PDAC leads to hypoperfusion of the tumours which, together with the dense 
stroma, could represent a strong barrier for efficient drug delivery (56).  
 
Etiology of pancreatic cancer 
The etiology of PDAC is complex, with multiple gene/environmental interactions. CP is among 
the strongest risk factors for PDAC, especially long-standing inflammation, as found in 
hereditary pancreatitis (57,58). Smoking and alcohol abuse, which both are risk factors for CP, 
are known to increase the risk for PDAC 2-fold (59) and 1.5-fold respectively (60). 
 
Other risk factors that contribute to this malignancy are diabetes mellitus, obesity, old age, 
positive family history and high fat-dietary regimens (61). Individuals infected with the gastric 





Germline mutations as a cause of PDAC  
Hereditary pancreatic cancer is defined by at least two PDAC diagnoses among first-degree 
relatives. It is estimated that up to 10% of the patients with pancreatic cancer have a family 
history of the disease (63). There are at least six hereditary cancer predisposition syndromes 
where there is a clearly increased risk for developing PDAC. These are hereditary breast and 
ovarian cancer syndrome (with germline mutations in BRCA2), familial melanoma 
(P16/CDKN2A), Peutz-Jeghers syndrome (STK11), Lynch syndrome (MLH1, MSH2, PMS2 or 
EPCAM), familial adenomatous polyposis (APC) and Li-Fraumeni syndrome (TP53) (64). 
Moreover, germline mutations in hereditary pancreatitis genes such as PRSS1 are also 
associated with PDAC (65). Nevertheless, this group of diseases only account for around one 
tenth of familial pancreatic cancers. 
 
Apart from the rare, high-penetrant mutations in the genes mentioned above there are more 
common genetic variants associated with a modest increase risk of PDAC (66). One example 
is polymorphisms at the ABO blood group locus (67). In a large GWAS (67) where 558,542 
single nucleotide polymorphisms (SNPs) were genotyped in 1,896 individuals with pancreatic 
cancer and 1,939 controls, the C variant in SNP rs505922 in intron 1 of the ABO gene was seen 
to increase the risk for pancreatic cancer (odds ratio (OR) = 1.20; 95% CI: 1.12-1.28). Since 
then, this association has been confirmed in several other reports involving different ethnicity 
groups (68,69). Additional susceptibility alleles with moderate to small effects identified by 
GWAS are the nuclear receptor NR5A2 (70) that is predominantly expressed in exocrine 
pancreas and liver, and involved in pancreatic differentiation and inflammation (71); two 
Kruppel-like transcription factors, KLF5 and KLF12, that regulate cell growth and 
transformation (70); and the cleft lip and palate transmembrane 1-like gene (CLPTM1L), part 
of the CLPTM1L-TERT locus that includes the telomerase reverse transcriptase gene (TERT; 
(70)). 
 
Somatic mutations in PDAC 
With the aim of understanding the somatic DNA changes underlying the development of PDAC 
the first whole-exome sequencing study on pancreatic cancer was carried out in 2008 (72). In 
this paper, Jones et al. reported the sequencing of 23,219 transcripts representing 20,661 
protein-coding genes in PDAC tumours from 24 different patients. The most frequently 




mutations in the tumour suppressor genes p16/CDKN2A and TP53 (70-80%, plus 15% 
hypermethylation-silencing of p16/CDKN2A), and inactivation of SMAD4/DPC4 (60%) (72).  
Several follow-up studies have validated these results including two studies published by the 
Cancer Genome Atlas Research Network (73) and Bailey et al. (74), where 150 and 456 PDAC 
cases, respectively, were examined. In the latter report, based on RNA expression profiles, the 
authors delineated four different subtypes of PDAC. These were: 1) The squamous type, which 
showed expression of genes related to inflammation, hypoxia response, metabolic 
reprogramming, TGF-β signaling, MYC pathways activation and autophagy. This type showed 
the worst prognosis and was enriched in TP53 and KDM6A mutations; 2) the progenitor type 
which expressed genes involved in early pancreatic development (FOXA2/3, PDX1 and MNX1) 
as well as MUC5AC and MUC1; 3) the immunogenic tumour type, which shared many of the 
characteristics of the progenitor class, but was associated with a significant immune infiltrate. 
Associated gene programs included B cell signaling pathways, antigen presentation, CD4+ T 
cell, CD8+ T cell and Toll-like receptor signaling pathways; and 4) the aberrantly differentiated 
endocrine/exocrine type characterized by upregulated networks of KRAS activation, exocrine 
and also endocrine differentiation.  
 
1.2.2. Pancreatic cancer biomarkers 
The majority of cancer biomarkers in clinical use are glycoconjugates, i.e. macromolecules 
containing glycans; a glycan is a carbohydrate molecule formed by different or the same sugar 
monomer (monosaccharide) assembled in a very specific manner (75-77). Glycans whose 
expression is related to cancerous states are often termed tumour-associated carbohydrate 
antigens (TACA). The most widely known serum biomarker for PDAC, Carbohydrate Antigen 
19 (CA19.9), was originally isolated in 1979 from a colorectal carcinoma cell line using a 
mouse monoclonal antibody (78,79). CA19.9 began to attract attention in the pancreatic cancer 
field because its serum levels were found to be increased in patients suffering from the disease 
(80).  
Although CA19.9 is the only clinically approved biomarker for pancreatic cancer, its use is 
limited to monitoring therapy response, and not as a diagnostic marker. This is partially because 
1) CA19.9 serum levels are elevated in only two-thirds of early stage PDAC cases (81); 2) 




chemically characterized as a so-called sialyl-Lewis A (sLea) glycan, which means that CA19.9 
tests always will give negative results in Lewis blood type negative (Lea-b-) individuals. These 
persons (around 10% of the Caucasian population) are unable to synthesize the CA19.9 
structure due to a non-functional α-1,3/4-fucosyl-transferase (FUT3) (80,84,85). 
Other carbohydrate-based biomarkers that have been employed in pancreatic cancer detection 
are CEA (86), CA242 (87), sialyl-Lewis x, (sLex (88)), and the non-fucosylated sialyl-Lewis C 
(detected with the monoclonal antibody Dupan-2 (89)). A recently discovered and promising 
biomarker for early detection of PDAC is glypican-1, a heavily glycosylated protein, which has 
been detected in the serum of pancreatic patients only (90). Potential PDAC biomarkers not 
directly involving glycans include the serum protein named C4b-binding protein alfa-chain 
(C4BPA) (91), and the macrophage inhibitory cytokine 1 (MIC-1), which has been reported to 
have a diagnostic accuracy for pancreatic cancer similar to CA19.9 (92).  
1.3. Protein glycosylation  
Glycosylation is a post-translational, covalent modification where carbohydrates are attached 
to a protein or other organic molecule. Virtually, every secreted and cell surface protein become 
glycosylated as they pass through the endoplasmatic reticulum (ER) and Golgi apparatus. The 
glycome, or complete profile of glycan modifications in a specific macromolecule, is assembled 
by the coordinated action of numerous glycan modifying enzymes including 
glycosyltransferases and glycosydases. The monosaccharide units, the building blocks of 
glycans, are usually represented in a uniform symbol nomenclature (93). There are many 
different types of protein glycosylation. In this thesis, only mucin-type O-linked glycosylation 
(the glycan is attached through the hydroxyl group of a serine or a threonine residue) and N-
linked glycosylation (attachment through the amino group of an asparagine residue) will be 
addressed.  
 
1.3.1. Mucin-type O-linked glycosylation 
A mucin is a large protein where the amino acid sequence contains peptide segments rich in 
Ser, Thr and Pro that are repeated hundreds of times. Mucins have a very high content of 
glycans which is responsible for their large molecular weight and for the water-holding 
properties that the mucins confer in the intestine and other locations where they are produced 




protein backbone in an extended conformation, transforming it from a globular to an extended 
rod-like structure (95) and also protects against proteolysis (96). O-liked glycans in cell surface 
proteins and secretions mediate cell adhesion, recognition, and cell-to-cell communication 
(97,98). These glycan structures also interact with the microbiota (99) as they can be used as 
energy sources for enteric bacteria (100) or as anchoring receptors (101). Moreover, glycans 
have been suggested to mediate the cross-talk between the intestinal cells and the immune 
system (102).  
 
O-glycans are assembled in the Golgi apparatus following a series of steps where different 
glycosyl-tranferases build different core structures (core 1 to 4; Fig. 3). There exist eight 
different core structures; however, only core 1-4 have been found in human gastrointestinal 
mucins (Table 1). The different core structures are further extended or “capped” by sialic acid 






























Figure 3: O-linked glycan synthesis pathways. O-glycosylation is initiated by a family of enzymes called 
polypeptide N-acetylgalactosaminyl-transferases (ppGalNAc-Ts), which is comprised of 20 related enzymes 
in humans. ppGalNAc-Ts catalyze the addition of GalNAc (via an O-glycosidic linkage) to the hydroxyl 
groups of Ser/Thr, form an initial structure called Tn. The next step is the addition of galactose (Gal) to form 
core 1 (or T antigen) structure, catalyzed by the core 1 β1,3-galactosyl-transferase (T-synthase). Core 1 can 
be further modified to form core 2 structures by core 2 β1,6-N-acetylglucosaminyl-transferase (core 2 
synthase). The Tn antigen is also the precursor to core 3 and core 4 structures. All core structures are further 
modified into extended structures with the addition of other sugars such as Gal, N-acetylgalactosamine 
(GalNAc), N-acetylglucosamine (GlcNAc), fucose (Fuc), and sialic acid (NeuAc), creating linear or 








Table 1. O-glycan cores and common antigenic epitopes found in mucins   
Core  Glycan         
 Tn antigen GalNAcαSer/Thr   
 Sialyl-Tn antigen Siaα2-6GalNAcαSer/Thr   
 Core 1 or T antigen Galβ1-3GalNAcαSer/Thr   
 Core 2 GlcNAcβ1-6(Galβ1-3)GalNAcαSer/Thr 
 Core 3 GlcNAcβ1-3GalNAcαSer/Thr  
 Core 4 GlcNAcβ1-6(GlcNAcβ1-3)GalNAcαSer/Thr 
Terminal antigen*           
 Blood group H Fucα1-2Gal-    
 Blood group A GalNAcα1-3(Fucα1-2)Gal-  
 Blood group B Galα1-3(Fucα1-2)Gal-   
 Blood group Lewis a Galβ1-3(Fucα1-4)GlcNAc-  
 Blood group Lewis x Galβ1-4(Fucα1-3)GlcNAc-  
    Blood group Lewis y Fucα1-2Galβ1-4(Fucα1-3)GlcNAc- 
    Sialyl-Lewis x Siaα2-3Galβ1-4(Fucα1-3)GlcNAc-  
*Terminal antigens can also be part of N-linked glycans 
 Sia, sialic acid or (NeuAc in humans); Ser/Thr, serine or threonine residues. 
 
 
1.3.2.  N-linked glycosylation 
One of the most common forms of modification for proteins that traverse the ER and secretory 
pathway is N-linked glycosylation (Fig. 4). This attachment occurs early in protein synthesis 
as the enzyme responsible for the N-glycan transference, the oligosaccharyl-transferase (OST), 
is part of the ribosome-translocon complex (103,104). 
 
As the newly synthesized peptide emerges in the ER it receives the initial structure (a 14-
monosaccharide high mannose glycan) on the amide nitrogen of asparagine in the context of 
the consensus sequence Asn-X-Ser/Thr (in which X is not a proline). About 70% of proteins 
contain this recognition sequence. However, it has been estimated that only two-thirds of all N-
X-S/T motifs are occupied by N-linked glycans (105). The inital step is followed by a complex 
process of hydrolytic removal of sugar residues (trimming) and then re-glycosylation with 
additional sugar residues (processing) such as galactose, fucose, or sialic acid during transit 
through the endoplasmic ER and Golgi. Contrary to O-glycosylation where biosynthesis occurs 
by the sequential addition of single monosaccharides, the synthesis of N-glycosylation begins 
on a lipid and the initial structure is moved en bloc to the protein. Fig. 4 provides a more detailed 




is that they can assist the glycoprotein maturation process by guiding the protein through a 





Figure 4: N-glycosylation pathway in the ER and Golgi apparatus. The oligosaccharide 
GlcNAc2Man9Glc3 is transferred from dolichol-phosphate to the asparagine side chain of the sequence N-
X-S/T by the enzyme oligosaccharyl-transferase. Following the transfer of the initial glycan to the protein, 
glucosidases in the ER remove three glucose (Glc) residues, and ER mannosidase removes a mannose (Man) 
residue. These reactions are intimately associated with the folding of the glycoprotein assisted by the lectins 




Another lectin, termed ER degradation-enhancing α-mannosidase I-like protein (EDEM), binds to Man 
residues on misfolded glycoproteins and escorts them via retro-translocation into the cytoplasm for 
degradation. For correctly folded human proteins, α-mannosidase II removes outer Man residues. The 
resulting N-glycan is extended by the addition of Fuc, Gal, and NeuAC to generate a complex N-glycan with 
two or more branches. Image from the book Essentials of Glycobiology. 2nd edition (108).  
 
 
1.3.3. Changes in glycosylation associated with pancreatic disease 
Abnormal glycosylation is one of the hallmarks of cancer cells (109,110). Cancer progression 
and metastasis are characterized by a significant alteration in the glycans signature (111). Such 
aberrant glycans are functionally important as they can alter cell adhesion, proliferation, 
survival and metastasis and well as interaction with the immune system (112). Next, a very 
brief description of the most pronounced changes, with a focus in pancreatic cancer, is provided. 
 
Abnormal O-glycosylation 
Abnormal mucin glycosylation is seen in many diseases (113-115). Among the changes seen 
in pancreatic cancer, perhaps the most predominant is the emergence of the sialylated blood 
group sLea (CA19.9) and sLex glycan structures on mucins (116). CA19.9 assays are antibody-
based tests (117) that measure the total carbohydrate antigen present in the plasma, although 
the structure can be attached to different proteins carriers. Yue et al. showed that CA19.9 carrier 
proteins shift between disease states: MUC16 was the preferential carrier in chronic pancreatitis 
whereas MUC5AC and MUC1 were the most predominant mucin carriers in pancreatic cancer 
(118). 
 
Another important hallmark of mucins in disease, specially cancer, is their incomplete or 
truncated glycosylation which leads to the expression of the T and Tn antigens (119) (see also 
legend to Fig. 3). Moreover, a general increase in sialylation accompanies cancerogenesis 
affecting both O- and N-glycans (120,121). T and Tn, as well as their sialylated variants sialyl-
T (sT) and sialyl-Tn (sTn), are small TACAs whose expression at the plasma membrane can 
enhance tumorigenic and invasive properties (122). This change is often accompanied by up-
regulation of sialyl-transferases, e.g. ST3GALI, which convert the T antigen into sialyl-T (sT) 





N-linked glycans also undergo changes during disease (110). One of the most characteristic 
changes in neoplastic cells is the increase in β1-6 branching, usually caused by upregulation of 
the MGAT5 gene that leads to overexpression of the enzyme N-acetylglucosaminyl-transferase 
V (121,124). Cells with elevated MGAT5 expression show an increased frequency of metastasis 
in mice, and revertants lacking MGAT5 lose the metastatic phenotype (125).  
 
Increase in fucosylation is also a hallmark of inflammation and cancer, and can affect both N- 
and O-linked glycans (121). Some proteins with a high degree of fucosylation have been 
suggested as pancreatic cancer biomarkers, e.g. serum haptoglobin (126) and circulating 
ribonuclease 1 (127). 
 
1.4. The ABO blood group system 
ABO is one of 34 different blood group system known today (128), and together with the 
Rhesus system, the one with the highest clinical relevance. The ABO antigens, also referred to 
as ABH, are terminal glycan chain parts of a large soluble or cell surface-anchored glycolipid 
or glycoprotein. In 1900, Landsteiner observed that the red blood cells of some individuals were 
agglutinated by the serum of other individuals (129). Looking at the pattern of agglutination he 
established three different blood groups: A, B and O. Blood group AB was added later, referring 
to a minority of individuals behaving both A and B. In 1924, Bernstein proposed the “one gene 
locus-three alleles” model to explain the inheritance of the ABO blood group (130). It was not 
until 1990 that the elucidation of the molecular genetic basis of the ABO polymorphism was 
achieved by Yamamoto et al. (131).  
 
1.4.1.  The ABO locus 
The ABO locus maps to the long arm of chromosome 9 at q34.2 and codes for different glycosyl-
transferases. The coding region comprises 19.5 kilobase (kb) distributed over seven exons. 
When transcribed, it gives rise to a 1062 base pair (bp) mRNA that is translated into a 41 kDa 
single pass-transmembrane Golgi-resident protein. Exons 6 and 7 encode over two-thirds of the 
total protein (354 amino acids) which comprise around 90% of the catalytic domain (131,132). 
Multiple SNPs have been identified in the ABO locus making it one of the most widely 




majority are very uncommon and are categorized as subgroups of the four main alleles: A1, A2, 
B and O (Fig. 5). The corresponding phenotypes are present worldwide, but their frequencies 
differ significantly among ethnicities (133). 
 
 
Figure 5. The four main ABO alleles. Schematic representation of the nucleotide substitutions in ABO gene 
exons 6 and 7 (letters above the line). The corresponding amino acid substitutions are represented below the 
line. The A2 and O allele contain a single base deletion of a C and a G, respectively. The consequence of the 
former is an extension of the polypeptide by 21 amino acids, whereas the latter results in a truncated protein 




1.4.2. The ABO glycosyltransferases  
The A and B alleles encode functional glycosyl-transferases with small differences between 
them. In contrast, the O allele has a single-base deletion, 261delG in exon 6, that shifts the 
reading frame and results in a truncated protein with no glycosyl-transferase function (131). 
The A and B alleles encode two related, but different glycosyl-transferases (Fig. 6). Seven 
SNPs, one in exon 6 and the rest in exon 7, make transferase A1 different from the B transferase.  
Four of these SNPs give rise to amino acid substitutions: Arg176Gly, Gly235Ser, Leu266Met 
and Gly268Ala. In the catalytic site, Leu266Met and Gly268Ala determine the substrate 
specificity of the enzymes. Although both enzymes are transmembrane proteins in the Golgi 
apparatus, it has been noted that upon proteolytical cleavage they can be found as soluble 








Figure 6. Glycosyl-transferases A1 and B and their catalytic reaction. Critical residues at the substrate 
binding pocket (marked in blue and red) determine the substrate specificity of the enzymes. The H antigen is 
formed by the α-1,2-fucosyl-transferase encoded by the FUT2 gene, and it is a substrate for A and B 
transferases to form the A and B antigens, respectively. L, leucine; G, glycine; M, methionine, A, alanine; 






The A2 allele is characterized by the deletion 1061delC that disrupts the stop codon. The 
resulting shift of reading frame yields a protein product with 21 extra amino acid residues at 
the C-terminus. This slightly longer protein has a diminished A transferase activity 
characterized by a higher Km. Consequently, there is a qualitative difference in the number of 
A antigens with 8-12x105 estimated in an A1 red blood cell versus 1-4x105 in an A2 cell (135). 
A1 and A2 enzymes also differ in biochemical aspects such as differences in optimal catalytic 
pH and isoelectric point (pI).  
 
1.4.3. The ABH antigens 
The reaction catalyzed by the ABO-coded enzymes is the transference of N-acetyl-
galactosamine-UDP (GalNAc-UDP) or galactose-UDP (Gal-UDP) to a precursor molecule, the 
so-called H antigen (Fuc-α1,2-Gal-), to form the A (GalNAc-α1,3(Fuc-α1,2)Gal) and B (Gal-
α1,3(Fuc α1,2)Gal) antigens, respectively. Blood group O individuals lack the A or B functional 
enzymes and therefore express the H antigen without modifications (131).  
 
In addition to red blood cells, the histo-blood group antigens A, B and H (O) are widely present 
in tissues and also in their soluble form in body fluids. The gene that controls the production 
and secretion of the H precursor structure in epithelial cells is FUT2 which determines the 
“secretor status” of an individual (136), whereas the synthesis of the H antigen in erythrocytes 
is controlled by a fucosyl-transferase encoded by the FUT1 gene (137). These genes are 
homologous and reside on chromosome 19. About 20% of Caucasians are non-secretors, i.e. 
homozygous for a nonsense mutation in FUT2, resulting in a truncated FUT2 fucosyl-
transferase (138). Thus, body fluids from A and B non-secretor subjects contain no A or B 
antigens despite that the subjects have active A and B glycosyl-transferases. 
 
ABH antigens can be present as terminal motifs on mucin-type O-glycans and N-linked 
glycoproteins that are secreted or membrane-bound. Loss of A and B blood group antigens and 
the subsequent exposure (or increase) in blood group H (Lewb) is a common change in 






1.4.4. Anti-ABH natural antibodies 
Anti-ABH antibodies are naturally occurring antibodies (NAbs) that belong mainly to the IgM 
class, but can also be of the IgG3 or IgA type (141). Nabs are part of innate immunity and are 
present in the blood of mammals at an early age and persist throughout life. They appear from 
enterobacterial stimulation and are crucially important as they constitute the first line of defense 
against infections (142). The genesis of Nabs can be understood by employing germ-free mice; 
In the recent study by Khasbiullina et al. (143), it was shown that sterile mice, that were never 
exposed to any bacteria, had no anti-glycan Abs in their bloodstream. In contrast, animals that 
were orally inoculated with several bacterial strains as part of the administered food, exhibited 
significant amounts of antibodies against bacterial polysaccharides, including some reacting 
towards human ABH blood group antigens. 
 
1.5. Carboxyl-ester lipase: gene and protein 
1.5.1. The CEL locus 
The human CEL gene is located on the long arm of chromosome band 9q34.13 and covers 
around 10 kb of genomic sequence distributed over 11 exons (144). The last exon contains a 
very GC-rich variable number of tandem repeats (VNTR) region, constituted by nearly identical 
33-bp segments. In all human populations investigated so far, the most frequent CEL allele has 
16 repeats, although repeat lengths between 3 and 23 have been observed (145,146). Moreover, 
additional variation is introduced by single-base insertions and deletions within the VNTR 
(147).  
 
The CEL locus also includes a CEL pseudogene that is located 11 kb downstream of the CEL 
gene. CELP lacks exons 2-7 but the remaining sequence shares 97% homology with CEL (148). 
The pseudogene is present only in man and great apes. It is likely to have originated from a 
duplication event which occurred relatively late in mammalian evolution (149), and it has been 
proposed that CELP is the original gene because of the sequence similarity between the 
promoter regions of the mouse Cel gene and that of human CELP. In humans, CELP is reported 
to be ubiquitously transcribed, but it is not expected to be translated into protein due to a stop 





1.5.2. CEL glycoprotein: expression, structure and function 
The CEL gene encodes carboxyl-ester lipase (CEL), also termed bile salt-dependent lipase 
(BSDL), bile salt-stimulated lipase (BSSL or cholesterol esterase (EC 3.1.1.13). CEL is one of 
four major lipases secreted by the pancreas to the duodenum, but the only with a requirement 
for bile salts to be fully active (3,150). CEL hydrolyses a broad spectrum of dietary fats 
including esters of cholesterol and fat-soluble vitamins (A, D, and E). Moreover, it was recently 
suggested that CEL has the ability to degrade branched fatty acid esters of hydroxyl fatty acids 
(FAHFAs), a novel type of fatty acids with anti-diabetic and anti-inflammatory properties 
(151).  
 
The CEL protein is mainly expressed in the acinar cells of the pancreas where it has been 
estimated to represent around 4% of the total proteins detected in pancreatic juice (152). 
However, it is also expressed in human lactating mammary glands, where it is secreted into 
mother's milk and assists fat digestion in newborns, presumably to compensate for the reduced 
lipolytic capacity of the newborn’s intestine (150). In addition to the high levels in pancreas 
and mammary glands, CEL expression has been documented in the pituitary gland (153), 
macrophages (154), eosinophils (155), endothelial cells (156), as well as in liver tissue during 
foetal development (157).  
 
CEL has two major structural domains: an N-terminal globular domain encoded by exons 1-10, 
and a C-terminal VNTR domain coded by exon 11 (Fig. 7). The globular domain is 535 amino 
acid long after the signal peptide has been cleaved off, and its three-dimensional structure 
belongs to the α/β-hydrolase-fold superfamily of hydrolases. The catalytic triad of CEL is 
composed of Ser194-His435-Asp320, and is part of the catalytic domain that is conserved in 
all vertebrate species examined to date (158). The asparagine residue at position 210 is modified 
by a covalently linked N-glycan. This carbohydrate structure has been reported to be required 
for maximal secretion of CEL (159) and altering it may compromise the enzymatic activity 
(160). Moreover, two intramolecular disulphide bridges, mediated by Cys64-Cys80 and 
Cys246-Cys257, stabilize the structure of the CEL globular domain (161). 
 
The COOH-terminus of CEL consists of a VNTR or mucinous domain. This is a structurally 
disordered tail that adopts a rod-like topological disposition, with a typical architecture of 




of 16 peptide segments of 11 residues each, all being proline-rich sequences. The repeat 
numbers 4-9, 11-13, and 15 consist of the basic sequence GAPPVPPTGDS, repeats 1-2 and 14 
have EATPVPPTGDS, and the remaining repeats contain minor substitutions of these 
sequences. The presence of aspartic acid in every repeating unit, and glutamic acid in some, 




Figure 7. Schematic structure of the CEL protein. The drawing shows the most common CEL variant with 16 
tandem repeats in the C-terminal VNTR region. Numbers refer to amino acid positions. An example of the 11 
amino acid VNTR repeat sequence (second repeat) is displayed. Vertical lines in the mucin-like domain represent 
all potential O-glycosylation sites. The structure at residue 210 symbolizes the N-glycan added at the consensus 
sequence NXT. Two disulfide bridges are also marked. Red dots symbolize bile salt molecules.  
 
 
1.5.3.  CEL protein glycosylation and secretion 
The fully processed CEL protein with 16 VNTR repeats is detected by immunoblotting at 
around 100 kDa in pancreatic secretions (162). This differs from the molecular weight of 79 
kDa estimated in silico from the 16-repeat protein sequence. This discrepancy is mainly due to 
O-linked glycosylation of the C-terminus which contains multiple sites susceptible for mucin-
type O-glycosylation. According to in silico predictions, there are two or three theoretical sites 
(Ser or Thr) per repeat (163). Studies in BSSL, the milk counterpart of CEL, have found that 
the sugar content corresponds to Fuc, Gal, GlcNAc, GalNAc, and NeuAc in a molar ratio of 
1:3:2:1:0.3 (164). The high content of sialic acid, a negative charged sugar residue, contributes 





The CEL protein begins its journey at the rough ER where the protein is translated. While the 
nascent polypeptide is still emerging from the ribosome it receives an N-glycan with the 
structure Glc3Man9GlcNAc2 (165). As shown in Fig. 4, this N-glycosylation event marks the 
beginning of a series of steps where the glucose residues are trimmed or added back allowing 
the correct folding of the protein through the calnexin/calreticulin cycle (166,167). CEL 
continues to the Golgi apparatus where the N-glycan is further modified (160). Here mannose 
residues are trimmed off and the remaining core structure acquires extensions terminating in 
Fuc and NeuAc residues. In the Golgi apparatus, CEL also undergoes O-glycosylation of the 
VNTR domain initiated by Golgi-resident ppGalNAcTs (Fig. 3). Once fully N- and O-
glycosylated, CEL is phosphorylated at Thr340, which allows final translocation through the 
secretory pathway, followed by co-storage with other digestive enzymes in zymogen granules 
(168). 
 
1.5.4. CEL in human pancreatic diseases 
FAPP – an oncofetal protein form of CEL? 
The term oncofetal antigen refers to a substance which is produced by tumours and also by fetal 
tissues, but is absent or produced in much lower quantities in adult tissues. The term was first 
used by Gold and Freedman (169) in 1965 to refer to CEA, a cell surface glycoprotein of 180 
kDa that was overexpressed in 90% of gastrointestinal malignancies and with 50% of its mass 
being glycans (170). Soon after, the hepatic glycoprotein α-fetoprotein was also added to this 
category (171).  
 
To characterize tumour-associated antigens, earlier studies employed xenogeneic antisera. For this, 
an animal, typically a rabbit or a hamster, was immunized with fetal tissue extract or cancer cell 
protein extracts, and the antisera used for identifying oncofetal components by posterior 
immunodetection in diseased or fetal tissues. Using antisera against embryonic pancreas extracts 
to stain tissue sections of experimentally-induced pancreatic cancer (172) or human pancreatic 
cancers (173-175), Escribano et al. identified an acinar cell-derived molecule which was termed 
feto-acinar pancreatic protein (FAPP). Later, in the work by Mas et al. it was reported that 
FAPP seemed to have the same amino acid composition as the N-terminal globular domain of 
CEL (176) and they postulated that it was a CEL variant expressed in embryogenesis that 




in the C-terminus, it was claimed that a deletion of 330 bp in exon 11 of the CEL gene was 
associated with pancreatic cancer.  
 
Subsequently, several papers have been published where FAPP is considered an oncofetal form 
of CEL (177-179). The monoclonal antibody mAb16D10 was raised against CEL isolated from 
pancreatic juice of a PDAC patient and was reported to recognize specifically the oncofetal 
form of CEL (177). In SOJ-6 pancreatic cancer cells, mAb16D10 was found to target an antigen 
present on the plasma membrane (178), to inhibit the growth of tumour xenografts (178), and 
to induce cell death by the p53/caspase-dependent apoptotic pathway (177). In human 
pancreatic tissue sections, mAb16D10 was described to discriminate pancreatic cancer from 
non-neoplastic tissues and other cancers (179). Although 16D10 glycotope has been reported 
to be a CEL- and pancreatic cancer-specific glycan in several publications, its exact structure 
and whether it corresponds to one of the previously described tumour-associated glycan 
structures is still unknown. 
 
CEL gene variability in pancreatic cancer 
Two recent studies have reported that variants within the CEL VNTR may contribute to 
pancreatic cancer risk. Martinez et al. (180) claimed that the SNP rs488087 in the second VNTR 
repeat might serve as a predictive risk factor for pancreatic cancer as carriers of the T variant 
were overrepresented in a very small set of PDAC cases when compared to different sets of 
controls. Moreover, from the same group, another report suggested that single-base pair 
insertions of a cytosine in the VNTR sequence could be early events occurring during 
pancreatic tumorigenesis (147). This insertion shifts the reading frame and gives rise to a 
premature stop codon. The result is a slightly truncated protein that the authors propose might 
be useful for early detection of pancreatic cancer.  
 
The MODY8 syndrome 
In 2006, Ræder et al. reported that a single-base deletion in the first and fourth repeats of the 
CEL VNTR caused a syndrome of exocrine and endocrine pancreatic dysfunction (33). The 
disease was discovered in two Norwegian families and fulfilled the MODY criteria (see Section 
1.2.1 above). It was later denoted MODY8 or CEL-MODY (Online Mendelian Inheritance in 
Man Database # 609812). Both single-base deletions cause a shift in the reading frame and 




variants in Fig 8). The resulting protein contains a truncated COOH-terminus with considerably 
altered biochemical properties: the CEL-MODY COOH-terminal domain has a very high pI 
value due to an increase in positively charged Arg residues (19 compared to none in normal 
CEL). As a consequence, this value is shifted from 3.3 in normal CEL to 11.8 in CEL-MODY 
VNTR domain, and from 5.5 to 9.6 in the overall protein. Moreover, the C-terminal domain of 
CEL-MODY contains ten Cys residues whose reactive thiol groups can form covalent 
disulphide bridges (S-S bridges) upon oxidation. The mucinous properties of CEL-MODY are 
also expected to be altered as it contains a considerably reduced number of putative O-
glycosylation sites. Based on the glycosylation-predictor algorithm NetOGlyc 4.0 (163), there 





Figure 8. CEL protein variants, their VNTR length, pathogenicity and allele frequency in Northern 
Europeans. The stippled box represents the CEL globular domain encoded by exons 1-10. The normal 
VNTR segments are illustrated by blue boxes and the amino acids tailing the VNTR region are marked by a 
purple box. The most common VNTR variant has 16 repeats (REP16). One extremely short VNTR (REP3) 
and one very long (REP23) are shown below. INS9 is a normally occurring variant that contains an insertion 
in the 9th repeat introducing a premature stop codon. A change to red color represents that a frame shift has 
occurred due to a 1-bp deletion mutation in the first or fourth repeat (DEL1, DEL4), which are the two known 




encoded by a recombined allele with three VNTR segments originating from CELP (green). Figure published 
in (181). 
 
Functional studies by Johansson et al. and Xiao et al. have shown that CEL-MODY adheres to 
membranes, forms both intra- and extracellular aggregates and introduces ER stress in cell lines 
(162,182). However, there were discrepancies regarding to which extent the protein was 
secreted; in the Johansson et al. paper, the V5 epitope-tagged mutant protein was constitutively 
secreted from human embryonic kidney 293 (HEK293) cells, while Xiao et al. (182) found that 
the untagged protein exhibited impaired secretion from rat acinar cells. In the work by Torsvik 
et al. (183), it was demonstrated that CEL-MODY can be endocytosed by HEK293 cells, mouse 
acinar 266 cells and β-cell-like INS1 cells. Once taken up, the CEL protein seem to undergo 
lysosomal degradation in the studied cell models (183).  
 
The CEL-HYB allele in chronic pancreatitis 
CEL-HYB is a deletion allele and therefore a copy number variant (CNV) of CEL that involves 
the neighbouring CELP gene (Fig. 9). CEL-HYB was most likely formed by a fusion between 
the proximal part of CEL and the distal part of the pseudogene, resulting in a “hybrid” allele.  
 
Figure 9. CNVs of the human CEL gene. A, structure of the CEL locus. The missing region (exon 2–exon 
7) in CELP is marked in grey in the CEL gene. B, proposed mechanism generating CEL-HYB by non-allelic 
homologous recombination between CEL and CELP. The cross symbolizes a crossover event in the exon 10–





In 2015, Fjeld et al. reported that CEL-HYB represents a novel genetic risk factor for chronic 
pancreatitis (184). In a discovery cohort consisting of 71 German familial chronic pancreatitis 
cases, CEL-HYB was significantly overrepresented among individuals compared to healthy 
controls (OR = 15.5). This association was replicated in three independent non-alcoholic CP 
cohorts from France and Germany (n = 1122 cases, OR = 5.2). In an alcoholic CP cohort of 853 
cases, there was a smaller, but still significant overrepresentation of the CEL-HYB allele (OR = 
2.3).  
 
The CEL-HYB allele encodes a chimeric CEL protein consisting of the globular domain derived 
from CEL and a COOH-terminal VNTR domain originating from CELP. The VNTR domain 
is shorter, consisting only of 31 amino acids that are arranged in 3 amino acid segments (see 
HYB in Fig. 8) and the total predicted molecular weight of the protein is 65 kDa. When 
functional consequences of CEL-HYB were investigated in HEK293 cells, retention of the 
protein along the secretory pathway and poor secretion were observed compared to the wild 
type protein, (184). Moreover, the enzymatic activity of the secreted CEL-HYB fusion protein 
was reduced to around 40% of the normal CEL protein’s activity. Intracellular retention was 
confirmed by cycloheximide treatment, and an increase of the autophagosomal marker LC3-II 
suggested that autophagy could be involved in the disease mechanism. Notably, CEL-HYB 
represents a novel type of CP genetic risk factor as it is not implicated in the well-known trypsin 
pathway that most CP risk genes are part of. 
 
In an attempt to replicate the CEL-HYB association in Asian populations, Zou et al. (185) 
carried out a study using CP patient cohorts from China, Japan and India. They failed to detect 
the CEL-HYB allele in any of the cohorts. Quite surprisingly, though, they discovered a different 
CEL-HYB allele that contained a premature stop-codon in exon 10. This allele was named CEL-
HYB2 and was not associated with increased CP risk, most likely because it resulted in very 









2. Aim of the thesis 
The general aim of this thesis was to obtain new knowledge about carboxyl-ester lipase and its 
involvement in human pancreatic diseases. The focus of the work was on genetic variants, 
glycan patterns and ABO blood groups. Specific aims were as follows: 
1) To examine whether CEL VNTR length polymorphisms and copy number variants are 
associated with PDAC risk (Paper I).  
 
2) To investigate whether common variants of the ABO blood group gene confer susceptibility 
to PDAC in a Norwegian patient cohort (Paper II).  
 
3) To elucidate whether glycosylated CEL might be linked to pancreatic cancer and ABO blood 
groups by examining CEL expression in PDAC tissues, revealing the nature of the 16D10 
glycan structure, and identifying O-linked glycans in the mucinous tail region of CEL (Paper 
III). 
 
4) To determine the glycosylation patterns of pathogenic CEL protein variants expressed in 









3. Summary of results 
Paper I: Copy number variants and VNTR length polymorphisms of the carboxyl-ester lipase 
(CEL) gene as risk factors in pancreatic cancer. 
In Paper I, we examined whether CEL CNVs and VNTR length polymorphisms affect the risk 
for developing pancreatic cancer. CEL CNVs (i.e. duplications and deletions) as well as VNTR 
lengths were genotyped in 197 Norwegian and 265 German patients diagnosed with pancreatic 
adenocarcinoma, and in 882 healthy blood donor controls from the same populations. A 
German family with non-alcoholic chronic pancreatitis and pancreatic cancer was also 
examined. CNV screening was performed using PCR assays followed by agarose gel 
electrophoresis, whereas VNTR lengths were determined by DNA fragment analysis and 
capillary electrophoresis. The investigated family was CEL-HYB-positive. However, an 
association of CEL-HYB or a duplication CEL allele with pancreatic cancer was not seen in the 
two patient cohorts examined. The frequency of the 23-repeat VNTR allele was borderline 
significant in Norwegian cases when compared with controls (1.2% vs. 0.3%; p = 0.05). For all 
other VNTR lengths, no statistically significant difference in frequency was observed. 
Moreover, no association with pancreatic cancer was detected when CEL VNTR lengths were 
pooled into groups of short, normal or long alleles. Thus, we were not able to reveal any 
association between pancreatic cancer and CEL CNVs or CEL VNTR lengths. Nevertheless, 
an effect of very short or long VNTR lengths cannot be ruled out and analyses in larger 
materials or in other ethnicities are recommended. 
 
Paper II: Associations between ABO blood groups and pancreatic ductal adenocarcinoma: 
Influence on resection status and survival. 
Here we investigated the relationship between ABO blood group status and pancreatic ductal 
adenocarcinoma (PDAC) in a patient cohort from Western Norway (n = 237) and two control 
materials (healthy blood donors, n = 379; unselected hospitalized patients, n = 6149). When 
analyzing phenotypes, blood group A was overrepresented among PDAC cases compared to 
blood donor controls (50.8% vs. 40.6%; OR = 1.51, p = 0.021). This enrichment could be 
explained by the A1 subgroup distribution as only the A1 allele (and not A2) was found to be 
associated with significantly higher risk for PDAC (23.8% vs. 17.9%; OR = 1.43, p = 0.018). 




lower in cases than in blood donors (33.8% vs. 42.7%; OR = 0.69, p = 0.039); this association 
was also seen when the hospitalized patients group was used for comparison (33.8% vs. 42.9%; 
OR = 0.68, p = 0.012). Results for blood group B were affected by the type of controls selected 
for statistical comparison. When PDAC patients were divided according to being resected or 
not, the enrichment of blood group A was most prominent among unresected cases (54.0%), 
who also had the lowest prevalence of O (28.7%). There was a statistically significant better 
survival (p = 0.04) for blood group O cases than non-O cases among unresected but not among 
resected patients. The ABO antigens secretor status, assessed by FUT2 genotyping, did not 
show an association with PDAC risk in any of the performed comparisons. Thus, we have 
demonstrated that pancreatic cancer risk is influenced by ABO status in Norwegian patients 
and, interestingly, that this association might reflect in tumour resectability and survival.  
 
Paper III: The mucinous domain of pancreatic carboxyl-ester lipase (CEL) contains core 
1/core 2 O-glycans that can be modified by ABO blood group determinants. 
CEL has been linked to pancreatic cancer through a postulated oncofetal CEL variant termed 
feto-acinar pancreatic protein (FAPP). This molecule contains a presumably unique glycan 
structure, 16D10, which is recognized by the monoclonal antibody mAb16D10. However, in 
this work, we found that CEL was not detectably expressed in neoplastic cells, implying that 
FAPP is unlikely to be a glyco-isoform of CEL in pancreatic cancer. To investigate whether the 
16D10 antigen was an already known cancer-related carbohydrate antigen, we combined 
characterization by glycan-arrays with matrix-assisted lased-desorption ionization time of flight 
mass-spectrometry (MALDI-TOF MS) analyses. The mAb16D10 antibody recognized 
structures containing terminal GalNAc-α1,3(Fuc-α1,2)Gal (= blood group A antigen) and also 
repeated protein sequences containing GalNAc residues linked to Ser/Thr (= Tn antigen). These 
findings were supported by immunostainings of human normal and cancerous pancreatic tissue. 
Further, we used MALDI-TOF mass spectrometry to characterize the released O-glycan pool 
from isolated CEL from human pancreatic juice. We found that the O-glycome of CEL 
consisted mainly of core 1/2 structures with a composition depending on FUT2 and ABO gene 
polymorphisms. When pancreatic juice samples were immunoblotted with anti-Tn antibody, 
very low levels of Tn antigen were detected at protein bands corresponding to CEL. Moreover, 
mAb16D10 and anti-A antibodies gave identical immunoblotting patterns suggesting that in 
pancreatic juice the so-called 16D10 structure corresponds to the A-antigen itself. We conclude 




by the pancreas. This supports the view that CEL could serve biological functions 
complementary to its cholesteryl esterase activity in the duodenum. 
 
Paper IV: Altered O- and N-linked glycosylation profiles in carboxyl ester lipase (CEL) protein 
variants involved in MODY8 syndrome and chronic pancreatitis. 
The aim of this paper was to test whether glycan patterns of the two known pathogenic CEL 
variants (CEL-HYB, CEL-MODY) would differ from that of the normal CEL protein. To this 
end, we expressed various CEL constructs in HEK293 cells and determined their O- and N-
glycosylation patterns by high-sensitivity MALDI-TOF mass spectrometry. O-glycans attached 
to the normal CEL protein were found, in almost equal proportions, to be core 1 or core 2 
structures terminating with sialic acid but lacking fucose residues. In contrast, over 90% of the 
O-glycans in CEL-MODY and CEL-HYB were core 1 capped with one or two sialic acids. The 
N-glycosylation site at N210 carried a mono-sialylated, core-fucosylated bi-antennary structure 
in normal CEL and CEL-MODY, but contained high levels of fucosylated LacNAc motifs 
(GalNAc-GlcNAc) in CEL-HYB. In the latter, also the level of unprocessed high mannose 
structures was increased. When N-glycosylation was disabled by genetically ablating the N210 
N-glycosylation site, changes in the subcellular distribution of the CEL variants were noted, 
indicating that this protein-modification is crucial for correct protein folding, processing and 
secretion. In conclusion, we observed substantial changes in glycosylation when modelling the 
two known pathogenic CEL variants in HEK293 cells. To which degree these CEL alterations 
occur in human acinar tissue and whether they are involved in the initiation/progression of the 











4. General discussion  
4.1. Patient and control selection for association studies 
The pancreatic cancer cases from Haukeland University Hospital included in Paper I and Paper 
II were carefully selected to fulfil diagnostic criteria for PDAC. Histology sections and 
pathology reports were reviewed by two pathologists. A surgeon collected additional 
information (i.e. radiology reports, survival data) from the patients’ clinical records. In Paper I, 
197 Norwegian cases were analysed, of which 156 had a diagnosis of PDAC and 41 were 
other/unspecified adenocarcinomas anatomically located to the pancreas. This cohort was also 
studied in Paper II. However, to enlarge the study population we then added a collection of 39 
PDAC cases and one other pancreatic adenocarcinoma, for which only formalin-fixed paraffin-
embedded samples were available. This cohort had previously been characterized by Immervoll 
et al. (186). As many cases that are referred to as “pancreatic cancer” in the literature are not 
necessarily of the classical PDAC type, we decided to perform the initial allele frequency 
analysis of Paper II both for all adenocarcinomas and for the cohort of verified PDAC cases 
alone. Although our PDAC case number in Paper II is relatively small (n = 195), we consider 
it a strength that this cohort is very well classified with regard to diagnosis. 
 
We used two control groups, one of 379 blood donors used in both Paper I and II, and another 
which consisted of 6149 patients admitted Haukeland University Hospital and serotyped during 
a randomly chosen period of six months. The reason for choosing an additional control group 
for the ABO study was that there could be a bias in ABO blood group distribution among the 
healthy donors because blood groups is known to associate with some diseases (187). Another 
point of concern could be that persons with some specific blood types might be more preferred 
as donors than others. A third problem might be that there are considerable geographical 
variations in ABO frequencies, reflecting human migration movements and possibly also 
selection pressures from the environment (188,189). Also within Norway, the ABO blood type 
distribution differs according to geographical localization with the highest blood group O 
frequency observed in the Western part of the country and the highest B frequency in the 
northernmost region (190). Blood donors were typically 30 years younger than our patients 
(Paper II, Table 1), and might be expected to have a wider geographical distribution with regard 
to origin. The frequency of blood group O was almost identical in the two control groups (42.7 
% and 42.9 %), but blood group A and B frequencies varied considerably (A: 40.6 % and 45.8 




to people with blood group A more frequently being admitted to hospital than blood group B 
individuals, whether they have conditions were blood typing is more often needed or whether 
it reflects a difference in ethnicity of the two control groups, we do not know. 
 
4.2. CEL VNTR length polymorphisms in pancreatic disease  
Noteworthy, only mammalian CEL genes contain the VNTR region as it is absent in lower 
invertebrates such as fish, reptiles, birds and amphibians (191,192). In mouse and rat, there are 
3-4 repeats (192,193), whereas primates generally contain higher repeat numbers (e.g. 39 in 
gorilla; see refs. (149,192)). The by far most common allele of the human CEL gene contains 
16 repeats (see e.g. Paper I). How the repetitive tail of CEL evolved in mammals is not known. 
It would be interesting to understand why the tail region expanded in primates and why 16 
repeats might be the “optimal” number in humans. We speculate that this new addition to the 
CEL protein brings along beneficial properties such as better solubility, increased stability 
and/or enhanced protein secretion. There is also a possibility that the VNTR region confers 
CEL with advantageous features not related to its role in duodenal hydrolysis of lipids (See 
Discussion in Paper III). On the other hand, the VNTR did not develop without a cost. A typical 
sequence of the repeated 33-bp region is GGGGCCCCCCCCGTGCCGCCCACGGG-
TGACTCC. The many consecutive guanine and cytosine bases represent a challenge during 
DNA replication as insertion/deletion mutations tend to arise in such homopolymeric stretches 
(194). Thus, the MODY8 syndrome mutations are deletions of one base pair within or adjacent 
to homopolymeric tracts (33). 
 
Due to its polymorphic nature, high GC-content and considerable length variation, sequencing 
of the VNTR-containing exon 11 of CEL is inherently difficult. To capture the full range of 
variation in this region, DNA sequencing is not sufficient and specific assays such as that 
developed by Torsvik et al. (145) are necessary to perform. This screening method, which 
consists of a PCR followed by DNA fragment analysis by capillary electrophoresis, was used 
in Paper I to determine CEL VNTR length. We found no association between VNTR length 
and pancreatic cancer, although an effect from rare alleles could not be excluded and needs to 





Several other studies have linked CEL VNTR length to disease susceptibility. Miyasaka et al. 
(195) reported an association between CEL VNTR length and alcohol-induced pancreatitis in a 
Japanese patient cohort. This association, however, was not replicated when German cohorts 
of idiopathic and alcohol-induced pancreatitis were examined (146). A larger and independent 
study of German and British patients also failed to replicate the findings of Miyasaka et al. but 
did, on the other hand, observe an association between CEL VNTR length and liver cirrhosis 
(196). 
 
Moreover, a Swedish group (197) reported an association between VNTR length and serum 
cholesterol profile: carriers of at least one allele with fewer than the common 16 repeats had 
significantly lower cholesterol levels compared to individuals carrying two normal alleles. A 
study from the Netherlands, reported that VNTR length polymorphisms are associated with 
HIV-1 disease progression (198). Heterozygous individuals carrying one short allele (< than 16 
repeats) were found to have accelerated disease progression compared to subjects with two 
normal or longer alleles (≥ 16 repeats). In conclusion, relatively few studies of associations 
between the highly polymorphic CEL VNTR region and human disease have been performed. 
Although some interesting associations were observed, additional investigations are necessary 
for verification and for further exploring the role of VNTR-length variation. 
 
4.3. CEL CNVs in pancreatic disease  
Copy number variation refers to a type of structural genetic variants where a substantial number 
of base pairs are deleted or duplicated. For the CEL gene, both deletions and duplications are 
known (184,199). However, due to the intrinsic analytical problems regarding the VNTR region 
(see previous section) and the presence of the neighbouring pseudogene CELP, CNVs of CEL 
are not straightforward to identify using high-throughput assays such as GWAS, whole-exome 
sequencing or whole-genome sequencing (184).  
 
In Paper I, we investigated the association of CEL CNVs with pancreatic cancer using a targeted 
approach. We screened for one deletion (CEL-HYB) and one duplication (CEL-DUP) variant. 
CP is a well-established risk factor for pancreatic cancer (200); the discovery of CEL-HYB as a 
CEL allele that is associated with CP therefore motivated us to explore whether CEL CNVs 




the finding of CEL-HYB carriers in a pedigree with a history of both CP and pancreatic cancer. 
Nevertheless, we found no association of this CEL variant with pancreatic cancer.  However, 
this may not be surprising as there are previous examples where CP genetic risk factors such as 
CFTR, SPINK, CTRC and PRSS1 mutations did not associate with increased pancreatic cancer 
risk (201). In addition, the population carrier frequency of CEL-HYB is low, typically less than 
1% (184), so that much larger cohorts than ours would be needed if the effect was moderate. 
 
After Paper I was published, a report from Shindo et al. also examined CEL-HYB in pancreatic 
cancer (202). The evaluated patient cohort consisted of 850 Americans, of whom 52 were of 
African descent. At a first glance, their negative result seemed well in line with ours. However, 
the screening strategy of Shindo et al. was probably suboptimal as next-generation sequencing 
was employed for screening. This most likely implies that a certain number of false positives 
is expected, which is supported by the relatively high frequency of CEL-HYB carriers (2.6% in 
cases, 1.8% in controls). It is therefore needed to stress the importance of a targeted approach 
when studying CEL genetic diversity. Moreover, when a CEL-HYB allele is detected, it should 
always be verified by Sanger sequencing (184).  
 
Intriguingly, there may exist ethnic-specific variants of CEL-HYB. Zou et al. (185), when 
attempting to replicate the association between CEL-HYB and chronic pancreatitis in patient 
cohorts from China, Japan and India, failed to identify any CEL-HYB allele carriers. 
Surprisingly, a different CEL-HYB allele that exhibited a premature stop-codon in exon 10, was 
detected. This variant was named CEL-HYB2 and did not associate with chronic pancreatitis 
risk. Based on these findings, it seems that CEL-HYB is an ethnic-specific risk allele since it is 
present in Caucasian populations but not in Asian subjects. Whether CEL-HYB is present in 
other non-Caucasians and, if so, whether it is associated with increased risk for chronic 
pancreatitis, remains to be investigated.  
 
In Paper I, we also investigated a CEL duplication allele (CEL-DUP; (184)) with regard to 
pancreatic cancer risk, again with no significant findings. A limitation to the screening method 
employed is that it fails to detect duplicated VNTRs of the same length, meaning that a fraction 
of the “heterozygous samples” (e.g. subjects with VNTR lengths of 15/16) could in fact 
correspond to CEL-DUP carriers with VNTR lengths of 15/16/16 or 15/15/16. Interestingly, 
some samples that had a read-out of three different values when assayed for VNTR lengths (e.g. 




duplication alleles must exist. In fact, a novel duplication allele has recently been discovered in 
our group (199). In contrast to the duplication allele that we first identified (now denoted CEL-
DUP1), the newly characterized allele (designated CEL-DUP2) contains two complete CEL 
genes which both may give rise to a translated protein. Whether this results in higher levels of 
CEL protein (e.g. in the duodenum, mother’s milk or blood) and whether there are any 
biological consequences at all of CEL-DUP2, remains to be investigated. Fjeld et al. also 
studied CEL-DUP2 in the context of chronic pancreatitis. The allele frequency was 
considerably higher in the Chinese than in the French and German materials examined (199). 
Nevertheless, in none of the cohorts an association was seen with chronic pancreatitis.  
 
4.4. Other variants of the CEL gene in pancreatic cancer 
One study by Martinez et al. (180) has reported an association between a single-nucleotide 
polymorphism in CEL and pancreatic cancer. The authors suggested that C/T at rs488087 in 
the second VNTR repeat could be a useful marker for defining a population at risk for 
developing pancreatic cancer as the presented an odds ratio of 4.7 for the T-allele. However, 
there is a fundamental drawback in this study: an extremely small cohort of pancreatic cancer 
patients was examined (n = 36); of which 6 cases in fact had a non-PDAC tumour. Moreover, 
when analysing a small cohort of Norwegian patients (n = 50, of which 31 were PDAC cases 
and 19 had benign tumours or other pancreatic disease), we found exactly the same T-allele 
frequency (0.31) as generally seen in European population (203). 
 
In another study by Martinez et al. (147), it was claimed that a one-bp insertion in the poly-C 
tract of the CEL VNTR sequence is associated with pancreatic cancer. In human germline DNA, 
such insertions are commonly seen as 7 of 50 screened samples were positive (203) (see also 
(33)). The insertions give rise to a premature stop-codon that results in a truncated protein (203). 
Unfortunately, the patient cohort analysed by Martinez et al. was again extremely small (n = 
32) and it appears unclear whether the authors refer to germline or somatic insertions variants. 
The authors present some convincing data with regard to the production of antibodies that are 
specific for detecting CEL insertion variants at the protein level (147). However, they claim 
that these antibodies also are positive in pre-neoplastic lesions of the pancreas. In the work 
carried out in Paper III of this thesis, PanINs as well as malignant infiltrating ducts were 




Therefore, the results presented in (147) seem somewhat conflicting with ours in terms of CEL 
expression. 
 
In a recent study, germline mutations within exons 1-10 in the CEL gene have been identified 
in pancreatic cancer patients. In their patient cohort (n = 1579), Tamura et al. (204) described 
16 missense mutations in the carboxypeptidase genes CPA1 and CPB1 predicted to cause ER-
stress as associated with pancreatic cancer risk. No statistical significance was, however, seen 
with regard to mutations in CEL. 
 
4.5. Is there an oncofetal variant of CEL? 
In Paper III, contrarily to the work of Benköel et al. (179), we did not find evidence that the 
CEL protein is expressed in PDAC cells. In fact, expression was not detectable at the very early 
event of acinar-to-ductal metaplasia. Based on the reactivity of the antibodies mAbJ28 and 
mAb16D10, which recognize glycan structures presumably located in the mucinous domain of 
CEL, an oncofetal CEL variant has been suggested to exist and denoted FAPP (179). By testing 
the mAb16D10 antibody in a glycan microarray we demonstrated that it recognized structures 
containing the blood group A antigen as well as repeated protein sequences containing GalNAc 
residues linked to serine/threonine (Tn antigen). We did not see a strong Tn band coinciding 
with CEL on immunoblots (Figure 8 in Paper III). We therefore believe that, when CEL isolated 
from pancreatic juice was used to produce monoclonal antibodies (178), a blood group A 
individual may have been selected and that the reactivity of the mAb16D10 antibody then was 
directed against the blood group A antigen decorating the CEL protein. The findings of Paper 
III were supported by immunostainings of human pancreatic tissue where anti-A antibodies 
displayed the same pattern as mAb16D10 in normal or cancerous human pancreatic tissues.  
 
In the study by Pasqualini et al. (205), the postulated FAPP was cloned from SOJ-6 cells, and 
the sequence was reported to contain only six VNTR repeats followed by the normal 
KEAQMPAVIRF sequence. In light of CEL being a very polymorphic gene due to the VNTR 
region (Paper I) and knowing the complexity of glycosylation of CEL and its variants (Papers 
III and IV), we think it is very unlikely that SOJ-6 cells (and other pancreatic cancer cells) 
contain a specifically glycosylated CEL form with a cancer-specific number of VNTR repeats. 




repeats or that it mutated to this repeat number due to the genetic instability of cancer cells. The 
large majority of pancreatic exocrine cancers exhibits ductal differentiation and are negative 
for acinar markers. Acinar carcinoma, a very rare subtype of pancreatic cancer, is the only 
malignant neoplasms where CEL expression would be expected to be present (206). 
 
From this and the previous sections, it is clear that CEL has been studied in the context of 
pancreatic cancer in a number of different ways. The work presented here as Paper III makes it 
unlikely that CEL is expressed in PDAC neoplastic cells, and our data therefore seriously 
question the existence of the postulated oncofetal variant FAPP. Taken together, CEL has so 
far not been convincingly linked to pancreatic cancer risk or progression in any study, neither 
at the genetic nor at the protein level. 
 
4.6.  Glycosylation studies of CEL 
4.6.1. Glycosylation of native CEL derived from PDAC patients 
In Paper III, the O-glycan profile of CEL was characterized using an MS approach. The protein 
was purified from pancreatic juice of patients who had been operated for PDAC. The isolated 
protein could not have stemmed from cancer cells as we found that only the preserved acinar 
tissue within the morphologically normal-looking pancreatic parenchyma was positive for CEL 
expression. Notably, the O-glycome of native CEL presented in Paper III varied in composition 
according to both ABO and FUT2 gene polymorphisms. No classical tumour associated 
antigens such as sLewx or sLewa (CA19.9) were detected, which may support that the protein 
stemmed from preserved and functionally secreting acini. Moreover, we did not detect the Tn 
antigen (a structure that results from the truncation of O-glycans to the first monosaccharide 
only), neither as a molecular ion at m/z 330, nor in immunoblots of isolated CEL protein. 
However, relatively high levels of sT antigen were seen, but only in the non-secretor sample. 
These changes in glycosylation among individuals of different ABO/FUT2 gene makeup reflect 
an additional level of complexity with regard to CEL protein variability. Whether these 
differences could accompany a variation in susceptibility risks for certain diseases represents a 
very interesting question. 
 
The N-glycans of pancreatic CEL are not presented in this thesis. However, our preliminary 




antennary complex type with fucose and sialic acid substitutions involving ABH and Lewis 
blood type terminal moieties. These observations are well in line with previous work on 
pancreatic CEL (160,207) as well as mother’s milk BSSL (208).  
 
 
4.6.2. Glycosylation studies on recombinant CEL 
DNA, RNA or proteins are linear macromolecules that are synthesized by following template 
structures, and in a similar manner in different cell types. In contrast, glycosylation is a 
dynamic, not template-driven and strongly cell type-specific process that lead to a 
heterogeneous pool of branched or linear structures. A group of specific enzymes acts in a 
sequential manner to build or modify glycans that are generally present in a heterogeneous pool 
of structures. The same protein expressed in two different cell types can often be modified 
differently (209-211). Thus, an appropriate selection of cellular model system is pivotal in any 
glycosylation study.  
 
Although not so widely used as mammalian cells, yeast cells and insect-derived cells have also 
been exploited with regard to their N- and O-glycosylation capabilities. In the study of Trimble 
et al. (212), CEL was expressed in the yeast Pichia pastoris. Not only the N-glycosylation site 
at N210 of CEL was occupied by high mannose structures, which is the common type of 
glycosylation in yeast cells, but also the O-linked glycans at the mucinous domain. To avoid 
this type of structures, which  often can be antigenic, human recombinant glycoproteins (e.g. 
for therapeutic purposes) are preferably produced in mammalian cells (213). Landberg et al. 
(208) compared the O-glycan pattern of native human mammary CEL (i.e. BSSL) to 
recombinant CEL expressed in CHO cells, the most commonly employed cell line for 
expressing mammalian glycoproteins. The differences found between the two species of CEL 
were considerable: native milk CEL contained predominantly large O-linked oligosaccharides, 
whereas the recombinant form was composed mostly by short O-glycans with a high content 
of sialic acid. This finding could be reflecting the inability of CHO cells to produce core 2-
based O-glycan structures (214,215).  
 
Host selection does not only affect the glycosylation profile, but also the glycosylation site 
density (210). Consequently, the number of O-glycans attached to native milk CEL estimated 




recombinant form produced in CHO cells (between 11 and 16) (208). In another report, Mas et 
al. suggested that pancreatic CEL contained 12-14 O-linked glycans (216). The number of 
glycosylation sites in CEL will also depend on the number of repeated segments in the 
mucinous domain, a fact not so often taken into account when studying the protein. 
 
Glycosylation of recombinant CEL-MODY and CEL-HYB 
In Paper IV, glycosylation of the pathogenic variants of CEL-MODY and CEL-HYB was 
examined using HEK293 cells as expression system. With regard to O-linked glycans there 
were differences between the CEL-WT protein compared to CEL-MODY and CEL-HYB. It 
has been speculated that the O-glycosylation machinery recognizes the peptide sequence PVPP 
as consensus motif in CEL (164). The synthesis of core 2-based structures was very low or 
absent for both pathogenic variants, while nearly half of the CEL-WT O-glycans were core 2-
based. Intriguingly, CEL-HYB seemed to be devoid of O-glycans although this finding needs 
to be verified, for instance, by a glycoproteomics approach or, if possible, by analysing native 
CEL-HYB protein from carriers of the allele. 
 
The lack of core-2 structures in CEL-MODY glycosylation could be due to the altered peptide 
backbone biochemical properties, i.e. the high amount of positively charged amino acids and 
Cys residues, disrupting the glycosyl-transferase-substrate recognition. Whether the lack of 
proper glycosylation is inducing or contributing to the observed ER stress (182) or other 
negative intracellular effects, or if the altered glycan pattern is the consequence of the abnormal 
behavior of the CEL-MODY protein, e. g. by inducing certain glycosyl-transferases such as 
sialyl-transferases (217), remains to be investigated. Moreover, whether glycosylation of 
normal CEL (in heterozygous individuals) or other secretory or cell-surface glycoproteins also 
is affected, is an important question to address.  
 
In the analyses of native pancreatic CEL (Paper III), we did observe fucose residues involved 
in Lewis and ABO blood group terminal epitopes. However, when analysing O-glycans of 
recombinant CEL (Paper IV), both core 1- and core 2-based structures were devoid of fucose 
residues and H antigens were not detected, although ABO and FUT2 genotyping of the HEK293 
cells showed that they are derived from a blood group O and a secretor-positive individual. This 
illustrates that glycosylation patterns obtained from cellular models may not always reflect the 





The N-glycan pattern of CEL-WT presented in Paper IV, is consistent with reports from others 
on HEK293 cells with regard to the presence of GalNAc-β-1,4GlcNAc structures (LacdiNAc) 
(210,218) and of core-fucosylation (219) in mainly bi-antennary complex structures. While 
CEL-MODY displayed an N-glycan profile similar to that of CEL-WT, the pattern of CEL-
HYB was strikingly different. The higher proportion found of oligo- and high-mannose 
structures could be due to incomplete trimming of the high-mannose glycans, and may reflect 
a defect in the maturation process of N-glycans. N-glycans are known to be crucial for correct 
protein folding of glycoproteins (107). In line with this, we observed abnormal CEL-WT/Q210 
protein distribution in the cells (Paper IV, Fig. 5). Using the rat acinar cells AR42-J cells, 
Abuakil et al. (160) showed that tunicamycin treatment, which inhibits the first step of N-glycan 
synthesis, leads to a misfolded CEL protein with a dramatic decrease in catalytic activity. 
Moreover, in the recent report by Dewal et al. (220) it was shown that N-glycan architecture is 
altered upon chemical induction of unfolded-protein response (UPR). Whether the changes in 
glycosylation seen in CEL-HYB reflect intracellular stress responses to a misfolded CEL-HYB 
protein requires further investigations.  
 
4.7. The ABO gene as a risk factor in pancreatic cancer 
The association between ABO blood group and PDAC risk was first reported in 1960 (221), 
with nearly consistent results in the many studies published since then (for some recent 
examples, see (67,222-224)). In Paper II, we examined this association in the Norwegian 
population for the first time (as far as we know). We included the novel aspect of looking into 
also tumour resectability and survival. We confirmed that the O blood group confers a lower 
risk for PDAC, as compared with the non-O phenotype. Despite the many published risk 
studies, the influence of ABO status in cancer prognosis has not been examined extensively. In 
Paper II we found, in the group of unresected cases, that patients with blood group O survived 
longer than non-O patients (median 6.7 vs. 5.5 months, respectively; p = 0.04). In line with our 
results, Ben et al. (225) found that blood group O subjects had better outcome that those with 
non-O blood group. However, there is a contrary report, by Rahbani et al. (226), where the 
authors observed no statistically significant associations between ABO blood group and PDAC 
survival. Although the influence of blood groups in PDAC risk is widely accepted, additional, 




common ABO genetic polymorphisms in aggressiveness of the disease, as reflected in 
resectability and survival. In further studies, care should be taken to obtain a correct 
classification of the PDAC cases, as the term “pancreatic cancer” in many reports may involve 
cancers originating from the duodenum or bile duct (227) or even endocrine tumours (180). 
 
In Paper II, we also examined the FUT2 gene variants controlling the ABH blood group secretor 
status in relation to PDAC risk. FUT2/secretor status seems to affect the composition of the 
intestinal microbiota (228) and the susceptibility to certain gastrointestinal infections (229). 
Nevertheless, we did not observe a difference in FUT2 allele distribution or phenotype among 
pancreatic cancer cases and controls, similar to what a previous report showed (138). 
 
4.7.1. Possible mechanisms behind the ABO and pancreatic cancer link 
There is no doubt that ABO locus variability influences PDAC risk. However, the exact 
underlying mechanism by which ABO variants interplay with cancer development has not been 
fully delineated. Molecular mimicry of host glycans by cancer cells and immune system escape 
is likely to be involved. Upon malignant transformation, truncation of O-linked glycans to small 
un-extended Tn, or core 1 structure (T antigen) is well documented, especially in mucins 
(230,231). The structural resemblance of Tn (GalNAc-α) and T (Gal β-1,3GalNAc-α) with the 
A and B antigens i.e. displaying terminal GalNAc and Gal residues, respectively, could explain 
the cross-reactivity of naturally occurring anti-A and anti-B antibodies towards such cancer-
associated structures. 
 
Having this idea as hypothesis, Hoffman et al. (232) showed that sera from healthy blood group 
O individuals (which contain naturally occurring anti-A and anti-B antibodies), could recognize 
Tn and T cancer-associated antigens, apart from the A and B antigens. If extensive protein 
stretches displaying Tn and T antigens, such as seen in cell surface mucins, mimic blood group 
antigens on epithelial cells of persons of blood group A and B, it is conceivable that cancer cells 
bearing these antigens more likely would escape the immune system.  
 
Moreover, ABO blood group-containing glycans can modulate the interaction between host and 
intestinal microbiota by serving as receptors for microorganisms, parasites, and viruses. This is 
the case of Helicobacter pylori which uses Lewis b and blood group O (H) antigens as receptors 




the gastrointestinal microbiota is becoming a topic receiving increasing attention. Although no 
bacterium has been directly linked to PDAC, it cannot be excluded that yet unidentified 


































5. Concluding remarks 
 
The extremely polymorphic nature of CEL represents a challenge in genetic studies. In addition 
to the various SNPs located throughout the gene, CEL contains a VNTR region that varies from 
3 to 23 repeats. Within the VNTR, there are single-base insertions and deletions that alter the 
reading frame. Moreover, the presence of an adjacent pseudogene increases the genetic 
diversity even further, as it predisposes for formation of duplications and deletions involving 
the whole CEL-CELP locus. In this thesis, CEL VNTR length and two CEL CNVs were 
examined as potential genetic risk factors for PDAC (Paper I). No associations were revealed. 
Nevertheless, due to the considerable genetic variability of CEL it is still too early to exclude 
entirely that this gene may influence pancreatic cancer risk. 
 
In contrast, ABO blood group status is a well-established risk factor in pancreatic cancer. We 
replicated this association in the Norwegian population as we found that both the blood group 
O allele and the O phenotype was somewhat protective for PDAC and that it also may influence 
survival (Paper II). Whether naturally occurring antibodies that vary between blood types, 
contribute to immune protection towards cancer cells by recognizing some tumour-associated 
carbohydrate antigens, is a very interesting hypothesis that needs to be addressed as a potential 
PDAC risk modifier. 
 
The VNTR region is an intriguing add-on to the CEL enzyme. The variety of genetic events 
that alter this region, including some that have been linked to human diseases, suggest that the 
repetitive C-terminal domain of CEL is relevant for proper functionality of the enzyme. In Paper 
III, we demonstrated that CEL O-glycans are composed mainly of core 1/core 2 structures with 
terminal substitutions that depend on the individual’s ABO/FUT2 genetic makeup. Thus, the 
combination of extensive genetic variations in the VNTR and a large number of covalently-
coupled carbohydrate branches on the VNTR-encoded protein tail, represents a tremendously 
large source of CEL protein diversity. Since it is well known that ABO and FUT2 status confer 
protection/susceptibility to some human disorders, the question of whether specific VNTR 
lengths in concert with ABO and FUT2 phenotype can be linked to disease is interesting. 
Moreover, given the very polymorphic nature of the CEL gene, it is plausible that new and still 





When expressing CEL proteins in HEK293 cells (Paper IV) we observed substantial structural 
changes in glycosylation of the pathogenic CEL-MODY and CEL-HYB variants. Whether 
similar glycosylation profiles are present in CEL originating from the pancreatic acinar cells of 
CEL-MODY and CEL-HYB allele carriers, remains to be investigated. If present, these 
alterations may play a role in explaining why the pathogenic CEL variants predispose for 
pancreatic disease. Alternatively, the changed glycan profiles may themselves have no 








6. Future perspectives 
 
The presence of a large and varying set of glycan molecules in the CEL VNTR opens up new 
possibilities for the roles of this protein, in addition to being a cholesterol esterase in the 
duodenum. Adhesive properties of the mucinous domain could potentially confer protection 
against pathogenic viruses or bacteria in the gut and in mother’s milk (198,234). Whether 
changes in glycosylation status, characteristic for certain CEL alleles, could be compromising 
this or other yet uncharacterized functionalities of the CEL glycoprotein remains to be 
investigated. 
 
The role of the mucinous C-terminal tail of CEL is still enigmatic. As this domain is not needed 
for enzymatic activity (235,236), it is remarkable that the CEL-HYB protein with only three 
repeated segments shows a clearly reduced activity in comparison to a variant with no repeats 
(CEL-TRUNC) (162,184). The latter had an activity similar to CEL-WT when tested in vitro 
(162). Thus, it seems that having no VNTR repeats is less deleterious than having the tail of 
CEL-HYB with regard to keeping the three-dimensional structure required for a catalytically 
active enzyme. This may suggest an effect from the two new cysteine residues introduced in 
the last repeat segment of the CEL-HYB protein (sequence RVCPRPCNG). Potential folding 
defects compromising the catalytic activity could arise from the presence of reactive thiol 
groups in these residues, by forming covalent bridges with the four other cysteine residues in 
the globular domain. Therefore, experiments where the folding of CEL and its protein variants 
are examined, are highly warranted. This may also shed light on the properties of the CEL-
MODY variant, in which there are ten new cysteine residues added, with a great potential for 
forming intra- and intermolecular cross-linkages that may lead to aggregate formation. Whether 
the lack of glycosylation sites also contributes to the aggregative behaviour of CEL-MODY is 
another issue that needs to be addressed. 
CEL-HYB increases the risk for chronic pancreatitis in individuals of European ancestry five-
fold (184). Still, most carriers of the allele remain healthy, implying that additional genetic 
and/or environmental factors probably are necessary to precipitate the disease. The dramatic 
changes that we observed in N-glycosylation of CEL-HYB might be understood in the context 
of UPR. A very recent study of mice deficient in the UPR/ER stress regulator XBP1 reported 
that ethanol treatment can cause dimerization of the normal mouse Cel protein, which also 




on CEL-HYB due to cysteine-mediated misfolding should now be investigated in order to 
determine if alcohol abuse could serve as susceptibility factor for chronic pancreatitis 
development in CEL-HYB carriers. 
Changes in glycosylation are a common feature in inflammation and cancer, in which an 
increase in sialylation that particularly affects mucins has been reported (230,231). We propose 
experiments where stably transfected CEL-MODY-expressing cells are co-transfected with 
CEL-WT or other secreted mucinous proteins. Such studies might reveal whether the presence 
of the pathogenic CEL-MODY protein disturbs the glycosylation machinery in general, thereby 
altering the glycosylation profile of other glycoproteins. Our group has previously shown that 
the CEL variants, and in particular CEL-MODY, can be endocytosed by non-expressing cells 
(183). There is also evidence that this process is occurring in the alimentary canal (237). To 
study whether a possible under-glycosylation of CEL-MODY´s C-terminal tail could stimulate 
endocytosis, truncation of O-glycosylation should be carried out before performing cellular 
internalization experiments. To this end, CEL-WT and CEL-MODY Tn antigens could be 
generated by expression of the protein variants in COSMC chaperon-deficient cells, which are 
available for CHO (238) or HEK293 cells (163).  
 
In the work done in Paper IV, we employed HEK293 cells because the available acinar cells 
models, which derive from mouse (266 cells) or rat (AR-42J cells), have proven difficult to 
transfect with conventional methods. Recently, we have successfully transfected mouse 266 
acinar cells with CEL-containing plasmids by using electroporation (Johansson et al., 
unpublished). This opens the possibility to investigate in detail the behaviour of the CEL protein 
variants in a more relevant model system, although glycosylation differences between rodent 
and human cells will represent a challenge. 
 
Furthermore, animal studies may serve to give important insights in the pathogenic mechanisms 
of the CEL-MODY and CEL-HYB variants. A study of whole-body Cel knock-out mice 
reported no alterations in pancreatic endocrine or exocrine function (239). It was therefore 
suggested that the MODY8 disease mechanism does not involve a simple loss-of-function and 
that absent catalytic activity cannot explain the pancreatic phenotype (239). A mouse model is 
now under construction by our group, and will consist of a humanized knock-in mice where the 
endogenous mouse Cel VNTR is exchanged with the VNTR sequence of CEL-WT, CEL-HYB 




does not involve disruption of the protease-antiprotease system within the pancreatic acinar 
cells. Moreover, effects of other risk factors such as smoking and alcohol consumption, can be 
tested in these mice, with the aim of identifying the precipitating factors of chronic pancreatitis 
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Variable number of tandem repeats
a b s t r a c t
Background/Objectives: We have recently described copy number variants (CNVs) of the human carboxyl-
ester lipase (CEL) gene, including a recombined deletion allele (CEL-HYB) that is a genetic risk factor for
chronic pancreatitis. Associations with pancreatic disease have also been reported for the variable
number of tandem repeat (VNTR) region located in CEL exon 11. Here, we examined if CEL CNVs and
VNTR length polymorphisms affect the risk for developing pancreatic cancer.
Methods: CEL CNVs and VNTR were genotyped in a German family with non-alcoholic chronic pancre-
atitis and pancreatic cancer, in 265 German and 197 Norwegian patients diagnosed with pancreatic
adenocarcinoma, and in 882 controls. CNV screening was performed using PCR assays followed by
agarose gel electrophoresis whereas VNTR lengths were determined by DNA fragment analysis.
Results: The investigated family was CEL-HYB-positive. However, an association of CEL-HYB or a dupli-
cation CEL allele with pancreatic cancer was not seen in our two patient cohorts. The frequency of the 23-
repeat VNTR allele was borderline significant in Norwegian cases compared to controls (1.2% vs. 0.3%;
P ¼ 0.05). For all other VNTR lengths, no statistically significant difference in frequency was observed.
Moreover, no association with pancreatic cancer was detected when CEL VNTR lengths were pooled into
groups of short, normal or long alleles.
Conclusions: We could not demonstrate an association between CEL CNVs and pancreatic cancer. An
association is also unlikely for CEL VNTR lengths, although analyses in larger materials are necessary to
completely exclude an effect of rare VNTR alleles.
© 2016 IAP and EPC. Published by Elsevier B.V. All rights reserved.
1. Introduction
The human carboxyl-ester lipase (CEL) gene is expressed mainly
in pancreatic acinar cells [1] and lactating mammary glands [2]. CEL
encodes a digestive enzyme, which is secreted into the duodenum
as a component of pancreatic juice [3]. Upon activation by bile salts,
CEL participates in the hydrolysis and absorption of cholesterol and
lipid-soluble vitamins [4,5]. The human CEL gene spans approxi-
mately 10 kb on chromosome 9q34.3 and contains eleven exons
[6,7]. The CEL locus also includes a CEL pseudogene (CELP), which
lacks the region corresponding to exons 2e7 of CEL. Otherwise the
two genes show a high degree of sequence homology [7,8].
The last exon of CEL contains a variable number of tandem
repeat (VNTR) region. Each repeat consists of nearly identical 33-
base pair segments. The number of repeated segments has been
observed to vary between 3 and 23, with 16 repeats being the by far
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most frequent number in all cohorts studied [9e13]. We have found
that a single-base deletion in the first repeat of the CELVNTR causes
maturity-onset diabetes of the young, type 8 (MODY8). This is an
autosomal dominantly inherited disease, characterized by diabetes
and pancreatic exocrine dysfunction [11] and triggered by altered
biochemical and cellular properties of the mutant protein [14,15].
Notably, the number of CEL VNTR segments has been reported to
influence cholesterol profile of serum [16], rate of HIV-1 disease
progression [17] and risk for alcohol-induced pancreatitis [18],
although a study from our group could not replicate the latter as-
sociation [13].
In addition to the VNTR region, copy number variants (CNVs)
involving the CELP gene contribute to the extensive genetic vari-
ability of the CEL locus [12,19]. We have recently characterized two
such CNVs, one duplication allele (CEL-DUP) and one deletion
hybrid allele (CEL-HYB) [19]. These variants most probably origi-
nated from non-allelic homologous recombination between CEL
and CELP. Intriguingly, CEL-HYB emerged as a novel genetic risk
factor for chronic pancreatitis (CP) where, in contrast to most other
known CP genes, the disease mechanism does not directly impli-
cate the protease/antiprotease system of the exocrine pancreas
[19].
CP is among the well-established risk factors for pancreatic
cancer [20e22]. For patients with hereditary pancreatitis, the life-
time risk of developing pancreatic cancer can be 40% or more
[20]. Thus, genetic variants that associate with CP should be
considered potential risk factors for pancreatic cancer. Genome-
wide association studies (GWAS) have identified multiple loci
linked to CP [23,24] and pancreatic cancer [25e27], including a
common association with the ABO locus [23,26,28]. Also PRSS1
intron mutations have been reported to confer a risk for both
pancreatitis and pancreatic cancer [29], as have mutations in the
CP-associated gene CFTR [30,31].
Analyses based on GWAS will easily fail to capture associations
between the highly polymorphic CEL gene and disease [19], and
little is known about the gene in the context of malignant
pancreatic disease. In light of the well-known links between
chronic pancreatitis and pancreas cancer, we therefore investigated
whether CEL CNVs and VNTR polymorphisms could be genetic risk
factors for this form of cancer.
2. Methods
2.1. Patients and DNA samples
This study was performed according to the Helsinki Declaration
and all patients gave their written informed consent. The project
was approved by the ethical committee of the University of
Greifswald and by the Regional Ethical Committee of Western
Norway. The patient cohort consisted of 265 German subjects with
a diagnosis of pancreatic ductal adenocarcinoma (PDAC) and 197
Norwegian subjects with a diagnosis of PDAC (n ¼ 156) or other/
unspecified adenocarcinoma anatomically located to the pancreas
(n ¼ 41). Healthy blood donors (German: n ¼ 502, Norwegian:
n¼ 380) were used as control groups. A German family with CP and
pancreatic cancer was included for CEL-HYB screening and DNA
samples were available from eight members. The proband of the
family had in a previous study been identified as a CEL-HYB carrier
[19]. Peripheral EDTA blood samples were drawn from all in-
dividuals and genomic DNA was extracted according to standard
procedures.
2.2. Screening for CNVs of the CEL locus
For screening of the CEL-HYB allele, we used the long-range,
duplex PCR approach previously described [19]. A similar strategy
was used for screening of CEL-DUP and both assays are illustrated in
Supplementary Fig. 1. Primers used for the CEL CNV screenings are
listed in Supplementary Table 1. We performed the PCR reactions in
a total volume of 10 ml, containing 1" GC buffer, 0.4 mM of each
dNTP, 1 M betaine solution, 0.5 U La Taq polymerase (TaKaRa Bio
Inc.), 0.4 mM of each primer (0.1 mM of Kir6.2 1F and Kir6.2 6R) and
10e50 ng genomic DNA. For CEL-HYB, the PCR conditions were as
follows: 94 #C for 1 min; 14 cycles of 94 #C for 20 s and 60 #C for
6 min; 16 cycles of 94 #C for 20 s and 62 #C for 6 min; a final
elongation step of 72 #C for 10 min and cooling to 4 #C. We used the
same conditions for CEL-DUP, except that DNA synthesis was
extended to 12min and the number of cycles was 14 followed by 18.
Amplified PCR products were analyzed by agarose gel
electrophoresis.
2.3. Analysis of CEL VNTR length polymorphisms
CEL VNTR lengths were measured as previously described [12].
In short, PCR amplification of the VNTR was carried out using the
unlabeled forward primer Celex11F and the fluorescently NED-
labelled reverse primer Celex11R-NED (Supplementary Table 1).
The PCR product covered the complete VNTR region as illustrated in
Supplementary Fig. 2A. One ml of the PCR product was added to a
mixture of 0.2 ml X-Rhodamine MapMarker 1000 (BioVentures Inc.)
and 8.8 ml HiDi formaldehyde (Applied Biosystems), and fragment
analysis was performed on an ABI3100 capillary sequencer (Applied
Biosystems), using Gene Mapper software version 4.0 to analyze
the data. Examples of the resulting electrophoretic spectra are
given in Supplementary Fig. 2B.
2.4. Statistics
Differences between CEL CNVs or CEL VNTR length allele fre-
quencies in cases and controls were tested by the two-tailed
Fisher's exact test or Pearson's Chi-square test. Odd ratios (OR)
and 95% confidence intervals (CI) were calculated by using two-by-
two table analysis (http://www.quantitativeskills.com/sisa/). P-
values <0.05 were considered to be statistically significant.
3. Results
3.1. A CEL-HYB-positive family with pancreatic cancer
During our identification of CEL-HYB as a risk factor for CP we
analyzed a German discovery cohort of probands with familial
idiopathic CP [19]. In one of the CEL-HYB-positive families, we
noted that two family members also had a diagnosis of pancreatic
cancer (Fig. 1). There were reportedly three additional cases of
pancreatic cancer in the family (relatives of subject I-2). Although
that branch of the pedigree was unavailable for further study, the
family history could indicate increased risk for pancreatic cancer
among carriers of CEL-HYB. Screening for the CEL-HYB allele
revealed four positive members, including the only cancer case for
which DNAwas available (Fig. 1). All CEL-HYB carriers were affected
with CP except for the relatively young subject IV-I. Among the CEL-
HYB negatives, one subject (III-6) was diagnosed with recurrent
acute pancreatitis. However, she also had a history of gallstone,
which could explain her disease. Analyzing the VNTR length poly-
morphism, three of the CEL-HYB-positive family members had a
single-peak pattern of 14 or 16 repeats, indicating one deletion
hybrid allele and onewild type (CEL-WT) allele. Subject IV-I was not
available for VNTR analysis. Moreover, CEL-HYB-positive subjects
from a cohort of patients with familial idiopathic CP [19], in which
this family's proband originally was included, were analyzed. All
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CEL-HYB carriers exhibited a single-peak pattern, with VNTR seg-
ments varying from 13 to 17 repeats.
3.2. Analysis of CEL copy number variants
Given the possible link between CEL-HYB and pancreatic cancer
in the CP family described above, we investigated the prevalence of
CEL-HYB, as well as the CEL duplication allele, in a cohort of German
patients with pancreatic adenocarcinoma (Table 1). For CEL-HYB,
we found a carrier frequency of 2.3% (6/263) in cases and 0.8% (4/
495) in controls (OR ¼ 2.87; 95% CI ¼ 0.80e10.25; P ¼ 0.10). When
screening the same material for CEL-DUP, the carrier frequency was
4.2% (11/265) in cases and 5.2% (26/502) in controls (OR¼ 0.79; 95%
CI ¼ 0.39e1.63; P ¼ 0.60).
We also screened a Norwegian cohort of subjects with pancre-
atic adenocarcinoma (Table 1). Here, no carriers of CEL-HYB were
observed, and there was only one (0.3%) among 380 controls. The
CEL-DUP allele had a carrier frequency of 5.6% (11/197) in cases and
2.6% (10/380) in controls (OR ¼ 2.19; 95% CI ¼ 0.91e5.25; P ¼ 0.10)
(Table 1). Taken together, we were therefore unable to detect any
association between CEL CNVs and pancreatic cancer in our two
study materials.
3.3. Analysis of CEL-VNTR length polymorphisms
We determined the number of CELVNTR repeats in all cases and
controls. Overall, we observed that the VNTR lengths varied be-
tween 4 and 23 repeats, with 16 being clearly the most frequent
repeat number in both populations (Tables 2 and 3). Alleles with
less than 13 repeats or more than 17 repeats were generally rare,
with frequencies below 2%. The electrophoretic spectra obtained in
the DNA fragment analysis showed either a single-peak (homozy-
gous) or a double-peak (heterozygous) pattern for the large ma-
jority of samples (Supplementary Fig. 2B, panels i-iii). However, as
also described previously [12], some samples gave rise to a pattern
of three peaks (Supplementary Fig. 2B, panel iv), indicating that
they harbor three copies of the complete CEL VNTR [12]. We
counted the result of these genotypings as three alleles when
calculating the allele frequencies. Thus, the number of recorded
alleles is slightly higher than twice the number of subjects in
Tables 2 and 3.
When comparing VNTR lengths, we noted that the shorter al-
leles of 4, 6 or 9 repeats were detected in Norwegian controls only
(Tables 2 and 3). Moreover, the 23-repeat allele was enriched in
Norwegian cases (5/401, 1.2%) when compared with controls (2/
768, 0.3%) with a borderline statistical trend (OR ¼ 4.84; 95%
CI ¼ 0.93e25.04; P ¼ 0.05). Otherwise, no significant associations
between a specific VNTR length and pancreatic cancer were
observed (Tables 2 and 3).
Next, we classified the CELVNTR lengths into groups of short (S,
4e15 repeats), normal (N,16) and long (L,17e23) alleles. Also in this
pooled analysis, the VNTR distribution did not differ significantly
between pancreatic cancer patients and controls (Tables 2 and 3).
Finally, we analyzed the CELVNTR length polymorphisms according
to genotypes. Each case and control subject was classified into
one of the following seven groups: SS, SN, NN, NL, LL, SL and
samples harboring three VNTR lengths. The genotypes SN and
NN were by far the two most common genotypes in both pop-
ulations (Tables 4 and 5). None of the differences in genotype fre-
quencies between cases and controls reached statistical
significance. When the different genotypes of samples with three
VNTR lengths were grouped (e.g. as SSN) and tested, no significant
differences in distribution between cases and controls were
observed (Supplementary Tables 2 and 3, and data not shown).
4. Discussion
Variants of CEL are known to cause a rare monogenic disease of
the pancreas and to influence the risk of chronic pancreatitis
[11,19,32]. In contrast, little is known about the role of this gene as
Fig. 1. Pedigree of a CEL-HYB-positive family with chronic pancreatitis and pancreatic cancer. Squares represent male family members and circles are females. DNA samples
were available for subjects indicated by small circles. Deceased subjects are indicated by a slash through the symbol. The proband is marked with an arrow.
Table 1
CNVs of the CEL locus in pancreatic cancer.
Cohort CNV type Cases Controls P-value Odds ratio 95% CI
German CEL-HYB 0.023 (6/263) 0.008 (4/495) 0.10 2.87 0.80e10.25
CEL-DUP 0.042 (11/265) 0.052 (26/502) 0.60 0.79 0.39e1.36
Norwegian CEL-HYB 0.000 (0/197) 0.003 (1/380) e e e
CEL-DUP 0.056 (11/197) 0.026 (10/380) 0.10 2.19 0.91e5.25
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risk factor in pancreatic cancer, which is the 4-5th most common
cause of cancer-related death in Western societies [33]. Martinez
et al. recently analyzed a French material for the SNP rs488087
located within the CEL VNTR, and reported an association between
this variant and pancreatic cancer [34]. Their cohort was, however,
extremely small (n ¼ 36) and also included pancreatic
neuroendocrine neoplasms, so the observation needs independent
verification before this SNP can be considered a pancreatic cancer
risk factor.
GWAS of pancreatic cancer have never revealed associations
between CEL and this disease [27,35,36]. It is to be noted, though,
that the CEL gene is extremely polymorphic and that SNP sets used
Table 2
Distribution of CEL VNTR lengths in the German pancreatic cancer cohort.
Allele frequency P-value OR 95% CI
Cases (n ¼ 265) Controls (n ¼ 497)
Number of VNTR repeats 11 0.007 (4) 0.015 (15) 0.24 0.49 0.16e1.49
12 0.013 (7) 0.018 (18) 0.53 0.72 0.30e1.74
13 0.052 (28) 0.053 (53) 1.00 0.98 0.61e1.57
14 0.118 (64) 0.115 (116) 0.85 1.03 0.75e1.43
15 0.155 (84) 0.138 (139) 0.35 1.15 0.86e1.54
16 0.619 (335) 0.624 (629) 0.85 0.98 0.79e1.22
17 0.031 (17) 0.035 (35) 0.77 0.90 0.50e1.63
20 e 0.001 (1) e e e
21 0.002 (1) 0.001 (1) 1.00 1.87 0.12e29.87
23 0.002 (1) 0.001 (1) 1.00 1.87 0.12e29.87
Sum 1.000 (541) 1.000 (1008) e e e
Pooled VNTR lengths Short (<16) 0.346 (187) 0.338 (341) 0.77 1.03 0.83e1.29
Normal (16) 0.619 (335) 0.624 (629) 0.85 0.98 0.79e1.22
Long (>16) 0.035 (19) 0.038 (38) 0.89 0.93 0.53e1.63
Sum 1.000 (541) 1.000 (1008) e e e
Table 3
Distribution of CEL VNTR lengths in the Norwegian pancreatic cancer cohort.
Allele frequency P-value OR 95% CI
Cases (n ¼ 197) Controls (n ¼ 378)
Number of VNTR repeats 4 e 0.001 (1) e e e
6 e 0.001 (1) e e e
9 e 0.001 (1) e e e
11 0.007 (3) 0.005 (4) 0.70 1.44 0.32e6.46
12 0.012 (5) 0.008 (6) 0.53 1.60 0.49e5.29
13 0.055 (22) 0.057 (44) 0.89 0.96 0.56e1.62
14 0.100 (40) 0.091 (70) 0.63 1.10 0.73e1.66
15 0.142 (57) 0.113 (87) 0.15 1.30 0.91e1.86
16 0.621 (249) 0.661 (508) 0.17 0.84 0.65e1.08
17 0.045 (18) 0.044 (34) 1.00 1.02 0.57e1.82
18 0.002 (1) 0.009 (7) 0.28 0.27 0.03e2.22
21 0.002 (1) 0.004 (3) 1.00 0.64 0.07e6.15
23 0.012 (5) 0.003 (2) 0.05 4.84 0.93e25.04
Sum 1.000 (401) 1.000 (768) e e e
Pooled VNTR lengths Short (<16) 0.317 (127) 0.279 (214) 0.17 1.20 0.92e1.56
Normal (16) 0.621 (249) 0.661 (508) 0.17 0.84 0.65e1.08
Long (>16) 0.062 (25) 0.060 (46) 0.87 1.04 0.63e1.73
Sum 1.000 (401) 1.000 (768) e e e
Table 4
Genotype distribution of CEL VNTR lengths in the German pancreatic cancer cohort.
Genotypes of pooled allelesa Frequency P-value OR 95% CI
Cases (n ¼ 265) Controls (n ¼ 497)
SS 0.094 (25) 0.111 (55) 0.54 0.84 0.51e1.38
SN 0.442 (117) 0.400 (199) 0.27 1.18 0.88e1.60
SL 0.015 (4) 0.016 (8) 1.00 0.94 0.28e3.14
NN 0.377 (100) 0.394 (196) 0.65 0.93 0.69e1.27
NL 0.030 (8) 0.048 (24) 0.26 0.61 0.27e1.39
LL e 0.002 (1) e e e
3 VNTRb 0.042 (11) 0.028 (14) 0.39 1.49 0.67e3.34
Sum 1.000 (265) 1.000 (497) e e e
a Short (S); 4e15 repeats, Normal (N); 16 repeats, Long (L); 17e23 repeats.
b Samples harboring three copies of the VNTR region. Their genotypes are listed in Supplementary Table 2.
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in genotyping arrays are inadequate to cover the extensive genetic
variation of the CEL locus [19]. Possible disease associations of CEL
must therefore be explored also by a targeted approach. Accord-
ingly, we set out to investigate whether CEL CNVs or VNTR length
influence pancreatic cancer risk. To improve the power of our study,
we included two independently collected cohorts of pancreatic
cancer patients from Germany and Norway.
In recent years, accumulating evidence has defined pre-existing
longstanding CP as a strong risk factor for pancreatic neoplastic
disease. During a 20 year period around 5% of patients with CP will
present with cancer of the pancreas. The risk of developing this
cancer form appears to be highest in rare types of pancreatitis with
an early onset, such as hereditary pancreatitis [37], whereas the
most common type, alcoholic CP, does not necessarily involve
higher pancreatic cancer susceptibility [38]. Interestingly, cystic
fibrosis, a recessive early-onset genetic disorder affecting many
organ systems including the pancreas, has been associated with a
~5-fold increased risk of pancreatic cancer, often occurring at a
relatively young age [39]. Therefore, CEL and any other new gene
causing or being associated with pancreatic inflammatory disease
should be investigated also in the context of pancreas cancer.
We were, however, unable to reveal an association between the
CEL CNVs and pancreatic cancer, even though the CEL-HYB allele is a
CP risk factor that we also had detected in a pedigree with a history
of CP and pancreatic cancer. For this family, other pancreatic cancer
risk factors (genetic and/or environmental) might be present. There
are also previous examples where CP genetic risk factors have failed
to be linked to increased pancreatic cancer risk [40,41]. The pop-
ulation carrier frequency of the CEL-HYB allele is low and its asso-
ciated CP risk is intermediate [19]. It may therefore not be
surprising that CEL-HYB is a rare event in cohorts of pancreatic
cancer. Nevertheless, this allele could confine an increased risk in
those carriers that develop CP, especially if pancreatitis onset is
relatively early in life. Additional epidemiologic studies in large
materials may be able to clarify this question. These studies should
also take into account how smoking might interact with CEL-HYB
and other CEL variants. Unfortunately, data on smoking status were
available only for about half of our cases and unknown for the
controls, which prohibited us from drawing any conclusions about
how smoking may have influenced our results.
To further investigate CEL in the context of pancreatic cancer, we
studied CELVNTR length polymorphisms. VNTR lengths pooled into
groups of short, normal and long alleles did not show any associ-
ation. When analyzing the VNTR alleles one by one, the most
notable observation was an enrichment of the 23-repeat allele
among Norwegian cases (Table 3). This association was borderline
(P ¼ 0.05), it was not found in the German material, and will not be
significant if correction for multiple testing is performed. We
therefore conclude that it is a spurious finding. Nevertheless, it
should be noted that extreme-length VNTR alleles (<13 and >17
repeats) are rare, and analysis in very large materials would be
needed to gain sufficient power to firmly conclude about their ef-
fects on human disease.
When analyzing CEL as genetic risk factor one also needs to
consider that some alleles may be population-specific. Zou et al.
recently attempted to replicate the association between CEL-HYB
and CP in Indian, Chinese and Japanese cohorts, but discovered that
this allele was completely absent in these Asian populations [42]. In
this respect it is noteworthy that the distribution of VNTR allele
sizes between our Norwegian and German control materials
differed. Short alleles were significantly more frequent among
German than in Norwegian controls (0.338 vs. 0.279; P ¼ 0.007),
whereas long alleles were less common among Germans (0.038 vs.
0.060; P ¼ 0.029; Pearson's Chi-square test, data taken from
Tables 2 and 3). Moreover, the frequencies of the CEL-DUP allele
were close to being significantly different in the two control ma-
terials (0.052 vs. 0.026; P ¼ 0.06).
Another caveat when genotyping CEL VNTR lengths is the
presence of CNV alleles where the complete VNTR itself has been
duplicated [12]. During our analyses we identified a total of 44
individuals who carried three copies of the CEL VNTR region
(Supplementary Tables 2 and 3). Interestingly, only 18 of these
subjects tested positive for the CEL-DUP allele. This strongly sug-
gests that there exist duplication CNVs of the CEL locus that remain
to be characterized.
Moreover, in the current VNTR assay, any sample harboring
three complete VNTRs of which two are of equal lengths (e.g. 16, 16,
18) is not distinguishable from a standard heterozygous sample
(e.g.16,18). In total, we identified 58 subjects who tested positive in
the CEL-DUP-specific assay (Table 1), but when performing VNTR
analysis only 18 of these samples resulted in a genotype pattern
consisting of three different peaks (Supplementary Fig. 2B, panel
iv). Thus, the true number of individuals with an extra CEL VNTR
copy could be substantially higher in our populations than what
recorded in the present study. This observation shows that there is
a need for better methods to genotype CNV alleles of the CEL locus.
Taken together, our results do not indicate any association be-
tween the two analyzed CEL CNVs or CEL VNTR length poly-
morphisms and pancreatic cancer risk. However, CEL is a highly
polymorphic gene where yet uncharacterized CNVs are very likely
to exist and where also some disease-associated alleles may be
confined to specific populations. It is therefore too early to rule out
that genetic variants of CEL could play a role in pancreatic cancer.
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Supplementary Figure Legends 
Supplementary Figure 1 –  Long-PCR assays for detection of CEL CNVs. A) Schematic 
model of how the CELHYB and CEL-DUP alleles have arisen by non-allelic, homologous 
recombination. B) Principle of the CEL-HYB screening assay. Primer binding sites are marked 
in the upper panel. The L11F and CELP VNTR-R primers amplify a 3.2 kb product specific for 
the CEL-HYB allele, whereas primers L11F and IAR amplify a 4.2 kb PCR product from the 
normal CEL gene (internal control). A typical image of the PCR products analyzed by agarose 
gel electrophoresis is shown in the lower panel. Note that there is a double band for sample 1, 
probably reflecting the difference of its CEL VNTR lengths (13 and 23 repeats). C) Principle 
of the CEL-DUP screening assay. Primer binding sites are marked in the upper panel. The IDF 
and IAR primers amplify an 8.0 kb product specific for the CEL-DUP allele. Primers Kir6.2 1F 
and Kir6.2 6R amplify a 1.4 kb product from the unrelated KCNJ11 gene (not shown) and serve 
as internal control for the assay. A typical image of the PCR products analyzed by agarose gel 
electrophoresis is shown in the lower panel. 
 
 
 Supplementary Figure 2 –  Analysis of CEL VNTR length. A) Location of primer binding 
sites in CEL exon 11. The forward primer (Celex11F) binds partly into the first repeat of the 
CEL-VNTR whereas the NED-labelled revers primer (Celex11R-NED) binds downstream of 
the exon. B) Examples of capillary electrophoresis spectra after DNA fragment analysis. Peak 
sizes (base pairs) of the NED-labelled fragments reflect the repeat number of each CEL VNTR 
allele, as indicated under the peaks. The illustrated spectra are screenshots of four samples 
corresponding to i) homozygous 16-repeat alleles, ii) heterozygous 13- and 16-repeat alleles, 


































Supplementary Table 1. Primers used for CEL genotyping 
Name Sequence (5’-3’) 
L11F GTCCCTCACTCATTCTTCTATGGCAAC 
CELP VNTR-R CTGTGGAGGGCATGGAACT 
IAR  TCCAAAGCCCTAGCAGTAACGA 
IDF CTGCCCACCAGTCCTTTATGCT 
Kir6.2 1F CCGAGAGGACTCTGCAGTGA 
Kir6.2 6R CAAGTGCCTTGTAACACCCT 
Celex11F ACCGACCAGGAGGCCACCC 
Celex11R-NED CCTGGGGTCCCACTCTTGT 
Supplementary Table 2. Genotypes of observed CEL duplication alleles in the German pancreatic cancer 
cohort 
Materials Number of VNTR repeats S/N/La CEL-DUP 
Cases 12 12 16 SSN - 
(n=11) 13 14 16 SSN + 
 14 15 16 SSN - 
 14 15 16 SSN - 
 14 15 16 SSN - 
 14 15 17 SSL + 
 14 16 17 SNL + 
 14 16 17 SNL - 
 14 16 17 SNL + 
 15 16 17 SNL + 
 16 17 23 NLL + 
      
Controls 11 14 16 SSN + 
(n=14) 12 14 16 SSN + 
 13 14 16 SSN - 
 13 15 16 SSN - 
 14 15 16 SSN - 
 14 15 16 SSN - 
 14 15 16 SSN - 
 14 15 16 SSN - 
 14 15 16 SSN + 
 14 15 16 SSN - 
 14 15 16 SSN - 
 15 16 17 SNL - 
 15 16 17 SNL + 
 16 17 23 NLL + 

















Supplementary Table 3. Genotypes of observed CEL duplication alleles in the Norwegian pancreatic cancer 
cohort 
Materials Number of VNTR repeats S/N/La CEL-DUP 
Cases 13 14 15 SSS - 
(n=7) 11 14 16 SSN - 
 14 15 16 SSN - 
 14 15 16 SSN + 
 14 17 23 SLL + 
 15 17 23 SLL + 
 16 17 23 NLL + 
      
Controls 13 14 15 SSS - 
(n=12) 13 14 16 SSN - 
 13 14 16 SSN - 
 13 14 16 SSN - 
 13 14 16 SSN - 
 13 15 16 SSN - 
 14 15 16 SSN - 
 14 15 16 SSN - 
 14 15 16 SSN + 
 14 16 17 SNL - 
 15 17 23 SLL + 
 16 17 23 NLL + 



















Pancreatic cancer is one of the most dreaded malignant 
diseases. It ranks the fourth most common cause of cancer- 
related death in many Western countries and has a remark-
ably dismal prognosis with a 5- year survival rate of <5% 
[1]. The manifestation of symptoms occurs relatively late 
in the disease process. Most pancreatic cancer cases are 
therefore diagnosed at an unresectable stage and only 
15–20% of the patients undergo surgical resection, which 
is the only potentially curative treatment.
Histologically, the large majority of pancreatic cancer 
cases are exocrine and classified as pancreatic ductal 
adenocarcinoma (PDAC), in which the characteristic mor-
phological pattern consists of abundant duct- like neoplastic 
structures embedded in a dense desmoplastic stroma [2]. 
Accepted risk factors for PDAC include advanced age, 
cigarette smoking [3], and long- standing chronic 
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Abstract
Both serology- based and genetic studies have reported an association between 
pancreatic cancer risk and ABO blood groups. We have investigated this rela-
tionship in a cohort of pancreatic cancer patients from Western Norway (n = 237) 
and two control materials (healthy blood donors, n = 379; unselected hospital-
ized patients, n = 6149). When comparing patient and blood donor ABO allele 
frequencies, we found only the A1 allele to be associated with significantly higher 
risk for pancreatic ductal adenocarcinoma (PDAC) (23.8% vs. 17.9%; OR = 1.43, 
P = 0.018). Analyzing phenotypes, blood group A was more frequent among 
PDAC cases than blood donors (50.8% vs. 40.6%; OR = 1.51, P = 0.021), an 
enrichment fully explained by the A1 subgroup. Blood group O frequency was 
lower in cases than in blood donors (33.8% vs. 42.7%; OR = 0.69, P = 0.039). 
This lower frequency was confirmed when cases were compared to hospitalized 
patients (33.8% vs. 42.9%; OR = 0.68, P = 0.012). Results for blood group B 
varied according to which control cohort was used for comparison. When pa-
tients were classified according to surgical treatment, the enrichment of blood 
group A was most prominent among unresected cases (54.0%), who also had 
the lowest prevalence of O (28.7%). There was a statistically significant better 
survival (P = 0.04) for blood group O cases than non- O cases among unresected 
but not among resected patients. Secretor status did not show an association 
with PDAC or survival. Our study demonstrates that pancreatic cancer risk is 
influenced by ABO status, in particular blood groups O and A1, and that this 
association may reflect also in tumor resectability and survival.
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pancreatitis [4], whereas some studies also have implicated 
Helicobacter pylori infection [5] and diabetes mellitus [6]. 
In addition, inherited susceptibility plays a role in the 
disease, both as high- risk gene variants in the context of 
familial cancer syndromes [7] and as the presence of vari-
ants with modest effect, usually discovered by genome- wide 
association studies (GWAS) [8].
In a landmark GWAS paper, the Pancreatic Cancer 
Cohort Consortium (PanScan) reported that the statisti-
cally most significant variants associating with pancreatic 
cancer risk belonged to the ABO locus on chromosome 
9q34 [9]. ABO codes for a glycosyltransferase that gives 
rise to the histo- blood group antigens of the ABO system. 
Single- nucleotide polymorphisms (SNPs) of this gene 
determine the specificity of the enzyme [10, 11]. Hence, 
by adding either N- acetyl- D- galactosamine or D- galactose 
to the precursor H antigen, the A and B glycosyltrans-
ferases produce A or B antigens, respectively, on cellular 
surfaces and secretions. A frequent ABO variant is a one- 
base pair deletion that inactivates the encoded enzyme, 
leaving the H antigen unaltered and corresponding to the 
O phenotype [10]. This deletion is in strong linkage dis-
equilibrium with the T allele of SNP rs505922, which 
was identified as being associated with decreased suscep-
tibility for pancreatic cancer [9]. Accordingly, individuals 
with blood group O have a lower risk for this disease 
than those with other blood groups [12].
There are two major subtypes of the ABO allele deter-
mining the blood group A, namely A1 and A2. Data from 
PanScan demonstrated that, among all common ABO 
variants, the greatest risk of pancreatic cancer was con-
ferred by the A1 allele [13] which gives rise to the ABO 
protein with highest enzymatic activity [14]. This finding 
suggests that it is the glycosyltransferase activity itself 
that is linked to cancer risk rather than actions of other 
nearby genes on chromosome 9q34. Somewhat surpris-
ingly though, the association between blood group and 
pancreatic cancer was not influenced by the secretor 
phenotype, that is, a person’s ability to secrete A, B, and 
H antigens into body fluids [13]. This property is deter-
mined by FUT2, the gene encoding the glycosylating 
enzyme fucosyltransferase 2.
The initial reports [9, 12, 13] were followed up by 
genetic studies in various populations that confirmed the 
influence of ABO blood group alleles on pancreatic cancer 
risk [15–17]. The finding that blood group O confers 
protection was also consistent with older papers that had 
reported an association between ABO phenotype and gas-
trointestinal cancers including pancreatic cancer [18–20]. 
A meta- analysis including over 20 studies, both genetic 
and serology- based, concluded that all non- O blood groups 
have elevated risks for pancreatic cancer as compared with 
the O phenotype [16].
In this study, we aimed at evaluating the link between 
pancreatic cancer and ABO histo- blood groups in patients 
from Norway, a population in which this association has 
not yet been investigated. Our patients were carefully 
characterized to exclude non- PDAC cases and also clas-
sified according to tumor resectability and survival. Two 




The study was performed according to the Helsinki 
Declaration and all patients gave their written informed 
consent. The project was approved by the Regional Ethical 
Committee of Western Norway. The patient cohort con-
sisted of 237 cases of pancreatic adenocarcinoma seen at 
Haukeland University Hospital, Bergen, Norway between 
the years 1998 and 2012 (Table 1). Medical records, 
pathology reports, and/or tissue sections were examined 
by two pathologists (HI and SA) for diagnosis confirma-
tion. Final classification resulted in 195 PDAC cases and 









All pancreatic adenocarcinoma cases 237 119 50.2 69 118 49.8 69
Pancreatic ductal adenocarcinoma (PDAC) 195 97 49.7 69 98 50.3 69
Resected 108 50 46.3 70 58 53.7 68
Not resected 87 47 54.0 70 40 46.0 67
Other adenocarcinomas1 42 22 52.4 67 20 47.6 68
Controls
DNA- typed blood donors 379 189 49.9 39 190 50.1 44
Serotyped hospital patients 6149 2805 45.6 66 3344 54.4 64
1See Materials and Methods for description.
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42 other adenocarcinomas located within the pancreas. 
The latter group consisted of intraductal papillary muci-
nous neoplasm (5 cases) or mucinous cystic neoplasm 
with malignant component (1 case), intrapancreatic adeno-
carcinoma of the ampulla/papilla of Vateri (19 cases) or 
of ductus choledochus (9 cases), and unspecified adeno-
carcinoma of the pancreas (8 cases).
For the statistical comparison, two different control 
groups were employed (Table 1). One consisted of 379 
healthy blood donors from Haukeland University Hospital 
(49.9% females) that were genotyped in the same way as 
the cases. The other control group contained 6149 patients 
(45.6% females) born before 1.1.1970 and admitted to 
the same hospital during a randomly chosen period of 
six consecutive months in 2007. All patients had been 
blood- typed by serological means as part of their health 
care. No selection with regard to diagnosis was done.
DNA extraction and genotyping
EDTA- blood, frozen tissue and formalin- fixed paraffin- 
embedded (FFPE) tissue blocks were used for DNA extrac-
tion from the 237 pancreatic adenocarcinoma cases. DNA 
from frozen buffy coats from EDTA- blood (195 cases) 
were purified using MagAttract DNA Blood Midi M48 
kit on the BioRobot M48 workstation (both from Qiagen, 
Hilden, Germany) or manually processed with the E.Z.N.A 
DNA extraction kit (Omega Bio- Tek, Norcross, GA, USA), 
according to the manufacturers’ protocol. For 38 cases, 
only FFPE tissue samples were available; 10- micron sec-
tions were then sliced and subjected to manual depar-
affinization with xylene, followed by ethanol washes before 
overnight incubation at 56°C with Proteinase K (Qiagen) 
and processing with the E.Z.N.A. DNA extraction kit. For 
the final four cases, only fresh- frozen tissue samples were 
available. These were incubated directly with Proteinase 
K and then processed as the FFPE samples. DNA from 
the blood donor controls was isolated from EDTA- blood 
buffy coats using the same purification system as for the 
patient blood samples.
Genotyping was performed using TaqMan predesigned 
genotyping assays (Cat. No. 4351379; Applied Biosystems, 
Foster City, CA). Each sample was tested for three com-
mon SNPs at the ABO locus (Table S1): rs8176704 (intron 
3) for the A2 allele (Assay ID: C_30336657_10), rs8176746 
(exon 7) for the B allele (Assay ID: C_25610772_20), and 
rs505922 (intron 1) for the O allele (Assay ID: 
C_2253769_10). The samples were also screened for the 
FUT2 variant rs601338 (Assay ID: C_2405292_10), which 
determines secretor status of ABH antigens.
The genotyping assays were performed on the 7900 
Fast Real- time PCR System with the corresponding 
7900 Fast System SDS 2.4 Software (Applied Biosystems). 
Positive and negative controls were included to ensure 
appropriate clustering. Each assay was performed using 
10 ng template DNA, TaqMan Universal Master Mix buffer 
(Applied Biosystems), and 20x primer and probe mix as 
recommended by the manufacturer. Thermal cycling was 
performed by first activating the DNA polymerase at 95°C 
for 10 min and then running 40 amplification cycles, 
each consisting of denaturation at 92°C for 15 sec and 
combined annealing/extension at 60°C for 1 min.
Quality control
Misclassification of ABO genotypes was expected to be 
minimal, as genotyping results from the three different 
ABO SNPs matched the haplotype phasing of the ABO 
gene (Table 1 in [13]) for all analyzed samples. In addi-
tion, we compared our genotyping results for 40 cases 
(20 extracted from blood and 20 from FFPE tissues) with 
serologically determined ABO status as stated in the 
patients’ medical records. The concordance rate was 100%. 
Genotyping quality for the blood donor control group 
was assessed by testing for Hardy–Weinberg equilibrium 
using the Haploview Software [21]. The distribution of 
genotypes was as expected from the SNP frequencies.
Statistical analysis
Each SNP was tested under various genetic models 
 (dominant, codominant, recessive, additive) using the 
software PLINK (http://pngu.mgh.harvard.edu/~purcell/plink). 
Assess ment of differences in genotype or phenotype dis-
tributions between cases and controls was carried out by 
the two- tailed Fisher`s exact test or Pearson`s chi- square 
test. Odds ratios (OR) and 95% confidence intervals (CI) 
were calculated using two- by- two contingency table analysis 
on the SISA webpage (http://www.quantitativeskills.com/
sisa). Survival analysis was performed using the software 
package STATISTICA version 12 (StatSoft, Tulsa, OK). 
The Product–Limit (Kaplan–Meier) Analysis Module was 
employed for comparing survival between groups by log- 
rank test of significance. Survival times versus cumulative 
proportion surviving, according to breakdown by blood 




From our biobank of patients with pancreatic tumors, 
we initially selected the patients diagnosed with adeno-
carcinoma of the exocrine gland. This cohort consisted 
of 237 cases (50.2% females), with a median age at 
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diagnosis of 69 years in both sexes (Table 1). We reviewed 
all cases to identify those that were consistent with a 
diagnosis of PDAC (n = 195, 82.3%). The cases were 
also classified according to whether or not the tumor had 
been judged resectable at the time of diagnosis (Table 1).
Association between ABO blood group and 
pancreatic cancer risk
The genotype frequencies for all adenocarcinoma cases 
and blood donor controls are given in Table S2. In both 
groups, the most common ABO genotypes were A1O and 
OO, and the least frequent were BB and A2A2. We first 
compared allele frequencies of A1, A2, B, and O in the 
whole adenocarcinoma cohort with frequencies observed 
in the blood donors (Table 2, ‘All cases’). The A1 allele 
frequency was higher among the patients (22.4% vs. 17.9%) 
but the difference did not quite reach statistical significance 
(P = 0.057). When the analysis was limited to PDAC 
cases only, there was a significant difference in A1 fre-
quency (23.8% vs. 17.9%; OR = 1.43, CI = 1.06–1.93; 
P = 0.018). Interestingly, the A2 frequency appeared almost 
identical between the groups compared (7.6–7.8%). The 
B and O allele frequencies varied, but were not statisti-
cally different.
For the further analyses, we restricted our analysis to 
the PDAC cases only. We deduced ABO phenotypes from 
the genotype data of the cases and the blood donors. 
The blood group distributions are shown in Table 3. The 
blood group A prevalence was clearly different (50.8% 
vs. 40.6%; OR = 1.51, CI = 1.06–2.13; P = 0.021,) and, 
in keeping with the data of Table 2, the subgroup A1 
frequencies fully explained the observed difference (42.6% 
vs. 29.3%; OR = 1.79, CI = 1.25–2.56; P = 0.001). Moreover, 
the prevalence of blood group O was lower in cases than 
in controls (33.8% vs. 42.7%; OR = 0.69, CI = 0.48–0.98; 
P = 0.039). Blood group B did not show a statistically 
significant difference in distribution. Neither did blood 
group AB, although in this case, the number of subjects 
was too small for meaningful comparisons to be made.
Healthy blood donors may not always serve as an opti-
mal control group in case–control studies [22]. We therefore 
collected information on ABO blood group distribution 
from a large control cohort of unselected hospitalized 
patients (see Materials) from the same geographical region 
as our pancreatic cancer patients. The subgroup A1/A2 
distribution was not known for the hospitalized patient 
cohort. Notably, the hospitalized patients had a significantly 
higher blood group A prevalence than the blood donors 
(45.8% vs. 40.6%; OR = 1.24, CI = 1.00–1.53; P = 0.049). 
Similarly, blood group B was significantly less frequent 
(7.7% vs. 12.1%; OR = 0.60, CI = 0.44–0.83; P = 0.002). 
Blood group O had very similar prevalence in the two 
control groups (42.7% and 42.9%).
When the PDAC blood group distribution was compared 
with that of the hospitalized patients, the enrichment of 
blood group A among the PDAC cases no longer reached 
statistical significance (50.8% vs. 45.8%; OR = 1.22, 
CI = 0.92–1.62; P = 0.173) (Table 4). On the other hand, 
the blood group B difference was now significant (12.8% 
vs. 7.7%; OR = 1.76, CI = 1.15–2.71; P = 0.009). The 
lower frequency of blood group O in the PDAC cohort 
remained significant with almost identical odds ratio (33.8% 
vs. 42.9%; OR = 0.68, CI = 0.50–0.92; P = 0.012).
Tumor resectability
To further explore the association between blood group 
frequencies and PDAC, the patients were stratified into 
two subgroups: those who had their pancreatic tumor 
resected and those who were considered surgically unre-
sectable at the time of cancer diagnosis (Table 1). The 
latter group consisted of patients with locally advanced 
tumors with encasement of adjacent large blood vessels 
(Clinical stage III) or with metastatic disease at the time 
of diagnosis (Clinical stage IV) [23]. We observed that 
Table 2. ABO and FUT2 allele frequencies of blood donor controls compared with pancreatic cancer cases.
Allele
Controls 
(n = 758) All cases (n = 474) PDAC cases only (n = 390)
% % P OR (95% CI) % P OR (95% CI)
ABO
A1 17.9 22.4 0.057 1.32 (0.99–1.75) 23.8 0.018 1.43 (1.06–1.93)
A2 7.8 7.6 1.000 0.97 (0.63–1.50) 7.7 1.000 0.99 (0.63–1.56)
B 8.7 7.6 0.491 0.86 (0.56–1.32) 7.7 0.556 0.87 (0.56–1.37)
O 65.6 62.4 0.266 0.87 (0.69–1.11) 60.8 0.109 0.81 (0.63–1.05)
FUT2
Se 51.5 51.5 1.000 1.00 (0.79–1.26) 52.1 0.847 1.02 (0.80–1.31)
Se0 48.5 48.5 1.000 1.00 (0.79–1.26) 47.9 0.847 0.98 (0.77–1.25)
n, number of genotyped alleles; PDAC, pancreatic ductal adenocarcinoma; P, P - value from chi- square test (df = 1); OR (95% CI), odds ratio (95% 
confidence interval). Significant P- value is shown in bold face.
1535© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
ABO Blood Groups In Pancreatic CancerK. El Jellas et al.
the blood group A and subgroup A1 prevalences were 
highest among the unresected cases (54.0% and 44.8%, 
respectively) and both were significantly different from 
the frequencies found in blood donors (A: OR = 1.72, 
CI = 1.07–2.74, P = 0.023; A1: OR = 1.96, CI = 1.22–3.16, 
P = 0.005) (Table 3). Moreover, the unresected cases had 
the lowest frequency of blood group O (28.7% vs. 42.7%; 
OR = 0.54, CI = 0.33–0.90; P = 0.016). A comparison 
with the cohort of hospitalized patients (Table 4) revealed 
significant differences for the unresected patients, both 
with regard to blood group B (14.9% vs. 7.7%; OR = 2.11, 
CI = 1.16–3.83; P = 0.012) and blood group O (28.7% 
vs. 42.9%; OR = 0.54, CI = 0.34–0.86; P = 0.008).
Survival
Data on survival after time of diagnosis was available for 
all PDAC cases. As expected, survival was significantly 
better among resected than among unresected cases 
(median survival 18.1 months vs. 5.6 months, respectively; 
P < 0.001) (Fig. 1A). Given that blood group is a risk 
factor for PDAC and that it also may influence resection 
status, we also analyzed survival according to ABO phe-
notype. When all 195 patients were classified as O or 
non- O cases, survival of the two groups was not signifi-
cantly different (median 10.4 vs. 9.3 months, respectively; 
P = 0.23) (Fig. 1B). We then looked at resected and 
unresected cases separately. Among the resected cases, 
survival did not differ between patients with O and non- O 
blood group (P = 0.93) (Fig. 1C). However, in the group 
of unresected cases, patients with blood group O survived 
longer than non- O patients (median 6.7 vs. 5.5 months, 
respectively; P = 0.04) (Fig. 1D). When the non- O cases 
were split into blood group A or B and compared to 
the O cases, the difference in survival reached significance 
for blood group B (median 2.7 months; P = 0.03), but 
not for A (median 5.6 months; P = 0.14) (Fig. 1E–F). 
Although it should be noted that the number of A2 cases 
Table 3. ABO blood group and secretor phenotype frequencies of blood donor controls compared with PDAC cases.
Phenotype Controls 
(n = 379) 
%
PDAC cases (n = 195) PDAC cases according to resection status
Resected (n = 108) Unresected (n = 87)
% P OR (95% CI) % P OR (95% CI) % P OR (95% CI)
ABO
A 40.6 50.8 0.021 1.51 (1.06–2.13) 48.1 0.163 1.36 (0.88–2.09) 54.0 0.023 1.72 (1.07–2.74)
A1 29.3 42.6 0.001 1.79 (1.25–2.56) 40.7 0.024 1.66 (1.07–2.59) 44.8 0.005 1.96 (1.22–3.16)
A2 11.3 8.2 0.241 0.70 (0.38–1.27) 7.4 0.238 0.63 (0.29–1.37) 9.2 0.562 0.79 (0.36–1.75)
B 12.1 12.8 0.814 1.06 (0.63–1.79) 11.1 0.771 0.91 (0.46–1.78) 14.9 0.478 1.27 (0.65–2.47)
AB1 4.5 2.6 0.359 0.56 (0.20–1.54) 2.8 0.586 0.61 (0.18–2.12) 2.3 0.548 0.50 (0.11–2.21)
O 42.7 33.8 0.039 0.69 (0.48–0.98) 38.0 0.374 0.82 (0.53–1.27) 28.7 0.016 0.54 (0.33–0.90)
FUT2
Secretor 77.6 76.4 0.753 0.94 (0.62–1.41) 72.2 0.248 0.74 (0.46–1.22) 81.6 0.410 1.28 (0.71–2.32)
Non- secretor 22.4 23.6 0.753 1.07 (0.71–1.61) 27.8 0.248 1.33 (0.82–2.16) 18.4 0.410 0.78 (0.43–1.41)
PDAC, pancreatic ductal adenocarcinoma; P, P - value from chi- square test (df=1); OR (95% CI), odds ratio (95% confidence interval). Significant 
P - values are shown in bold face.
1P - values from two- tailed Fisher`s exact test.
Table 4. ABO phenotypic frequencies of hospital patient controls compared with PDAC cases.
Blood types Controls 
(n = 6149) 
%
PDAC cases (n = 195) PDAC cases according to resection status
Resected (n = 108) Unresected (n = 87)
% P OR (95% CI) % P OR (95% CI) % P OR (95% CI)
A 45.8 50.8 0.173 1.22 (0.92–1.62) 48.1 0.632 1.10 (0.75–1.61) 54.0 0.128 1.39 (0.91–2.12)
B 7.7 12.8 0.009 1.76 (1.15–2.71) 11.1 0.188 1.50 (0.82–2.75) 14.9 0.012 2.11 (1.16–3.83)
AB1 3.5 2.6 0.690 0.72 (0.29–1.76) 2.8 1.000 0.78 (0.25–2.47) 2.3 0.771 0.64 (0.16–2.62)
O 42.9 33.8 0.012 0.68 (0.50–0.92) 38.0 0.301 0.81 (0.55–1.20) 28.7 0.008 0.54 (0.34–0.86)
PDAC, pancreatic ductal adenocarcinoma; P, P- value from chi- square test (df=1); OR (95% CI), odds ratio (95% confidence interval). Significant 
P - values are shown in bold face.
1P- values from two- tailed Fisher`s exact test
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Figure 1. Cumulative proportion survival (Kaplan–Meier) plot for the 195 pancreatic ductal adenocarcinomas according to breakdown by resection 
status and blood group phenotype. (A)-(F) Pairwise comparison of subgroups as specified in the heading of each panel. The observed survival times 
(months along the X- axis) are indicated by circles (complete) or crosses (censored observations). In panel A, survival curves for resected and unresected 
cases are shown by a blue and a red line, respectively. In all other panels, survival curves for blood group O and the comparison group are shown by 
a red and blue line, respectively.
A All cases - unresected versus resected  B All cases – group O versus non-O 
C Resected cases – group O versus non-O D Unresected cases – group O versus non-O 
E Unresected cases – group O versus A F Unresected cases – group O versus B 
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is relatively small (16/195 cases), we also examined whether 
there was a survival difference between patients of blood 
group A1 and A2. Neither among all cases nor when cases 
were classified according to resection status was any sta-
tistically significant difference observed (data not shown).
Secretor status
Because the secretion of soluble H antigen is associated 
with susceptibility to multiple pathogens through adherence 
to the gastrointestinal mucosa we looked at the secretor 
phenotype determined by the rs601338 FUT2 polymorphism 
(Tables S1, S2). Consistent with another study [13], there 
were no significant differences in prevalence of alleles or 
phenotypes when compared with the blood donor controls 
(Tables 2, 3). We further checked whether FUT2 could 
have an effect on resection status by comparing the groups 
of resected and unresected PDAC cases in Table 3 directly 
against each other. The difference in secretor status was 
not significant (72.2% vs. 81.6%; OR=0.59, CI=0.30–1.16; 
P = 0.124). Finally, we examined if secretor status might 
associate with survival in our patient cohort. No such 
association was seen (Fig. S1).
Discussion
A variety of biological traits have been linked to ABO 
histo- blood group phenotypes. Reported associations 
include, among others, plasma lipid levels [24], suscep-
tibility to H. pylori–associated disorders [25], cardiovascular 
disease [26], and cancer [27]. Here, we have investigated 
ABO genetic variants and phenotypes in the context of 
pancreatic cancer. A strength of our study is that a re- 
evaluation of the recorded pancreatic adenocarcinomas 
was performed to select only those cases consistent with 
a diagnosis of PDAC. Thus, from our initial cohort of 
adenocarcinomas with an anatomical location in the pan-
creas, 42 (17.7%) cases were excluded. Materials of pan-
creatic head cancers may contain a significant number of 
adenocarcinomas originating from the distal bile duct, 
ampulla, or duodenum [28], and proper classification of 
cases collectively regarded as pancreatic cancer should 
always be attempted.
One limitation of our study is the relatively low number 
of cases and blood donor controls. Another relates to the 
selection of control groups, which may pose a challenge 
for ABO phenotype and other traits with a distribution 
that varies by geography and ethnicity. The optimal control 
group for our study would have been randomly drawn 
individuals from the population of Western Norway, 
matched to cases by age, sex and county of residence. 
However, such a cohort could not be obtained within 
the restrictions of the present study.
We confirmed the association between the blood group 
O phenotype and reduced susceptibility to pancreatic 
exocrine cancer (frequency of 33.8% in cases versus 42.7% 
and 42.9% in the two control groups). When comparing 
with blood donors, blood group A was significantly over-
represented among cases. We made the interesting obser-
vation that the association with blood group A was 
explained by the A1 allele/blood group only, a finding 
previously reported by a few papers [13, 29]. Serology- 
based analyses and many genetic studies of ABO blood 
groups in pancreatic cancer do not distinguish between 
A1 and A2 subgroups. However, this distinction might be 
of biological importance as A1 and A2 glycosyltransferases 
display different catalytic activities, the A2 isoform having 
a higher Km and an estimated enzyme activity 30–50 times 
lower than A1 [14]. The finding that A1, but not A2, 
associates with pancreatic cancer could therefore suggest 
a role of blood group A glycosyltransferase activity in 
carcinogenesis.
Studies of associations between ABO blood groups and 
human disease are challenging for at least two reasons. 
Firstly, across the globe there are important variations in 
ABO frequencies, reflecting human migration movements 
and possibly also selection pressures from the environment 
[30, 31]. Within Norway, the ABO distribution differs 
according to geographical localization with the highest 
blood group O frequency observed in the Western part 
of the country and the highest B frequency in the north-
ernmost region [32]. Secondly, healthy blood donors might 
not always serve as appropriate controls for epidemiological 
studies in general and, studies of ABO in particular. There 
could, for example, be a bias in ABO distribution among 
donors because of the association of blood groups with 
a variety of diseases. Another potential selective effect 
could arise in that certain blood groups might be preferred 
as donors.
In the literature, it is well established that blood group 
O individuals have a lower risk of pancreatic cancer [33]. 
For the other blood types, the data are not always con-
sistent. Some authors report an association with blood 
group A, but not with B [29, 34] whereas others describe 
an association with B, but not with A [20] or even find 
AB to be protective [35]. One reason for this discrepancy 
might therefore be the way that control groups have 
been selected. We employed two different sets of controls: 
a limited number of blood donors and a large number 
of random patients from the same geographical area as 
our patients. The control groups exhibited very similar 
blood group O frequencies (close to 43%). Thus, we 
found a very consistent protective effect of blood group 
O on PDAC risk. On the other hand, the frequencies 
of blood groups A and B varied considerably among the 
two control groups, resulting in a significant association 
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of PDAC risk with blood group A when blood donors 
were used and with blood group B when employing 
hospital patients. Interestingly, in a recent large study 
where 1.6 million blood donors from Denmark and Sweden 
were followed over an average of 17 years, there was 
increased risk for pancreatic cancer in subjects with blood 
group A when compared with O subjects [36]. Blood 
group B did not associate with increased risk, that is, a 
result similar to what we observed when using blood 
donors as controls.
We also analyzed ABO blood group distribution in the 
context of resectability at the time of diagnosis (Tables 3 
and 4). In this respect, it should be noted that our cases 
were recruited at a surgical department to which patients 
usually are referred when they are to be evaluated for 
operation. Thus, those PDAC patients that at the time 
of diagnosis obviously are unresectable will be clearly 
underrepresented. This explains the relatively high fraction 
of operated patients in our material (55.4%) compared 
with the general low resection rate for pancreatic adeno-
carcinomas, which is around 20%.
We divided our PDAC patients into those who under-
went surgery to remove the primary tumor (Clinical stages 
I and II) and those who presented with an unresectable 
tumor (Stages III and IV). In the latter group, the O 
phenotype frequency dropped to 28.7% and the A1 and 
B frequencies increased to 44.8% and 14.9%, respectively 
(Table 3). Thus, the ABO frequency differences that we 
observed for the whole PDAC group versus the control 
groups appeared more prominent when analyzing unre-
sected cases only. This suggests an association between 
ABO phenotype and clinical stage which again could 
indicate that blood group O subjects diagnosed with pan-
creatic cancer have the best prognosis. Previous analyses 
in this regard are discrepant. In a study involving Han 
Chinese patients, blood group O subjects had better out-
come that those with non- O blood group [37]. However, 
in a German material, although the incidence of blood 
group O was significantly lower among the investigated 
cohort of pancreatic cancer patients, no association was 
seen between ABO status and survival [38]. Intriguingly, 
when we analyzed unresected cases only, there was a sig-
nificant association between having blood group O and 
better survival (Fig. 1D–F). This effect was not seen when 
the group of resected cases were analyzed according to 
blood group O status (Fig. 1C). Overall, the data from 
our material indicate that individuals with blood group 
O may have somewhat less aggressive PDACs than patients 
having other blood groups.
The implication of ABO glycosyltransferases in pancreatic 
cancer is still enigmatic. There is, however, strong evidence 
that the expression of ABH antigens in the gastrointestinal 
tract affects the anchoring efficiency of certain pathogenic 
strains to the mucosa and influences bacterial and/or viral 
colonization and infectivity [39]. In this context, H. pylori 
infection as risk factor in pancreatic pathologies has been 
extendedly researched [40], and it was shown that the 
increased risk of non- O individuals for PDAC became 
even greater if these subjects were positive for the CagA- 
negative H. pylori strain [41]. FUT2 secretor status seems 
to affect the composition of the intestinal microbiota [42] 
and the susceptibility to certain gastrointestinal infections 
[43]. Nevertheless, we did not observe a difference in 
FUT2 allele distribution or phenotype among pancreatic 
cancer cases and controls, similar to what a previous 
report showed [13]. Similarly, there was no association 
between secretor phenotype and survival (Fig. S1).
Naturally occurring alloantibodies (i.e., isoagglutinins) 
could also play a role in the association between ABO 
blood groups and pancreatic cancer. These antibodies 
provide immunity against pathogens expressing blood 
group- like antigens on their surface. Anti- A and anti- B 
isoagglutinins, present in the plasma of blood group O 
individuals, have been shown to react toward the Tn and 
T pancarcinoma antigens [44]. Tn and T may be struc-
turally related to A and B blood group antigens, respec-
tively [45] and could possibly render cancer cells 
immunologically less recognized in blood group A and 
B individuals.
In conclusion, although the choice of control material 
involves some particular challenges when studying ABO 
blood groups as a disease risk factor, our results confirm 
both a genetic and phenotypic association with pancreatic 
ductal adenocarcinoma. We found that the increased sus-
ceptibility connected with blood group A is likely to be 
caused by the subtype A1 only, and we suggest that also 
clinical stage at the time of diagnosis and survival could 
be influenced by blood group status. However, the biol-
ogy behind the fascinating ABO- pancreatic cancer link is 
poorly understood, and studies are warranted on how 
ABO glycosyltransferase activity may influence biological 
aggressiveness of pancreatic neoplastic cells.
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  Supplementary Table 1. SNPs used for ABO  and FUT2  allele genotyping
FUT2 SNP
Allele rs8176704 rs8176746 rs505922 rs601338
A1 G C C  -
A2 A C C  -
B G A C  -
O G C T  -
Se  -  -  - G
Se0  -  -  - A
ABO SNPs
Se and Se0 refer to secretor and non-secretor allele, respectively
Genotype n  % n  % n  %
ABO
A1A1 15 4.0 6 2.5 6 3.1
A1A2 5 1.3 14 5.9 13 6.7
A2A2 4 1.1 0 0.0 0 0.0
A1O 91 24.0 75 31.6 64 32.8
A2O 39 10.3 20 8.4 16 8.2
BB 3 0.8 0 0.0 0 0.0
BO 43 11.3 29 12.2 25 12.8
A1B 10 2.6 5 2.1 4 2.1
A2B 7 1.8 2 0.8 1 0.5
OO 162 42.7 86 36.3 66 33.8
FUT2     
SeSe 96 25.3 64 27.0 64 27.0
SeSe0 198 52.2 116 48.9 116 48.9
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ABSTRACT 
Carboxyl-ester lipase (CEL) is a pancreatic fat-
digesting enzyme associated with human disease. 
Rare mutations in the CEL gene cause a 
syndrome of pancreatic exocrine and endocrine 
dysfunction denoted MODY8, whereas a 
recombined CEL allele increases the risk for 
chronic pancreatitis. Moreover, CEL has been 
linked to pancreatic ductal adenocarcinoma 
(PDAC) through a postulated oncofetal CEL 
variant termed feto-acinar pancreatic protein 
(FAPP). The monoclonal antibody mAb16D10 
was previously reported to detect a glycotope in 
the highly O-glycosylated, mucin-like C-terminus 
of CEL/FAPP. We here assessed the expression of 
human CEL in malignant pancreatic lesions and 
cell lines. CEL was not detectably expressed in 
neoplastic cells, implying that FAPP is unlikely to 
be a glycoisoform of CEL in pancreatic cancer. 
Testing of the mAb16D10 antibody in glycan 
microarrays then demonstrated that it recognized 
structures containing terminal GalNAc-α1,3(Fuc-
α1,2)Gal (blood group A antigen) and also 
repeated protein sequences containing GalNAc 
residues linked to Ser/Thr (Tn antigen), findings 
that were supported by immunostainings of 
human pancreatic tissue. To examine whether the 
CEL glycoprotein might be modified by blood 
group antigens, we used high-sensitivity MALDI-
TOF mass spectrometry to characterize the 
released O-glycan pool of CEL 
immunoprecipitated from human pancreatic 
juice. We found that the O-glycome of CEL 
consisted mainly of core 1/2 structures with a 
composition depending on FUT2 and ABO gene 
polymorphisms. Thus, among digestive enzymes 
secreted by the pancreas, CEL is a glycoprotein 
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with some unique characteristics, supporting the 
view that it could serve additional biological 




Carboxyl-ester lipase (CEL; EC 3.1.1.13), also 
designated bile salt-dependent lipase (BSDL), is one 
of four major duodenal lipases secreted by pancreatic 
acinar cells (1). In addition, mammalian breast 
glands secrete CEL, alternatively called bile salt-
stimulated lipase (BSSL), into mother’s milk (2). 
CEL is involved in the hydrolysis and absorption of 
dietary fat, cholesteryl esters and fat-soluble 
vitamins. It constitutes a significant fraction of 
pancreatic juice, around 4% of the total protein 
content (3).  
The eleven exons of the CEL gene code for a short 
signal peptide and a globular N-terminal domain of 
538 amino acid residues in which the bile salt-
binding site and the catalytic activity of the enzyme 
reside (4). The last exon contains a variable number 
of tandem repeats (VNTR) that gives rise to a 
flexible C-terminus protruding from the globular 
core (5). The VNTR encodes 11-amino acid 
segments that are repeated from 3 to 23 times in 
humans (6), with16 repeats being the most common 
number (7-9). The variable length of the CEL VNTR 
makes this gene and its protein product highly 
polymorphic in human populations. In particular, 
rare mutational events affecting the VNTR region 
cause an inherited syndrome of diabetes and 
pancreatic exocrine dysfunction (MODY8) (10), 
most likely due to protein aggregation and 
endoplasmatic reticulum (ER) stress resulting from 
altered repeat sequences (11-13). Moreover, a 
recombined allele between the VNTR regions of 
CEL and the neighboring pseudogene CELP is 
associated with a significantly increased risk for 
chronic pancreatitis (14). 
The mature form of CEL is heavily glycosylated. Its 
globular domain contains a N-linked glycan at the 
conserved residue Asn210 (15-17), whereas the 
VNTR domain has a high occupation of O-linked 
glycans on its threonine, and probably serine, 
residues (15,18), similar to that found in mucinous 
glycoproteins (19). As a consequence of the VNTR 
length variability and possible differences in the 
glycan pool, the molecular weight of the CEL 
glycoprotein may span from 60 to 140 kDa (7,11).  
Glycosylation changes are a hallmark of disease, 
especially prominent in inflammation and cancer 
(20). Some studies have indirectly implicated 
glycovariants of CEL in malignant disease by using 
antisera against embryonic pancreas extracts to 
search for acinar cell factors that are absent in the 
adult pancreas and re-expressed during oncogenesis 
(21,22). Among many antibodies produced against 
fetal pancreatic tissue, the monoclonal antibody 
mAbJ28 detected a concanavalin A-reactive 
pancreatic glycoprotein with estimated molecular 
weight of 110 kDa (23). This acinar cell component 
was given the name feto-acinar pancreatic protein 
(FAPP) (23,24). FAPP was later reported to have the 
same amino acid composition as the N-terminal 
globular domain of CEL (25) and postulated to be a 
CEL variant expressed in embryogenesis, 
inflammation and cancer. However, whether 
oncofetal forms of CEL exist has not been 
confirmed. 
Another antibody that seemingly targets a CEL-
related glycotope on FAPP is mAb16D10. This 
monoclonal antibody was raised against CEL 
purified from pancreatic juice of a PDAC patient 
(26). In SOJ-6 pancreatic cancer cells, mAb16D10 
has been found to specifically recognize an antigen 
present on the plasma membrane (27), to inhibit the 
growth of tumor xenografts (27), and to induce cell 
death by the p53/caspase-dependent apoptotic 
pathway (26). In human pancreatic tissue sections, 
mAb16D10 was reported to discriminate pancreatic 
cancer from non-neoplastic tissue and other cancers 
(28).  
We sought to confirm and further characterize the 
postulated onco-glycoforms of CEL by 1) evaluating 
human CEL expression in PDAC surgical 
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specimens; 2) determining the identity of the 16D10 
glycotope by means of glycan arrays; and 3) 
identifying the O-glycan structures at the CEL 
mucinous tail by means of high-sensitivity MALDI-
TOF mass spectrometry. However, we could not 
detect CEL expression in neoplastic cells, and found 
that mAb16D10 did not target an epitope specific for 
CEL or for pancreatic cancer tissue. Instead, the 
antibody showed a high affinity for blood group A 
antigens, which led to the finding that ABO blood 




CEL expression in normal pancreas, PDAC and 
pancreatic cancer cell lines 
Initially, we performed fluorescent in situ 
hybridization and immunohistochemistry for 
simultaneous detection of CEL mRNA and protein, 
respectively, in morphologically normal pancreas 
(Fig. 1). Our staining method did not detect CEL 
transcripts or protein in ductal cells or in islets of 
Langerhans (Fig. 1A-B). The acinar cells were 
strongly positive, as expected, with CEL transcripts 
located basally and the protein accumulating apically 
in the zymogen granules (Fig. 1C). Having 
established the specificity of our method, we 
evaluated CEL mRNA and protein expression in 
adjacent sections from PDAC tumors by 
chromogenic staining (Fig. 2). CEL was detectable 
in preserved and atrophic parenchyma (Fig. 2A, B, 
E, F). In contrast, the epithelial lining of acinar-to-
ductal metaplasia (ADM), pancreatic intraepithelial 
neoplasia (PanIN) and malignant ducts was 
consistently negative (Fig. 2B-D, F-H). 
 
Next, RT-qPCR was performed on selected areas of 
unstained pancreatic FFPE sections, which were 
scraped off the glass slide after comparison with 
H&E-stained parallel sections. Neoplastic regions 
from nine different PDAC patients were compared 
with morphologically normal regions from four 
patients having non-neoplastic disease. Very low 
CEL mRNA levels were detected in the neoplastic 
areas compared with levels in normal pancreatic 
parenchyma (Fig. 2I).  In addition, the commonly 
used pancreatic cancer cell lines MIAPaCa-2, 
PANC-1 and BxPC-3 were tested for CEL 
expression (Fig. 3). MIAPaCa-2 and PANC-1 
exhibited very low mRNA levels (comparable to the 
basal levels in HeLa cells). BxPC-3 cells had a CEL 
mRNA level comparable to that of native HEK293 
cells. Immunoblots stained with an anti-CEL 
antibody detected a strong protein band in the control 
HEK293_CEL line and a weak band in BxPC-3 
cells, but no signal in the other cell lines (Fig. 3B). 
 
Characterization of the 16D10 glycotope 
The mAb16D10 antibody had been produced against 
purified CEL (26) and was shown to react well with 
pancreatic cancer tissue sections (28). Since we did 
not detect CEL mRNA or protein in neoplastic cells 
of PDAC tumors, we next sought an explanation for 
the reactivity of the mAb16D10 antibody. To this 
end, an aliquot of mAb16D10 was analyzed on a 
glycan microarray (see Experimental Procedures). 
By comparing bound and unbound structures, we 
concluded that mAb16D10 had a strong reactivity 
towards the structural motif GalNAc-α1,3(Fuc-
α1,2)Gal, which corresponds to the blood group A 
antigen (Fig. 4). To verify this result, the antibody 
was used to stain normal pancreatic parenchyma 
from subjects of blood group A and O. There was 
strong positivity towards normal acinar cells from 
individuals with blood group A, but not in blood 
group O pancreatic tissue (Fig. 5A, C). Similarly, 
mAb16D10 specifically stained both erythrocytes 
and endothelium of blood group A specimens (Fig. 
5B, D). 
 
We then examined the reactivity of mAb16D10 on 
pancreatic tissue sections from PDAC cases of 
different ABO phenotypes. Blood group A cases 
exhibited a virtually identical staining pattern when 
parallel sections were incubated with either anti-A 
antibody or mAb16D10 (Fig. 6A-H). There was 
strong reactivity with acinar cells, ducts, blood 
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vessels and red blood cells in areas of preserved 
morphology (Fig. 6A, E), as well as with epithelial 
cells of ADM, PanIN and malignant ducts (Fig. 6B-
D, F-H). However, mAb16D10 also stained sections 
from PDAC patients with blood group O. Weak 
positivity, in a dot-like apical pattern, was observed 
in normal-looking acinar cells close to the tumor area 
(Fig. 6I). When ADM was present nearby, 
expression of the mAb16D10 glycotope seemed to 
increase in the small intralobular ducts connecting 
the acini (Fig. 6J). Relatively strong positivity was 
observed in PanINs and malignant ducts (Fig. 6K, 
L). 
 
Based on the observed staining pattern in blood 
group O neoplastic tissue (Fig. 6L), it was clear that 
mAb16D10 also recognized some non-A epitope(s). 
Thus, to further characterize its specificity, 
mAb16D10 was tested on a second microarray, 
consisting of peptides with a varying number of 
GalNAc residues conjugated to Ser or Thr residues 
(Fig. 7). Among GalNAc-containing peptides the 
intensity of the binding increased as the number of 
GalNAc-α-Ser residues increased, indicating that 
mAb16D10 binds strongly to repeating poly-Ser-α-
GalNAc residues (Fig. 7A). Blood group A antigen 
bears similarity to the cancer-associated Tn antigen 
as they both carry a terminal GalNAc-α residue (Fig. 
7B). The glycan array experiment was therefore 
repeated using an anti-Tn antibody. A certain 
overlap between the reactivity of this antibody and 
that of mAb16D10 was indeed observed (Fig. 7A). 
We therefore assumed that mAb16D10 could 
recognize the Tn antigen in cancerous tissue, and 
parallel staining of PDAC sections for these two 
antigens showed very similar patterns in blood group 
O specimens (Fig. 7C). Moreover, we also found that 
mAb16D10 reacted with gastric and breast cancer 
tissue sections from blood group O individuals 
(Suppl. Fig. 1). 
 
mAb16D10 reactivity in pancreatic juice 
We were now left with the conundrum that 
mAb16D10 recognized the blood group A antigen 
very well, despite being produced against purified 
CEL from pancreatic juice. The most straightforward 
explanation would be that CEL, being a heavily O-
glycosylated protein (29), can be decorated with 
blood group A antigens, which then had stimulated 
mAb16D10 production. To investigate this 
hypothesis, we performed immunoprecipitation of 
CEL directly from pancreatic juice collected from 
pancreatic cancer patients of either blood type A or 
O. All four patients had functioning α1,2-
fucosyltransferase (as determined by their FUT2 
genotype) and were therefore able to synthesize the 
H antigen of the ABO blood group system on 
secreted glycoproteins. Such subjects are referred to 
as secretors and comprise 80% of the Caucasian 
population (30,31). 
 
The immunoprecipitated complexes were subjected 
to SDS-PAGE and immunoblotted with anti-CEL, 
mAb16D10, anti-A and anti-Tn antibodies. We 
compared two experiments, one where the 
immunoprecipitates were washed with PBS only 
(Fig. 8, upper panel) and another where more 
stringent washings with RIPA buffer were 
performed, aiming at dissociating possible 
complexes that CEL might form with other proteins 
(Fig. 8, lower panel). The anti-CEL antibody 
detected the protein in all samples as a band of 
around 110 kDa. After staining with mAb16D10 or 
anti-A antibody a band of similar size were detected 
in blood group A samples but not in samples from 
blood group O individuals (Fig. 8). This observation 
strongly supported that CEL could contain terminal 
blood group A antigens. Anti-Tn staining was 
negative with regard to detecting a band that 
corresponded to CEL in molecular weight. A high-
molecular weight band at ~170 kDa was seen for all 
antibodies except anti-CEL, but only when mild 
washing was applied (Fig. 8, upper panel). This 
might indicate that a CEL-binding protein is present 
in pancreatic juice and that this protein contains 
structures with terminal α-GalNAc residues that can 
be recognized by all three antibodies. 
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Characterization of the O-glycome of CEL 
Finally, we attempted to detect blood group A 
epitopes directly on CEL after immunoprecipitation 
from pancreatic juice as described above. The 
protein band at 110 kDa was excised. As quality 
control, a small fraction of this band was used for 
protein identification by MS after trypsin-cleaved 
peptides/glycopeptides had been extracted. CEL was 
the major protein species identified (not shown). 
Then, mass-spectrometric profiling of O-glycans in 
the excised band was performed using MALDI-
TOF-TOF after beta-reductive elimination of 
glycans. 
 
The CEL O-glycome was analyzed in three samples 
(Fig. 9): two FUT2-positive cases (secretors) of 
blood group O and A, respectively, and one FUT2-
negative case (non-secretor) of blood group O. The 
latter subject contained a mutation in the FUT2 gene 
that leads to a non-functional α1,2-
fucosyltransferase meaning that there are no H 
antigens on secreted glycoproteins to be further 
converted into A and B antigens. As described 
below, the identified O-glycan pool was in all three 
cases consistent with ABO and FUT2 genotyping of 
genomic DNA extracted from the patients’ blood 
samples (31). 
 
The blood group O/secretor sample (Fig. 9A) was 
dominated by the molecular ion m/z 708 which is 
consistent with a blood group O antigen (or H 
antigen) core 1 structure. Core 2 structures 
containing the H antigen were also seen with a single 
(m/z 1159, 1332 and 1519) or two or more LacNAc 
units (m/z 1607, 1781, 1968, 2056 and 2230) with or 
without sialic acid capping. In the blood group 
A/secretor sample (Fig. 9B), the two highest peaks 
corresponded to the molecular ion at m/z 953, which 
is consistent with a core 1 blood group A structure, 
and its precursor at m/z 708 (H antigen). A higher 
molecular mass structure containing one blood group 
A antigen on each antenna was detected at m/z 1822. 
LacNAc extensions of two units or more were not 
seen in this sample. 
When CEL was isolated from the pancreatic juice of 
a non-secretor patient (Fig. 9C), the glycan pool 
lacked the molecular ion m/z 708. As a consequence, 
the Gal residue of the precursor Gal-β1,3-GalNAc 
(m/z 534, not detected) could only undergo 
sialylation and therefore m/z 895 (mono-sialylated) 
and 1257 (di-sialylated) were the two most abundant 
structures. Core 2 structures were also seen at m/z 
983, 1344, 1433, 1519, 1607, 1794, 1882 and 1968. 
Fucoses were only part of core 2 structures (m/z 
1519, 1607 and 1968) attached most likely to a 
GlcNAc residue. 
 
Structural assignment was facilitated by all 
molecular ions from the MS spectra being examined 
by MS/MS analysis. In Fig. 10, fragmentation 
patterns of the selected ions m/z 1781, 1822 and 
1794 (from spectra in Figs. 9A, 9B and 9C, 
respectively) are shown. Moreover, three peaks 
observed in the blood group O secretor and non-
secretor samples had identical m/z values (1519, 
1607 and 1968; Fig. 9A, C). The fragmentation 
pattern showed that they corresponded to glycans of 
the same composition but with different architecture 
due to the position of the fucose residue. Such 
differences are exemplified in Suppl. Fig. 2 where 




CEL has been linked to the inherited pancreatic 
disease MODY8 (10) and to idiopathic chronic 
pancreatitis (14). However, whether CEL has a role 
in pancreatic malignancies is still an open question. 
No genome-wide association studies of pancreatic 
cancer have so far identified SNPs in the CEL gene 
as risk factor (32,33). Neither the CEL-HYB variant 
(the allele predisposing for chronic pancreatitis) nor 
specific CEL VNTR lengths were enriched among 
pancreatic cancer cases compared to controls (8,34). 
Nevertheless, the identification and characterization 
of FAPP, a postulated oncofetal variant of CEL, has 
raised the possibility that glycoisoforms of CEL 
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could serve as diagnostic markers or even targets for 
treatment in pancreatic cancer (26-28,35). 
 
In the current study, by using complementary 
techniques, we found that CEL was not detectably 
expressed in either neoplastic cells of PDAC tissue 
sections or in the pancreatic cell lines examined. The 
only exception was BxPC-3 cells, a cell line derived 
from a moderately well-differentiated 
adenocarcinoma with wild type KRAS gene (36,37), 
and therefore not fully representative for PDAC 
tumor cells. We observed that CEL expression 
disappeared when acinar-to-ductal metaplasia was 
present, suggesting that the protein is a marker of 
pancreatic acinar cells only when these remain 
polarized and in acini-like arrangement. Our results 
are consistent with those of Reuss et al. (38). When 
they examined 25 ductal or mucinous 
adenocarcinomas from the pancreas, all cases were 
negative for CEL mRNA by in situ hybridization. 
Notably, a single case of pancreatic acinar cell 
carcinoma showed slightly positive expression (38). 
Our results support the conclusion that CEL is 
unlikely to correspond to the oncofetal marker 
FAPP. 
 
Since acinar pancreatic markers expressed only 
during embryogenesis and oncogenesis have been 
identified and we could not detect CEL in neoplastic 
tissue or cells, we wondered which antigen the anti-
CEL antibody mAb16D10 did detect in pancreatic 
neoplastic cells (21,22). Knowing that mAb16D10 
reacts with the highly O-glycosylated C-terminal of 
CEL (27), we tested the antibody against an array of 
more than six hundred different mammalian glycan 
structures. Glycans containing the blood group A 
antigen consistently showed the highest binding 
(Fig. 4). The presence of blood group antigens in the 
O-glycome of CEL was then verified directly on 
CEL protein isolated from pancreatic juice (Figs. 8, 
9). The samples investigated, as well as the juice 
sample used for mAb16D10 production, all stemmed 
from patients operated for pancreatic cancer. 
Aberrant glycosylation is a common characteristic 
for malignant transformation. It will therefore be 
necessary to analyze pancreatic juice from healthy 
subjects to determine whether the same glycan 
structures are found and, in particular, whether A 
antigens attached to CEL are a common feature of 
blood group A subjects. Similarly, based on the 
finding of H and A antigens attached to CEL, we 
predict that the protein when isolated from blood 
group B individuals will be modified by blood group 
B antigens. 
 
It is perhaps not surprising that CEL’s mucin-like C-
terminal domain contains blood group antigens. 
Mucinous O-glycans consist mostly of core 1-4 
structures further elongated with lactosamine chains 
and terminated by fucose and sialic acid (39). 
Therefore, the presence of ABH or Lewis-type blood 
group antigens are not unusual on such proteins (40-
42). In studies of BSSL, the milk counterpart of CEL, 
the threonine residues flanking the consensus 
sequence PVPP of the mucinous domain were 
proposed to carry O-glycans (18), and terminal 
Lewis antigens Lea, Leb and Lex were suggested to be 
present on this protein region (18,43). Nevertheless, 
as far as we know, no previous study has detected 
blood group antigens directly on pancreatic CEL 
using high-sensitivity mass spectrometry. 
 
The antibody mAb16D10 also showed reactivity 
against Tn motifs. Truncation of the O-glycans in 
CEL and exposure of the first GalNAc residue 
(GalNAcα1-O-Ser/Thr) might have explained the 
reactivity of mAb16D10 towards both A and Tn 
antigens. However, in the MS analysis of purified 
CEL protein we did not detect any peak at m/z 330 
corresponding to Tn. A peak at m/z 691 initially 
suggested a sialylated Tn structure (= STn antigen), 
but this was not consistent with the predicted glycan 
fragmentation pattern obtained when MS/MS was 
performed. Moreover, in blots of 
immunoprecipitates, no band matching CEL in size 
was seen with the anti-Tn antibody, although this 
antigen might be present in a higher molecular 
weight protein of ~170 kDa protein that co-
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precipitated with CEL (Fig. 8, upper lane). Taken 
together, we find that mAb16D10 has reactivity 
towards Tn, but that CEL purified from pancreatic 
juice of PDAC patients does not seem to carry this 
antigen in detectable amounts. We speculate that the 
staining of mAb16D10 observed in gastric and breast 
cancer (Suppl. Fig. 1) could be due to Tn positivity 
and therefore consistent with the pancarcinoma 
nature of this antigen (44,45). 
 
Our finding that the C-terminal mucin-like domain 
of CEL can be modified by blood group antigens 
should stimulate discussions about this heavily 
glycosylated region and its significance for CEL 
function. Neither chicken nor fish CEL contain the 
VNTR region (46), and truncated human CEL 
variants (devoid of the VNTR) are enzymatically 
active (14,47,48). Thus, the C-terminal domain is 
clearly dispensable for the catalytic activity of the 
protein although a role in substrate specificity cannot 
be ruled out. It is conceivable that O-glycosylation 
serves to increase the stability of CEL as the C-
terminal region bears amino acid similarity to protein 
sequences that can be a signal for proteolytic 
degradation (49,50). 
 
Another possibility is that CEL, through its C-
terminal region, contributes to the mucosal barrier in 
the gastrointestinal tract. A main role of intestinal 
mucins is to provide lubrication and create a barrier 
that will prevent infection by the large number of 
microorganisms that populate the gut (51). This 
function is exerted through the ability of O-glycans 
to retain water and form mucus gels (52). Bearing in 
mind that CEL comprises up to 4% of the pancreatic 
acinar proteins (3), the molecule could to some 
extent add to the gastrointestinal mucosal barrier, 
with the potential of interacting with intestinal 
microorganisms (41,53). Even the presence of blood 
group antigens on CEL might be understood in this 
perspective. In the analyzed juice samples, the 
identified glycan pools of CEL were fully consistent 
with the patients’ ABO and FUT2 genotypes, with 
the H antigen core 1 structure being one of the most 
abundant motifs detected in the secretor samples. 
ABO blood groups are genetically determined 
factors that modulate the interaction between host 
and intestinal microbiota as well as the flora 
composition itself, by providing carbohydrate 
antigens which act as anchoring sites for commensal 
bacteria (53-55). 
 
CEL is, in some respects, unique among digestive 
enzymes of the pancreas. The protein is expressed in 
several non-acinar cell types and has been linked to 
non-pancreatic pathogenic processes (56-58). The 
CEL gene is exceptionally polymorphic involving 
both copy number variants, VNTR length variations 
and single-base VNTR insertions (4). Moreover, the 
repeat region has expanded during mammalian 
evolution into an O-glycosylated mucin-like domain 
(46), which our current study shows is modified by 
blood group antigens. Although it might very well be 
a pure coincidence, we also note that the ABO and 
CEL genes are positioned in close vicinity of each 
other on the chromosome 9q terminal end (59). This 
opens possibilities of interactions at the gene 
structural level such as in the regulation of 
expression. 
 
Intriguingly, ABO blood group status convincingly 
has been shown to associate with varying risk for 
developing pancreatic cancer (31,60). The 
mechanistic basis for this association remains to be 
explained. Whether variation in the glycosylation 
patterns of secreted gastrointestinal proteins such as 
CEL plays a role in the susceptibility to pancreatic 
cancer is therefore an intriguing matter that should 
be explored further. 
 
Experimental Procedures  
Antibodies ─ Three different anti-CEL antibodies 
were used: a polyclonal rabbit antiserum (against 
peptide sequence 299-427 of the CEL globular 
domain) for immunostainings (Sigma-Aldrich, Cat. 
HPA052701), a polyclonal rabbit antiserum for 
immunoblotting (generated against the truncated 
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CEL form pV562X; recently published in (13)), and 
the mouse monoclonal antibody As20.1 for 
immunoprecipitation (raised against the CEL 
globular domain; generous gift from Prof. Olle 
Hernell, Umeå University, Sweden). The 
monoclonal antibody mAb16D10 has been described 
previously (26-28). Anti-Tn antibody was a generous 
gift from Prof. Ulla Mandel (Copenhagen 
University, Denmark). Mouse monoclonal anti-A 
antigen (sc-69951) and goat polyclonal anti-GAPDH 
antibodies (sc-20357) were from Santa Cruz. 
Secondary antibodies were horseradish peroxidase 
(HRP)-donkey anti-mouse (Invitrogen, Cat. 
626520), HRP-donkey anti-goat (Novusbio, Cat. 
NB7379), FITC-donkey anti-rabbit (Jackson 
ImmunoResearch, Cat. 711-095-152) and HRP-goat 
anti-rabbit (Invitrogen, Cat. 656120), Alexa 488 
anti-mouse (Invitrogen, Cat. A-10680). MACH3 
anti-mouse (Cat. M3M530H) or anti-rabbit HRP-
conjugated polymer (Cat. M3R531H) were from 
Biocare Medical.  
 
Human pancreatic cancer samples ─ Formalin-
fixed, paraffin-embedded (FFPE) pancreatic tissue 
blocks from either blood group A or blood group O 
subjects were selected from a cohort of quality-
controlled PDAC cases that had been genotyped to 
determine ABO and FUT2 status, as described earlier 
(31). Pancreatic juice was obtained from patients 
undergoing Whipple’s procedure for resection of 
pancreatic head tumors. After transection of the 
pancreas, the distal, dilated pancreatic duct was 
cannulated, and a sample of juice was suctioned out 
and immediately stored at -80 °C. COmplete 
protease inhibitor cocktail (Roche, Cat. 
11697498001) was added when samples were 
thawed for analysis. Juice samples for the study were 
selected based on the patients’ ABO and secretor 
phenotype. The patients had consented to the study, 
which was approved by the Regional Ethical 
Committee of Western Norway and performed 
according to the Helsinki Declaration. 
 
Cell cultures ─ Human pancreatic cancer cell lines 
(BxPC-3, MIA PaCa-2, PANC-1) and HeLa cells 
(CCL-2) were obtained from American Type Culture 
Collection. HEK293 cells (Clontech Laboratories) 
were stably transfected with pcDNA3.1/V5-His 
plasmids containing either wild type CEL or no 
insert (11,12). PANC-1, Hela and HEK293 cells 
were cultured in Dulbecco's modified Eagle's 
medium (DMEM; Sigma-Aldrich) with 500 µg 
Geneticin (G-418; Invitrogen), 10% fetal bovine 
serum (FBS; Invitrogen) and 100 units/ml 
penicillin/streptomycin. BxPC-3 were maintained in 
Roswell Park Memorial Institute (RPMI; Sigma-
Aldrich) 1640 medium supplemented with 10% FBS 
and 100 units/ml penicillin/streptomycin. MIA 
PaCa-2 cells were cultured in DMEM supplemented 
with 10% FBS, 2.5% horse serum (ATCC, Cat. 30-
2040) and 100 units/ml penicillin/streptomycin. All 
cells were cultured in a standard humidified 
incubator at 37 °C in a 5% CO2 atmosphere. 
 
Immunohistochemistry ─ FFPE pancreatic tissue 
sections (3-5 µm) were placed onto SuperFrost Plus 
Adhesion slides (Menzel Gläser Laboratories), dried 
overnight at 56°C, deparaffinized in xylene, 
gradually rehydrated with decreasing concentrations 
of ethanol, and washed with distilled water and PBS 
containing Tween 0.05% (v/v). The slides were then 
incubated in Tris-EDTA buffer (pH 9) in a 
pressurized heating chamber at 120°C for 1 min. 
Next, the slides were cooled down under running tap 
water and incubated at 4°C overnight with the 
antibodies mAb16D10 (1:100 dilution), anti-A 
(1:2000) and anti-CEL (Sigma-Aldrich; 1:100), or 
for 1 h at room temperature with anti-Tn (undiluted 
supernatant). Blocking of endogenous peroxidase 
activity was done by incubating the sections in an 
aqueous solution of 3% hydrogen peroxide (v/v) for 
5 min at room temperature. Primary antibody 
detection was performed with MACH3 anti-mouse 
or anti-rabbit HRP-conjugated polymers (Biocare 
Medical) using two incubations of 20 min with 
vigorous washing after each step on a rocking 
platform. Staining was visualized by developing 
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with 3,3′-diaminobenzidine (DAB) as substrate. The 
sections were counterstained with Mayer’s 
haematoxylin (Dako) for 1 min and then dehydrated 
in alcohol, cleared in xylene, and eventually 
mounted with permanent mounting media. 
 
In situ hybridization ─ Using a custom-made CEL-
specific probe covering exons 2–7, the RNAscope 
2.0HD assay was employed according to the 
supplier’s instructions (Advanced Cell Diagnostics). 
Briefly, after deparaffinization and rehydration, 
tissue sections were sequentially treated with 
endogenous hydrogen peroxidase block solution for 
10 minutes at room temperature followed by an 
immersion in a 100°C-preheated retrieval solution 
for 15 min and subjected to protease digestion at 
40°C for 30 min, rinsing with distilled water after 
each step. The sections were then hybridized with the 
CEL probe at 40°C for 2 hours in a HybEZ oven 
(Advanced Cell Diagnostics). After wash buffer 
steps, signal detection and amplification were 
performed using the RNAscope 2.0HD detection 
reagents (Advanced Cell Diagnostics, Cat. 322310), 
starting with the application of the signal enhancer 
solutions, then washing vigorously between each 
step and eventually adding DAB as substrate for 
HRP. The sections were counterstained with 
Mayer’s haematoxylin for 1 min and then dehydrated 
in alcohol, cleared in xylene, and eventually 
mounted with permanent mounting media. Images 
were acquired at various magnifications using a 
MC170HD camera attached to a DM2000LED 
microscope (Leica) and processed using LAS V4.8 
software.  
 
When in situ hybridization was combined with 
immunofluorescence, the RNAscope 2.0HD 
detection system with alkaline phosphatase 
(Advanced Cell Diagnostics, Cat. 310036) was first 
used in conjugation with the Vector Red fluorescent 
substrate (Vector Laboratories, Cat. SK-5100). The 
sections were then incubated with anti-CEL antibody 
(Sigma-Aldrich; 1:100) overnight, and thereafter 
with secondary antibody (donkey anti-rabbit IgG-
FITC; 1:50) for 1 h. All washing steps were 
performed using TBS containing Tween 0.05% 
(w/v) when alkaline phosphatase was used instead of 
HRP. For mounting, Gold Antifade Solution with 
DAPI (Invitrogen) was used. Images were collected 
using a SP5 AOBS confocal microscope (Leica 
Microsystems) with 40x/1.4 NA and 63x/1.4 NA 
HCX Plan-Apochromat oil immersion objectives, 
~1.2 airy unit pinhole aperture, and appropriate filter 
combinations. Images were acquired with 405 Diode 
and Argon ion/Argon Krypton lasers (Leica). The 
obtained images were merged and processed using 
Photoshop CC and Adobe illustrator CC (Adobe 
Systems). 
 
RNA isolation and real-time quantitative PCR (RT-
qPCR) ─ FFPE tissue sections (3-5 sections, 10 µm 
each) from the tumor, corresponding to either 
neoplastic areas or morphologically preserved 
pancreatic parenchyma, were scraped off from the 
glasses after comparison with parallel sections 
stained with haematoxylin and eosin (H&E). After 
deparaffinization, RNA was isolated using the 
RNeasy FFPE Kit (Qiagen, Cat. 73504) or the 
RNeasy Micro kit (Qiagen, Cat. 74004), according 
to the manufacturer’s instructions. For cDNA 
synthesis, reverse transcription was performed on 
100 ng RNA utilizing the High-Capacity cDNA 
Reverse Transcription Kit (Applied 
Biosystems/Thermo Fisher Scientific). Specific 
predesigned PCR primers/probe sets were purchased 
from Applied Biosystems (CEL: Hs 01068709_m1; 
QARS: Hs00192530_m1 and GAPDH: 
Hs02758991_g1 as normalizing control). RT-qPCR 
was performed using TaqMan Universal PCR 
Master Mix (Applied Biosystems, Cat. 4440040) 
following the manufacturer´s instructions. The PCR 
conditions were 40 cycles of denaturation at 95°C for 
15 sec followed by combined annealing/extension at 
60°C for 1 min. Fluorescent intensity was measured, 
and results were processed with SDS software, 
version 2.2 (Applied Biosystems).  
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Cell lysis and western blot analyses ─ Pellets from 
cultured cells were washed with ice-cold PBS, 
treated with ice-cold RIPA lysis buffer (Thermo 
Fisher Scientific, Cat. 89900) and centrifuged for 30 
min at maximum speed at 4 degrees. Fifteen μg of 
total protein was mixed with sample buffer (Life 
Technologies, Cat. NP0007) and reducing agent 
(Invitrogen, Cat. NP009), boiled at 90°C for 5 min 
and resolved in NuPAGE Novex 7% Tris-acetate 
gels. Separated proteins were transferred to PVDF 
membrane following standard protocols, then 
immunoblotted with polyclonal rabbit anti-CEL 
antibody (13) (1:10000). Staining with anti-GAPDH 
antibody (1:500) was used as loading control. Blots 
were developed using Amersham ECL Prime 
Western Blotting Detection Reagent (GE 
Healthcare, Cat. RPN2232) and images were 
detected on the Syngene G:Box XR5 
chemiluminescent imaging system (ISS).  
 
Glycan arrays ─ An aliquot of the monoclonal 
antibody mAb16D10 was analyzed by glycan 
microarray technology at the Consortium for 
Functional Glycomics at Emory University, Atlanta, 
GA. The antibody was incubated at a concentration 
of 50 µg/ml on a Mammalian Printed Glycan Array 
Version 5.2 (609 structures, available on 
www.functionalglycomics.org/glycomics/publicdat
a/primaryscreen.jsp) or on a glycopeptide array (56 
compounds, Suppl. Table 1), and probed for binding 
using fluorescent Alexa 488 anti-mouse antibody 
(Invitrogen, Cat. A-10680). On the latter array, also 
an anti-Tn antibody was probed. The arrays were 
processed using published methods (61). Binding 
experiments were done in replicates of six, removing 
the highest and lowest values from each replicate set 
and calculating the mean binding efficiency from the 
remaining four values. 
 
Immunoprecipitation ─ CEL glycoprotein was 
purified from pancreatic juice with the Pierce co-
immunoprecipitation kit (Thermo Fisher Scientific, 
Cat. 26149) as follows: 50-400 µl pancreatic juice 
(protein concentration between 0.8 and 5.4 µg per µl) 
were incubated in a spin-column containing 
immobilized antibody to the agarose-resin 
(monoclonal As20.1 antibody for CEL or unspecific 
mouse immunoglobulin for negative control). The 
sealed columns were incubated overnight at 4°C on 
a rotating wheel. Washing steps were performed 
using either PBS or RIPA lysis buffer, and elution 
was achieved using 50 mM Tris-HCl (pH 8) with 
2.5% w/v SDS. Five µl eluate was separated by 
standard SDS polyacrylamide gel electrophoresis 
(SDS-PAGE) and immunoblotted with polyclonal 
rabbit anti-CEL antibody (13) (1:10000), 
mAb16D10 (1:100), anti-A (1:500) or anti-Tn (1:5) 
antibody. All incubations were done overnight at 
4°C on a rocking platform. For mass spectrometry 
analysis, the rest of the eluted protein was subjected 
to SDS-PAGE electrophoresis and the resulting gel 
stained with SimplyBlue SafeStain solution (Thermo 
Fisher Scientific, Cat. LC6065) and washed 
thoroughly with ultrapure water prior to in-gel 
digestion. 
 
In-gel digestion of purified glycoprotein ─ Excised 
bands corresponding to CEL were first destained in 
a 50% acetonitrile (MeCN) (v/v) solution in 50 mM 
ammonium bicarbonate for 10 min, followed by 
incubation in 10 mM dithiothreitol solution for 
30 min at 56 °C. The gel pieces were desiccated, 
followed by incubation with a 55 mM solution of 
iodoacetic acid for 30 min in darkness at room 
temperature. The gel pieces were desiccated again 
prior to incubation with 1 μg of porcine trypsin 
(Sigma-Aldrich, Cat. S8045) in 50 mM ammonium 
bicarbonate, pH 8.5 (adjusted with ammonia), 
overnight at 37 °C. Following extraction of the 
tryptic glycopeptides from the gel in 0.1% 
trifluoroacetic acid/MeCN (1:2 v/v), the volume was 
reduced by a vacuum concentrator and the samples 
were freeze-dried by complete lyophilizing before 
proceeding to reductive elimination. All solvents 
used for glycan purification and analysis were 
HPLC-grade or higher. 
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Release of O-glycans by reductive elimination ─ O-
glycans were released from the mixture of 
peptides/glycopeptides by reductive elimination in 
400 µL of potassium borohydride (55 mg/mL in 0.1 
M potassium hydroxide) at 45 °C for 16 h. After the 
reaction had been terminated by dropwise addition 
of glacial acetic acid, the mixture was passed through 
a Dowex-beads (Sigma-Aldrich, Cat. 217492) 
chromatography column and dried under a stream of 
nitrogen with repeated addition of 10% methanolic 
acetic acid to remove borates. 
 
Permethylation of dried O-glycans ─ Two mL of a 
slurry composed of freshly crushed sodium 
hydroxide pellets and DMSO was added to the 
sample, followed by 600 µL of methyl iodide. The 
mixture was vigorously mixed on an automatic 
shaker for 45 min at room temperature. One mL of 
water was added to terminate the reaction, followed 
by another 1 mL of chloroform to recover the 
permethylated glycans. The aqueous phase was 
washed three times to remove impurities, and the 
chloroform layer was then dried under a nitrogen 
stream. Permethylated O-glycans were purified 
using a Sep-Pak Classic C18 cartridge (Waters). The 
cartridge was conditioned successively with 
methanol, water, MeCN and water. The samples 
were dissolved in 1:1 (v/v) methanol-water, loaded 
onto the cartridge, washed with water and 15% (v/v) 
aqueous MeCN solution, and then eluted using a 
35% (v/v) aqueous MeCN solution. The organic 
solvent was removed on a vacuum concentrator and 
samples were lyophilized overnight prior to mass 
spectrometry (MS) analyses. 
 
MALDI-TOF mass spectrometry ─ MALDI-TOF-
MS data on permethylated samples were acquired in 
the reflectron positive-ion mode using a 4800 
MALDI-TOF/TOF mass spectrometer (Applied 
Biosystems). The instrument was calibrated 
externally using the Calmix 4700 calibration 
standard, samples were dissolved in 10 μL of 
methanol, and 1 μL was mixed at a 1:1 ratio (v/v) 
with 20 mg/mL 3,4-diaminobenzophenone (DMBP) 
in 75% (v/v) MeCN in water as matrix. The samples 
were then spotted onto a 384-well sample plate and 
dried at room temperature. Data were acquired using 
4000 Series Explorer instrument control software 
and were processed using the software Data Explorer 
(Version 4.9, Applied Biosystems). MS spectra were 
assigned and annotated with the help of the 
GlycoWorkbench software (62). 
 
Statistical analyses ─ Analyses were performed 
using GraphPad prism 5.03 for Windows (GraphPad 
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Figure legends 
FIGURE 1. CEL expression in the pancreas is restricted to acinar cells. A, double fluorescent labeling 
of CEL mRNA (red) and protein (green) in normal human pancreatic parenchyma. Acinar cells are strongly 
positive, whereas ductal cells are negative. The dotted line circumscribes a representative intralobular duct. 
White arrowheads indicate the epithelial lining of the duct lumen. B, a representative islet of Langerhans 
(circumscribed by dotted line) devoid of CEL expression. C, high magnification of an acinus with one well-
polarized acinar cell highlighted by the dotted line. Note the basal labeling of the mRNA and the apical 
position of the zymogen granules staining positive for CEL protein. Cell nuclei are stained blue with DAPI. 
A single z-plane is shown (0.19 µm). Scale bars represent 100 µm.  
 
FIGURE 2. Pancreatic premalignant and malignant lesions are negative for CEL expression. A-D, 
chromogenic in situ labeling of CEL mRNA in sections from representative pancreatic cancer cases. E-H, 
chromogenic immunostaining of CEL protein in adjacent sections of A-D. A and E, preserved pancreatic 
parenchyma with normal morphology. Acinar cells contain high levels of CEL mRNA and protein located 
basally and apically, respectively. B and F, areas of atrophy with acinar-to-ductal metaplasia (ADM, marked 
by red stars). Both CEL mRNA and protein cease to be expressed when a lumen is visible. C and G, a 
pancreatic intraepithelial neoplasia lesion (PanIN, circumscribed by dotted line). Insets, magnification of 
one papillary protrusion showing negative epithelial cells. The arrow in G indicates secreted CEL protein 
present in the duct lumen. D and H, malignant pancreatic ducts embedded in desmoplastic stroma. All 
structures in these areas were devoid of detectable levels of both CEL mRNA and protein. Scale bars in A-
H represent 100 µm. I, RT-qPCR comparing CEL transcript level in PDAC sections (areas corresponding 
to D/H; n=9 different patients) with level in normal pancreatic tissue from patients with non-pancreatic 




FIGURE 3. CEL expression is low or absent in pancreatic cancer cell lines. A, CEL mRNA levels of the 
pancreatic cancer cell lines BxPC-3, MIA PaCa-2 and PANC-1 compared with levels in HeLa cells and in 
stably transfected HEK293 cells (positive control: HEK293_CEL, transfected with a CEL-expressing 
plasmid construct; negative control: HEK293_EV, transfected with empty plasmid vector). GAPDH gene 
expression was used as loading control. Y-axis scale is logarithmic. Error bars represents standard deviation 
from three experimental replicates. B, a representative western blot (n=2) of protein lysates from the above 
cell lines stained with anti-CEL antibody. GAPDH protein levels in the lower panel was used as loading 
control.  
 
FIGURE 4. The monoclonal antibody mAb16D10 binds strongly to blood group A-containing 
structures in a glycan array. A, mAb16D10 screened against 609 different glycans on a printed microarray 
from the Consortium for Functional Glycomics (see Experimental Procedures). Binding was detected via 
Alexa Fluor 488-labeled anti-mouse secondary antibody. B, the 18 glycan structures with the highest affinity 
shown in decreasing order of binding. Numbers refer to position in the array in A. C, the structural motif 
common to all binding structures. This was the terminal glycan having the sequence GalNAc-α1,3(Fuc-
α1,2)Gal, which corresponds to the blood group A antigen.  
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FIGURE 5. mAb16D10 cross-reacts with blood group A antigens in normal pancreas tissue. A and C, 
normal pancreatic parenchyma of subjects with blood group A and O, respectively, immunostained with 
mAb16D10. Only specimens from blood group A subjects reacted with the antibody. B and D, blood vessels 
of the same specimens. The black arrows point at red blood cells, whereas the arrowheads point at the 
endothelial lining of the vessels. Pancreatic islets (unstained region in A; circumscribed by dotted line in C) 
were negative for both blood groups. Scale bars represent 100 µm. 
 
FIGURE 6. mAb16D10 cross-reacts with blood group A antigens in pancreatic cancer tissue. A-H, 
adjacent tissue sections from a patient with blood group A immunostained either with mAb16D10 or an 
anti-A antibody. I-L, tissue sections from a patient with blood group O immunostained with mAb16D10. A, 
E and I, preserved pancreatic parenchyma with normal morphology. The arrowhead points to pancreatic 
secretions within a small duct. B, F and J, areas of atrophy with acinar-to-ductal metaplasia (ADM, marked 
by red stars). C, G and K, pancreatic intraepithelial neoplasia lesions (PanIN). Inset in K, magnification of 
one papillary protrusion. D, H and L, malignant pancreatic ducts embedded in desmoplastic stroma. Scale 
bars represent 100 µm. 
 
FIGURE 7. The mAb16D10 antibody can recognize the cancer-associated Tn antigen. A, Comparative 
binding profile of mAb16D10 (upper part) and an anti-Tn antibody (lower part) on an array of synthetic Tn 
glycopeptides from the Consortium for Functional Glycomics (see Experimental Procedures). The array 
consisted of 56 compounds including the blood group A glycan structure (red box). Structures that bound 
both antibodies are highlighted by yellow boxes. Only mAb16D10 bound to blood group A antigen 
structures with high affinity. Note that peptides containing the sequence DVPVEG[Sn]TSTVAPANK 
showed increasing binding intensities as the number of GalNAc-conjugated serine residues was increased 
(array positions 45, 47, 49), whereas the same peptide sequences devoid of the sugar bound very weakly 
(positions 46, 48, 50). Compounds on the array and their binding affinities are listed in Suppl. Table 2. B, 
the terminal GalNAc-α residue shared by the Tn (GalNAc-α-Ser/Thr) and blood group A (GalNAc-
α1,3(Fuc-α1,2)Gal) antigens. C, immunostaining with mAb16D10 or the anti-Tn antibody in adjacent 
sections of malignant pancreatic ducts embedded in desmoplastic stroma (blood group O individual). Scale 
bars represent 100 µm. 
 
FIGURE 8. Immunoprecipitated CEL protein from pancreatic juice reacts with mAb16D10 and an 
anti-A antibody but not with anti-Tn. Co-immunoprecipitation (upper panel) and immunoprecipitation 
(lower panel) of CEL were performed on four juice samples, followed by parallel immunoblotting with anti-
CEL, mAb16D10, anti-A, or anti-Tn antibodies. CEL was detected at around 110 kDa in all samples. The 
mAb16D10 and anti-A antibodies gave the same staining pattern in samples from blood group A cases 
(juices 3 and 4). Tn did not react with CEL but showed reactivity towards a protein of higher molecular 
weight regardless of blood group (upper panel). Two different anti-CEL antibodies were used: the mouse 
monoclonal antibody As20.1 for immunoprecipitation and a rabbit polyclonal antibody (13) for 
immunoblotting. The dashed line indicates that the membrane part to the left was cut and exposed for a 
longer time in order to achieve better signals. 
 
FIGURE 9. The mucinous domain of CEL contains glycans reflecting the patients’ ABO and FUT2 
status. The O-glycan pool from the pancreatic juice of three PDAC cases was investigated by MALDI-
TOF-MS after alkaline beta-elimination and permethylation. The O-glycan population was composed of 
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core 1 and core 2 structures. A, spectrum showing O-linked glycans from a blood group O FUT2-positive 
(secretor) case. Inset, 34X magnification in the m/z range 1500-2400 showing core 2 extended structures of 
less abundance. B, corresponding spectrum from a blood group A FUT2-positive (secretor) case, with 15X 
magnification in the m/z range 1190-2400. C, corresponding spectrum from a blood group O FUT2-negative 
(non-secretor) case, with a 52X magnification in the m/z range 1500-2400. All molecular ions are present 
in singly charged sodiated form ([M+Na]+). Major peaks are annotated with their proposed carbohydrate 
structure, according to the symbolic nomenclature adopted by the CFG (63). Putative structures are based 
on monosaccharide composition, data from the MS/MS analysis of all molecular ions and knowledge of the 
biosynthetic pathways for O-linked glycans. MS and MS/MS spectra were annotated manually with the aid 
of the semi-automated tool Glycoworkbench (62). When structures have not been unequivocally defined 
from MS/MS information, the monosaccharide is shown after a bracket.  
 
FIGURE 10. MALDI-TOF/TOF-MS/MS fragmentation spectras confirm the annotation of selected 
precursor ions from the CEL O-glycome.  Molecular ions m/z 1781, 1822 and 1794 from Fig. 9A, B and 
C, respectively underwent collision-induced dissociation and the resulting spectra are shown.  Arrows 
pointing from the dashed line indicate the loss of a specific fragment from the precursor ion. All fragment 
ions are [M+Na]+. When structures have not been unequivocally defined from MS/MS information, the 
monosaccharide is shown after a bracket. 
 
SUPPLEMENTARY FIGURE 1. mAb16D10 stains gastric and breast cancer tissue. A, B, sections from 
gastric and breast cancer, respectively, both from non-A individuals. Scale bars represent 100 µm. 
 
SUPPLEMENTARY FIGURE 2. MALDI-TOF/TOF-MS/MS fragmentation spectra of the selected 
molecular ion m/z 1519 from two samples with different secretor status. A, fragmentation spectra of the 
molecular ion 1519 from the blood group O/FUT2-positive (secretor) case; B, same from the blood group 
O/FUT2-negative (non-secretor) case. All fragment ions are [M+Na]+. When structures have not been 
unequivocally defined from MS/MS information, the monosaccharide is shown after a bracket.  
 
SUPPLEMENTARY TABLE 1. List of compounds in the Tn microarray and their observed binding 
affinities to mAb16D10 and the anti-Tn antibody. Chart ID refers to the structures’ position in the array; 
STDV is the SD value calculated from 4 technical replicates. An asterisk within the sequence indicates that 
the residue before it contains a GalNAc residue, and the number between parentheses indicates how many 






























































































































































































































   3
α 
































































































8()*2:(α    3
α    
  2 
β
























%&'()*+,$ -./01203 %&'(). %&'()4&
5 . 5 . 5 . 5 .67889$:;8<=
















670 1016 1362 1708 2054 2400




























































































































































































)*+,-. )*+ )+.,-. /0. ,10-.
Mass (m/z )
SUPPLEMENTARY FIGURE 2
Chart ID Detail Sequence Average STDEV Average STDEV
1 a-100uM AcPT*TTPLKNH2 1509 688 1 1
2 b-100uM AcPTT*TPLKNH2 272 215 2 2
3 c-100uM AcPTTT*PLKNH2 743 288 6 11
4 d-100uM AcPT*T*TPLKNH2 2996 1951 76 75
5 e-100uM AcPT*TT*PLKNH2 4240 321 76 150
6 f-100uM AcPTT*T*PLKNH2 1071 241 1925 594
7 g-100uM AcPT*T*T*PLKNH2 4383 1581 4774 1952
8 R-100uM AcPTTTPLKNH2 73 142 1 2
9 I-100uM AcPPTTTTKKPNH2 166 172 2 1
10 II-100uM H-GTTPSPVPT*TSTTSAP-OH 72 148 20 14
11 III-100uM AcPTTDSTT*PAPTTKNH2 25 230 11 6
12 EA2 -1-100uM Ac-PTTDSTTPAPTTK-HH2 60 113 3 5
13 EA2 -2-100uM Ac-PPT*T*T*T*KKP-HN2 165 98 2 2
14 EA2 -3-100uM NH2-TSAPDT*RDAP-NH2 252 204 1 1
15 EA2 -4-100uM NH2-TSAPDTRPAP-NH2 152 293 5 6
16 G-8-Pep-100uM H-APGS*T*APP-NH2 6287 2287 7898 1724
17 P-8-mer-100uM H-APGSTAPP-NH2 321 308 2 3
18 PADRE-Tn3-100uM C107H178N26O38 - Sequence not given 4757 1818 4158 738
19 Tn3-linker-100uM C41H72N8O22 - Sequence not given 10640 7146 5284 2121
20 Tn-linker-100uM C17H32N4O8 - Sequence not given 3521 1316 27 10
21 Peptide-4-100uM AcHN-KTTT-CONH2 100 149 7 12
22 Peptide-5-100uM AcHN-KTTTG-CONH2 8 55 6 3
23 Ser1-100uM H-Ser(a-D-GalNAc)-NH2 -104 365 15 2
24 S2-100uM H-Ser(a-D-GalNAc)-OH 357 418 6 8
25 Thr1-100uM H-Thr(a-D-GalNAc)-NH2 -133 358 3 2
26 T1-100uM H-Thr(a-D-GalNAc)-OH -90 164 2 3
27 IgA-Pep01-100uM KPVPST*PPT*PS*C 7466 369 11 7
28 IgA-Pep02-100uM KPVPSTPPTPSC 630 507 1728 3449
29 S-GalNAc-100uM S-GalNAc 2521 1181 0 1
30 T-GalNAc-100uM T-GalNAc -111 88 153 187
31 Bloodgroup A Tetra-AEAB-100uM 22673 10527 37 60
32 Bloodgroup A penta-AEAB-100uM 13755 6708 60 116
33 LNnT-100uM 573 144 274 429
34 Man5-100uM 117 230 6 9
35 Crypto peptide 01-50uM H-ETS*EAAAT*VDLFAFT*LDGGK-NH2 10697 5063 102 192
36 Crypto peptide 02-50uM H-ETSEAAAT*VDLFAFT*LDGGK-NH2 3014 576 12 19
37 Crypto peptide 03-50uM H-ETS*EAAATVDLFAFT*LDGGK-NH2 9042 1926 13 6
38 Crypto peptide 04-50uM H-ETSEAAATVDLFAFT*LDGGK-NH2 2056 1519 110 218
39 Crypto peptide 05-50uM H-ETS*EAAAT*VDLFAFTLDGGK-NH2 16332 3763 89 58
40 Crypto peptide 06-50uM H-ETSEAAAT*VDLFAFTLDGGK-NH2 13248 6132 45 47
41 Crypto peptide 07-50uM H-ETS*EAAATVDLFAFTLDGGK-NH2 8165 1893 13 23
42 Crypto peptide 08-50uM H-ETSEAAATVDLFAFTLDGGK-NH2 316 115 17 14
43 Crypto peptide 09-50uM H-ETT*EAAAS*VDLFAFS*LDGGK-NH2 18958 2203 30 3
44 Crypto peptide 10-50uM H-ETTEAAASVDLFAFSLDGGK-NH2 1608 2215 2 2
45 Crypto peptide 11-50uM H-DVPVEGSS*(7)TSTVAPANK-NH2 4695 1544 2311 638
46 Crypto peptide 12-50uM H-DVPVEGSS(7)TSTVAPANK-NH2 1143 841 27 36
47 Crypto peptide 13-50uM H-DVPVEGSS*(16)TSTVAPANK-NH2 7407 3419 4676 1496
48 Crypto peptide 14-50uM H-DVPVEGSS(16)TSTVAPANK-NH2 249 131 1 2
49 Crypto peptide 15-50uM H-DVPVEGSS*(23)TSTVAPANK-NH2 25484 4147 5651 2361
50 Crypto peptide 16-50uM H-DVPVEGSS(23)TSTVAPANK-NH2 -68 286 2 3
51 Cp17 protein-200ug/ml 5324 1297 15 11
52 Cp23 protein-200ug/ml 308 473 62 8
53 PBS 182 317 25 29
54 PBS 191 332 3 2
55 PBS 400 185 6 7
56 Biotin 267 166 3 3
mAb16D10 anti-Tn
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